Role of motor neuron autophagy in a mouse model of Amyotrophic Lateral Sclerosis by Rudnick, Noam Daniel















Submitted	  in	  partial	  fulfillment	  of	  the	  requirements	  	  
for	  the	  degree	  of	  Doctor	  of	  Philosophy	  	  
under	  the	  Executive	  Committee	  































	   	  
Abstract	  
Role	  of	  motor	  neuron	  autophagy	  in	  a	  mouse	  model	  of	  Amyotrophic	  Lateral	  Sclerosis	  
Noam	  Rudnick
	  
Amyotrophic	  Lateral	  Sclerosis	  (ALS)	  is	  a	  neurological	  disease	  characterized	  by	  the	  
degeneration	  of	  upper	  and	  lower	  motor	  neurons.	  Genetic	  studies	  have	  revealed	  that	  many	  
ALS-­‐associated	  genes	  are	  involved	  in	  autophagy,	  but	  the	  role	  of	  this	  pathway	  in	  motor	  
neurons	  remains	  poorly	  understood.	  Here,	  we	  use	  the	  SOD1G93A	  mouse	  model	  to	  investigate	  
the	  role	  of	  autophagy	  in	  ALS.	  We	  find	  neuronal	  subtype-­‐specific	  regulation	  of	  autophagy	  
over	  the	  course	  of	  disease	  progression.	  Vulnerable	  motor	  neurons	  form	  large	  GABARAPL1-­‐
positive	  autophagosomes	  that	  engulf	  ubiquitinated	  cargo	  recognized	  by	  the	  selective	  
autophagy	  receptor	  p62.	  Other	  motor	  neurons	  and	  interneurons	  do	  not	  engulf	  cargo	  within	  
GABARAPL1-­‐positive	  autophagosomes	  and	  instead	  accumulate	  somatodendritic	  
aggregates.	  To	  investigate	  whether	  motor	  neuron	  autophagy	  is	  protective	  or	  detrimental,	  
we	  generated	  mice	  in	  which	  the	  critical	  autophagy	  gene	  Atg7	  is	  specifically	  disrupted	  in	  
motor	  neurons.	  Phenotypic	  analysis	  of	  these	  mice	  revealed	  that	  autophagy	  is	  dispensable	  
for	  motor	  neuron	  survival	  but	  plays	  a	  key	  role	  in	  regulating	  presynaptic	  structure	  and	  
function.	  By	  crossing	  these	  mice	  to	  the	  SOD1G93A	  mouse	  model,	  we	  find	  that	  autophagy	  
inhibition	  accelerates	  early	  neuromuscular	  denervation	  and	  neurological	  dysfunction.	  
However,	  loss	  of	  autophagy	  in	  motor	  neurons	  eventually	  leads	  to	  an	  extension	  of	  lifespan,	  
and	  this	  is	  associated	  with	  reduced	  pathology	  in	  interneurons	  and	  glial	  cells.	  These	  data	  
suggest	  that	  vulnerable	  motor	  neurons	  rely	  on	  autophagy	  to	  maintain	  neuromuscular	  
innervation	  early	  in	  disease.	  However,	  autophagy	  eventually	  acts	  in	  a	  non-­‐cell	  autonomous	  
	   	  
manner	  to	  promote	  disease	  spread	  and	  neuroinflammation.	  Our	  results	  reveal	  
counteracting	  roles	  for	  motor	  neuron	  autophagy	  early	  and	  late	  in	  ALS	  disease	  progression.
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Chapter	  1:	  General	  Introduction	  
	  
1.1	  Symptoms,	  epidemiology	  and	  genetics	  of	  ALS	  
Clinical	  features	  of	  ALS	  
	   Amyotrophic	  Lateral	  Sclerosis	  (ALS)	  is	  a	  progressive	  neurodegenerative	  disease	  
resulting	  from	  the	  degeneration	  of	  motor	  neurons.	  It	  is	  classically	  described	  as	  a	  disease	  
that	  begins	  with	  focal	  motor	  symptoms	  and	  eventually	  leads	  to	  widespread	  paralysis	  and	  
death	  from	  respiratory	  failure	  approximately	  3-­‐5	  years	  later.	  Patients	  are	  usually	  
diagnosed	  with	  ALS	  when	  they	  are	  40-­‐60	  years	  old,	  but	  onset	  of	  the	  disease	  can	  occur	  at	  
any	  age.	  Mirroring	  the	  variability	  in	  disease	  onset,	  the	  rate	  of	  disease	  progression	  is	  also	  
highly	  variable.	  Some	  patients	  survive	  for	  only	  a	  year	  after	  diagnosis,	  whereas	  
approximately	  10%	  live	  for	  more	  than	  10	  years	  with	  the	  disease	  (Swinnen	  and	  Robberecht	  
2014).	  
	   The	  initial	  symptoms	  of	  ALS	  can	  vary.	  The	  majority	  of	  patients	  present	  with	  spinal	  
onset	  ALS,	  which	  manifests	  as	  asymmetric	  weakness	  in	  one	  limb	  in	  the	  absence	  of	  pain.	  
Physical	  examination	  reveals	  additional	  signs	  of	  lower	  motor	  neuron	  (LMN)	  dysfunction	  
such	  as	  muscle	  atrophy	  and	  fasciculations.	  Patients	  may	  also	  show	  signs	  of	  upper	  motor	  
neuron	  (UMN)	  dysfunction	  such	  as	  hyperreflexia	  and	  hypertonia	  in	  the	  affected	  limb.	  In	  
contrast,	  20%	  of	  patients	  present	  with	  bulbar	  onset	  ALS,	  which	  manifests	  as	  difficulty	  
speaking	  or	  swallowing	  and	  carries	  a	  worse	  prognosis	  than	  spinal	  onset	  ALS.	  Lastly,	  3-­‐5%	  
of	  patients	  may	  present	  with	  respiratory	  onset	  ALS,	  which	  manifests	  initially	  as	  orthopnea	  
or	  dyspnea	  and	  carries	  the	  worst	  prognosis	  (Swinnen	  and	  Robberecht	  2014).	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   Though	  the	  initial	  site	  of	  symptom	  onset	  is	  focal	  and	  unique	  to	  each	  patient,	  a	  
defining	  feature	  of	  ALS	  is	  that	  the	  symptoms	  spread	  to	  anatomically	  contiguous	  regions	  of	  
the	  body.	  This	  spread	  generally	  reflects	  the	  organization	  of	  motor	  circuitry,	  which	  differs	  
for	  upper	  and	  lower	  motor	  neurons	  (Ravits	  and	  La	  Spada	  2009).	  For	  instance,	  symptoms	  
associated	  with	  LMN	  dysfunction	  are	  likely	  to	  spread	  contralaterally,	  mirroring	  the	  close	  
anatomical	  relationship	  in	  the	  spinal	  cord	  between	  LMNs	  innervating	  opposing	  limbs.	  In	  
contrast,	  symptoms	  of	  UMN	  dysfunction	  are	  more	  likely	  to	  spread	  ipsilaterally,	  mirroring	  
the	  proximity	  of	  UMNs	  controlling	  ipsilateral	  muscle	  groups	  (Ravits,	  Paul	  et	  al.	  2007).	  
Spread	  of	  ALS	  pathology	  between	  neurons	  may	  occur	  via	  synaptic	  connections,	  such	  as	  
those	  that	  link	  LMNs	  to	  UMNs,	  or	  via	  complex	  interactions	  with	  non-­‐neuronal	  cell	  types.	  
Though	  the	  mechanisms	  governing	  the	  spread	  of	  ALS	  pathology	  remain	  poorly	  understood,	  
they	  may	  involve	  prion-­‐like	  seeded	  fibrillization	  of	  aggregation-­‐prone	  proteins	  (Guo	  and	  
Lee	  2014).	  Elucidating	  the	  cellular	  processes	  involved	  in	  disease	  spread	  could	  have	  
profound	  therapeutic	  value	  for	  patients	  in	  the	  early	  stages	  of	  the	  disease.	  
	   Historically,	  ALS	  has	  been	  viewed	  as	  a	  disease	  that	  affects	  only	  motor	  circuitry.	  
However,	  it	  is	  now	  clear	  that	  ALS	  can	  be	  associated	  with	  cognitive	  impairment.	  The	  most	  
common	  form	  of	  this	  cognitive	  impairment	  is	  called	  Frontotemporal	  Dementia	  (FTD),	  
which	  is	  found	  in	  25%	  of	  ALS	  patients	  and	  can	  also	  occur	  in	  the	  absence	  of	  motor	  neuron	  
disease	  (Swinnen	  and	  Robberecht	  2014).	  	  Symptoms	  of	  FTD	  include	  apathy,	  disinhibition,	  
abnormal	  social	  interactions,	  language	  impairments	  and	  stereotyped	  behavior	  (Strong,	  
Grace	  et	  al.	  2009).	  There	  is	  substantial	  overlap	  between	  mutations	  that	  cause	  ALS	  and	  FTD,	  
although	  mutations	  in	  MAPT	  and	  GRN	  generally	  cause	  pure	  FTD	  and	  are	  not	  observed	  in	  
ALS	  patients.	  The	  symptoms	  of	  FTD	  are	  thought	  to	  be	  due	  to	  atrophy	  and	  neuronal	  cell	  loss	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in	  the	  frontal	  and	  temporal	  lobes.	  These	  degenerative	  changes	  are	  associated	  with	  similar	  
neuropathological	  findings	  to	  those	  that	  are	  seen	  in	  ALS	  patients,	  supporting	  the	  theory	  
that	  ALS	  and	  FTD	  represent	  two	  extremes	  of	  a	  single	  disease	  spectrum	  (Strong,	  Grace	  et	  al.	  
2009).	  
	   Post-­‐mortem	  evaluation	  of	  ALS	  patients	  has	  revealed	  several	  key	  pathological	  
features.	  These	  include	  the	  loss	  of	  upper	  and	  lower	  motor	  neurons	  from	  the	  primary	  motor	  
cortex	  and	  spinal	  cord,	  degeneration	  of	  corticospinal	  tracts	  and	  reactive	  gliosis	  (Brooks,	  
Miller	  et	  al.	  2000,	  Rowland	  and	  Shneider	  2001).	  Another	  major	  pathological	  finding	  is	  the	  
appearance	  of	  ubiquitinated	  protein	  aggregates	  within	  affected	  cells.	  These	  can	  resemble	  
the	  round	  inclusions	  seen	  in	  Parkinson’s	  disease,	  hence	  the	  name	  Lewy	  body-­‐like	  
inclusions	  (LBIs).	  Alternatively,	  ubiquitinated	  aggregates	  may	  take	  on	  a	  filamentous	  
appearance,	  in	  which	  case	  they	  are	  called	  skein-­‐like	  inclusions	  (SLIs)	  (Hirano	  1996).	  	  In	  
2006,	  it	  was	  discovered	  that	  the	  TAR	  DNA-­‐binding	  protein	  43	  (TDP-­‐43)	  is	  a	  major	  protein	  
component	  of	  these	  ubiquitinated	  aggregates	  (Neumann,	  Sampathu	  et	  al.	  2006).	  In	  addition	  
to	  inclusions	  that	  are	  immunoreactive	  for	  ubiquitin,	  post-­‐mortem	  analysis	  of	  ALS	  patients	  
has	  also	  led	  to	  the	  identification	  of	  Bunina	  bodies,	  which	  are	  tubulovesicular	  structures	  that	  
stain	  positive	  for	  Cystatin	  C	  (Hirano	  1996).	  
	   To	  date,	  there	  is	  only	  one	  FDA-­‐approved	  treatment	  for	  ALS.	  Riluzole,	  a	  sodium	  
channel	  blocker	  that	  also	  inhibits	  glutamatergic	  transmission	  through	  unknown	  
mechanisms,	  was	  shown	  to	  prolong	  survival	  by	  3-­‐6	  months	  (Bensimon,	  Lacomblez	  et	  al.	  
1994,	  Lacomblez,	  Bensimon	  et	  al.	  1996).	  However,	  this	  survival	  effect	  was	  not	  accompanied	  
by	  substantial	  functional	  improvements	  for	  patients	  (Rowland	  and	  Shneider	  2001).	  
Therefore,	  there	  is	  tremendous	  interest	  in	  the	  development	  of	  novel	  ALS	  therapeutics.	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Epidemiology	  of	  ALS	  
	   ALS	  is	  the	  most	  common	  adult	  motor	  neuron	  disease.	  For	  every	  100,000	  people	  in	  
the	  general	  population,	  approximately	  2-­‐3	  will	  be	  diagnosed	  with	  ALS	  per	  year.	  This	  
translates	  to	  an	  overall	  lifetime	  risk	  of	  about	  1:350	  for	  men	  and	  1:400	  for	  women	  (Al-­‐
Chalabi	  and	  Hardiman	  2013).	  However,	  these	  statistics	  are	  based	  on	  studies	  that	  examined	  
the	  incidence	  of	  ALS	  in	  individuals	  of	  European	  ancestry,	  and	  the	  incidence	  in	  other	  ethnic	  
populations	  may	  be	  lower	  (Gordon,	  Mehal	  et	  al.	  2013).	  	  Nonetheless,	  there	  are	  two	  
geographic	  regions	  with	  exceptionally	  high	  rates	  of	  ALS.	  One	  of	  these	  is	  the	  pacific	  island	  of	  
Guam,	  where	  the	  indigenous	  Chamorro	  tribe	  suffers	  from	  a	  high	  incidence	  of	  the	  disease.	  It	  
has	  been	  hypothesized	  that	  this	  could	  be	  due	  to	  a	  diet	  rich	  in	  cyanotoxins,	  although	  this	  link	  
has	  never	  been	  proven.	  	  The	  Kii	  peninsula	  in	  Japan	  also	  boasts	  a	  high	  rate	  of	  ALS,	  although	  
this	  may	  be	  due	  to	  genetic	  causes	  (Al-­‐Chalabi	  and	  Hardiman	  2013).	  
	   Many	  studies	  have	  attempted	  to	  address	  environmental	  contributions	  to	  ALS,	  but	  
methodological	  shortcomings	  prevent	  clear	  conclusions	  from	  being	  made	  (Al-­‐Chalabi	  and	  
Hardiman	  2013).	  Nonetheless,	  there	  is	  some	  evidence	  that	  ALS	  is	  more	  prevalent	  in	  people	  
who	  have	  a	  history	  of	  physical	  fitness	  and	  athleticism	  (Scarmeas,	  Shih	  et	  al.	  2002).	  A	  
separate	  study	  of	  Italian	  professional	  soccer	  players	  found	  a	  significantly	  increased	  risk	  of	  
ALS	  relative	  to	  the	  general	  population	  (Beretta,	  Carri	  et	  al.	  2003).	  Moreover,	  the	  dominant	  
arm	  is	  more	  frequently	  affected	  in	  patients	  with	  upper-­‐limb	  ALS	  onset,	  and	  this	  could	  be	  a	  
result	  of	  increased	  motor	  activity	  (Turner,	  Wicks	  et	  al.	  2011).	  An	  alternative	  interpretation	  
of	  these	  data	  is	  that	  athleticism	  or	  handedness	  may	  actually	  be	  a	  surrogate	  marker	  for	  
another	  underlying	  risk	  factor	  such	  as	  the	  level	  of	  neural	  connectivity	  in	  motor	  circuits.	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Additional	  proposed	  environmental	  factors	  include	  smoking,	  exposure	  to	  pesticides	  and	  
military	  service	  (Al-­‐Chalabi	  and	  Hardiman	  2013).	  The	  aforementioned	  studies	  are	  by	  no	  
means	  conclusive,	  and	  further	  research	  is	  necessary	  to	  determine	  the	  role	  of	  environment	  
as	  a	  modifier	  of	  ALS	  disease	  risk.	  
	   Approximately	  10%	  of	  ALS	  patients	  have	  an	  affected	  relative	  and	  these	  cases	  are	  
classified	  as	  familial	  ALS	  (fALS).	  In	  contrast,	  90%	  of	  patients	  do	  not	  have	  a	  family	  history	  
and	  these	  cases	  are	  therefore	  classified	  as	  sporadic	  ALS	  (sALS).	  Clinically,	  these	  two	  forms	  
of	  ALS	  are	  indistinguishable.	  Thanks	  to	  recent	  advances	  in	  DNA	  sequencing	  technology,	  
many	  the	  majority	  of	  fALS	  cases	  can	  now	  be	  explained	  genetically	  (Figure	  1.1).	  While	  the	  
causes	  sALS	  remain	  more	  enigmatic,	  recent	  genome	  sequencing	  efforts	  have	  revealed	  that	  
mutations	  in	  the	  same	  genes	  that	  cause	  fALS	  also	  predispose	  patients	  to	  sALS	  (Cirulli,	  
Lasseigne	  et	  al.	  2015).	  	  
	  
ALS	  Genetics	  
	   The	  first	  ALS-­‐causing	  mutations	  were	  found	  in	  the	  SOD1	  gene,	  which	  encodes	  a	  
cytosolic	  Cu/Zn	  superoxide	  dismutase	  (Rosen,	  Siddique	  et	  al.	  1993).	  Subsequent	  
overexpression	  of	  these	  pathogenic	  alleles	  in	  mice	  was	  sufficient	  recapitulate	  many	  key	  
features	  of	  the	  disease	  including	  motor	  neuron	  degeneration	  and	  paralysis	  (Gurney,	  Pu	  et	  
al.	  1994).	  In	  contrast,	  genetic	  deletion	  of	  the	  mouse	  Sod1	  gene	  did	  not	  cause	  overt	  
neurological	  impairment	  (Reaume,	  Elliott	  et	  al.	  1996).	  This	  result,	  combined	  with	  the	  
autosomal	  dominant	  pattern	  of	  inheritance,	  strongly	  suggested	  that	  mutant	  SOD1	  causes	  
disease	  through	  a	  toxic	  gain	  of	  function.	  Although	  SOD1	  mutations	  have	  been	  very	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influential	  in	  studies	  of	  ALS	  disease	  mechanisms,	  it	  is	  estimated	  that	  they	  only	  account	  for	  
12%	  of	  fALS	  and	  1%	  of	  sALS	  (Chio,	  Traynor	  et	  al.	  2008).	  
	   The	  next	  two	  ALS	  genes	  to	  be	  identified	  both	  encode	  RNA	  binding	  proteins	  
(RNABPs).	  Shortly	  after	  TDP-­‐43	  was	  identified	  as	  a	  common	  component	  of	  ubiquitinated	  
protein	  aggregates	  in	  ALS	  and	  FTD,	  it	  was	  found	  to	  cause	  ALS	  when	  mutated	  (Sreedharan,	  
Blair	  et	  al.	  2008).	  These	  mutations	  are	  mostly	  found	  in	  the	  C-­‐terminal	  region	  of	  TDP-­‐43,	  a	  
low-­‐complexity	  domain	  with	  prion-­‐like	  properties	  (King,	  Gitler	  et	  al.	  2012).	  Soon	  after	  this	  
discovery,	  ALS-­‐causing	  mutations	  were	  also	  identified	  in	  the	  Fused	  in	  sarcoma	  gene	  (FUS)	  
(Kwiatkowski,	  Bosco	  et	  al.	  2009,	  Vance,	  Rogelj	  et	  al.	  2009).	  These	  mutations	  tend	  to	  cluster	  
in	  a	  glycine-­‐rich	  region	  similar	  to	  that	  found	  in	  TDP-­‐43,	  or	  a	  C-­‐terminal	  region	  containing	  a	  
nuclear	  localization	  signal	  (NLS).	  	  Mutations	  in	  TDP-­‐43	  and	  FUS	  each	  account	  for	  a	  small	  
fraction	  of	  fALS	  cases	  (~4%)	  (Renton,	  Chio	  et	  al.	  2014).	  	  
Since	  the	  discovery	  of	  ALS-­‐causing	  mutations	  in	  TDP-­‐43	  and	  FUS,	  other	  genes	  
involved	  in	  RNA	  metabolism	  have	  been	  shown	  to	  cause	  ALS	  when	  mutated.	  Rare	  mutations	  
in	  the	  prion-­‐like	  domains	  of	  HNRNPA1/A2B1	  were	  found	  to	  cause	  a	  multisystem	  
proteinopathy	  that	  manifested	  with	  symptoms	  of	  ALS	  (Kim,	  Kim	  et	  al.	  2013).	  Additional	  
ALS	  causing	  genes	  code	  for	  the	  RNA	  helicase	  Senataxin,	  the	  ribonuclease	  Angiogenin	  and	  
the	  RNA-­‐binding	  proteins	  Matrin-­‐3	  and	  Ataxin-­‐2	  (Chen,	  Bennett	  et	  al.	  2004,	  Greenway,	  
Andersen	  et	  al.	  2006,	  Elden,	  Kim	  et	  al.	  2010,	  Johnson,	  Pioro	  et	  al.	  2014).	  A	  key	  unresolved	  
question	  is	  whether	  mutations	  in	  these	  genes	  cause	  disease	  by	  disrupting	  RNA	  metabolism,	  
by	  contributing	  to	  protein	  aggregation,	  or	  both.	  	  
Although	  most	  ALS	  genes	  only	  account	  for	  a	  small	  fraction	  of	  total	  ALS	  cases,	  this	  
changed	  in	  2011	  with	  the	  discovery	  of	  a	  noncoding	  hexanucleatide	  repeat	  expansion	  in	  the	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C9orf72	  gene	  (DeJesus-­‐Hernandez,	  Mackenzie	  et	  al.	  2011,	  Renton,	  Majounie	  et	  al.	  2011).	  
This	  expansion	  was	  found	  to	  account	  for	  4-­‐21%	  of	  sALS	  cases	  and	  23-­‐46%	  of	  fALS	  cases,	  
where	  differences	  in	  reported	  prevalence	  likely	  reflect	  demographic	  differences	  in	  the	  
populations	  being	  studied.	  The	  mechanism	  through	  which	  the	  repeat	  expansion	  causes	  ALS	  
is	  an	  area	  of	  active	  research.	  The	  expanded	  C9orf72	  allele	  may	  lead	  to	  haploinsufficiency	  of	  
the	  C9orf72	  gene	  product,	  though	  the	  function	  of	  this	  protein	  is	  currently	  unknown.	  
Alternatively,	  the	  repeat-­‐containing	  RNA	  may	  itself	  be	  toxic,	  leading	  to	  defects	  in	  cellular	  
function.	  Lastly,	  the	  hexanucleotide	  expansion	  may	  cause	  toxicity	  through	  repeat-­‐
associated	  non-­‐ATG	  (RAN)	  translation	  of	  aggregation-­‐prone	  dipeptides	  (Ling,	  Polymenidou	  
et	  al.	  2013).	  	  
In	  addition	  to	  genes	  described	  above,	  a	  large	  group	  of	  ALS	  genes	  have	  been	  
discovered	  that	  encode	  proteins	  involved	  in	  the	  autophagy	  pathway.	  Autophagy,	  discussed	  
in	  depth	  below,	  is	  a	  key	  cellular	  mechanism	  for	  degrading	  potentially	  toxic	  protein	  
aggregates	  and	  defective	  organelles.	  This	  pathway	  involves	  the	  formation	  of	  a	  membranous	  
autophagosome	  that	  captures	  substrates	  and	  then	  fuses	  with	  the	  lysosome,	  which	  
unleashes	  proteases	  and	  other	  degradative	  machinery.	  Autophagy	  receptors	  such	  as	  
Sequestosome-­‐1/p62	  (SQSTM1)	  and	  Optineurin	  (OPTN),	  which	  are	  responsible	  for	  
selecting	  substrates	  for	  degradation,	  are	  mutated	  in	  a	  small	  fraction	  of	  ALS	  patients	  
(Maruyama,	  Morino	  et	  al.	  2010,	  Fecto,	  Yan	  et	  al.	  2011).	  These	  autophagy	  receptors	  are	  
directly	  phosphorylated	  by	  Tank	  binding	  kinase	  (TBK1),	  which	  also	  causes	  ALS	  when	  
mutated	  (Cirulli,	  Lasseigne	  et	  al.	  2015,	  Freischmidt,	  Wieland	  et	  al.	  2015).	  The	  formation	  of	  
the	  mature	  autophagosome	  requires	  Valosin	  containing	  protein	  (VCP),	  an	  AAA+	  ATPase	  
that	  is	  also	  mutated	  in	  some	  ALS	  and	  FTD	  patients	  (Johnson,	  Mandrioli	  et	  al.	  2010).	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Mutations	  in	  Ubiquilin-­‐2	  (UBQLN2),	  which	  functions	  in	  autophagy	  and	  the	  ubiquitin	  
proteasome	  system,	  also	  cause	  ALS	  (Deng,	  Chen	  et	  al.	  2011).	  Finally,	  both	  ALS	  and	  FTD	  can	  
be	  caused	  by	  mutations	  in	  CHMP2B,	  a	  component	  of	  the	  ESCRT-­‐III	  complex,	  which	  is	  
required	  for	  multivesicular	  body	  (MVB)	  biogenesis	  and	  autophagy	  (Skibinski,	  Parkinson	  et	  
al.	  2005,	  Parkinson,	  Ince	  et	  al.	  2006).	  Thus,	  human	  genetic	  data	  strongly	  implicate	  
dysregulation	  of	  the	  autophagy	  pathway	  in	  the	  pathogenesis	  of	  ALS.	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1.2	  Cellular	  and	  molecular	  disease	  mechanisms	  in	  ALS	  
	   The	  discovery	  of	  pathogenic	  mutations	  in	  ALS	  patients	  has	  led	  to	  the	  creation	  model	  
systems	  for	  studying	  ALS	  disease	  mechanisms.	  Many	  of	  these	  are	  based	  on	  over-­‐expression	  
of	  mutant	  SOD1,	  although	  the	  emergence	  of	  additional	  model	  systems	  has	  made	  it	  possible	  
to	  test	  the	  broader	  relevance	  of	  putative	  pathogenic	  mechanisms.	  These	  models,	  in	  
combination	  with	  studies	  of	  biological	  samples	  from	  ALS	  patients,	  have	  already	  yielded	  




One	  potential	  disease	  mechanism	  involves	  the	  generation	  of	  reactive	  oxygen	  species	  
(ROS),	  which	  arise	  from	  the	  incomplete	  reduction	  of	  molecular	  oxygen	  (O2)	  during	  normal	  
aerobic	  respiration.	  This	  leads	  to	  the	  formation	  of	  superoxide	  O2-­‐,	  a	  toxic	  free	  radical	  that	  
can	  damage	  proteins,	  lipids	  and	  nucleic	  acids.	  These	  forms	  of	  oxidative	  damage	  have	  been	  
observed	  in	  postmortem	  tissue	  from	  ALS	  patients	  (Shaw,	  Ince	  et	  al.	  1995,	  Fitzmaurice,	  
Shaw	  et	  al.	  1996,	  Shibata,	  Nagai	  et	  al.	  2001).	  Microglia	  are	  major	  producers	  of	  ROS	  through	  
the	  activity	  of	  NADPH	  oxidase	  (NOX),	  and	  this	  protein	  is	  upregulated	  in	  the	  spinal	  cords	  of	  
SOD1G93A	  mice.	  This	  upregulation	  promotes	  neurodegeneration,	  as	  genetic	  deletion	  of	  NOX	  
isoforms	  has	  a	  protective	  effect	  on	  the	  SOD1G93A	  disease	  phenotype	  (Wu,	  Re	  et	  al.	  2006).	  
Although	  SOD1	  itself	  is	  involved	  in	  the	  neutralization	  of	  ROS	  and	  mutations	  may	  lead	  to	  
aberrant	  ROS	  handling,	  increased	  ROS	  is	  also	  seen	  in	  sALS	  and	  cellular	  models	  based	  on	  
mutant	  TDP-­‐43	  (Duan,	  Li	  et	  al.	  2010).	  Thus,	  oxidative	  stress	  may	  be	  a	  general	  feature	  of	  
ALS	  and	  could	  interact	  with	  other	  disease	  mechanisms.	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Mitochondrial	  dysfunction	  
	   Damage	  to	  mitochondria	  is	  thought	  to	  be	  another	  major	  ALS	  disease	  mechanism.	  
Morphological	  changes	  in	  mitochondria	  have	  been	  observed	  in	  the	  skeletal	  muscle	  and	  
spinal	  cords	  of	  ALS	  patients	  (Sasaki	  and	  Iwata	  2007).	  Accordingly,	  mitochondrial	  function	  
has	  also	  shown	  to	  be	  impaired	  in	  these	  patients,	  suggesting	  that	  defects	  in	  energy	  
metabolism	  could	  contribute	  to	  motor	  neuron	  degeneration	  (Wiedemann,	  Manfredi	  et	  al.	  
2002).	  In	  SOD1G93A	  mice,	  mutant	  SOD1	  has	  been	  shown	  to	  aggregate	  preferentially	  in	  
mitochondria	  and	  induce	  vacuolar	  changes	  early	  in	  disease	  progression	  (Wong,	  Pardo	  et	  al.	  
1995).	  Motor	  neuron	  axons	  in	  SOD1G93A	  mice	  show	  reduced	  mitochondrial	  content,	  and	  this	  
may	  contribute	  to	  muscle	  denervation	  (De	  Vos,	  Chapman	  et	  al.	  2007).	  	  
	  
Excitotoxicity	  
	   Motor	  neuron	  degeneration	  may	  also	  be	  mediated	  by	  excitotoxicity.	  Cerebrospinal	  
fluid	  (CSF)	  from	  ALS	  patients	  often	  contains	  elevated	  levels	  of	  the	  excitatory	  
neurotransmitter	  glutamate	  (Shaw,	  Forrest	  et	  al.	  1995).	  This	  abnormality	  may	  be	  due	  to	  
downregulation	  of	  EAAT2,	  the	  transporter	  responsible	  for	  removing	  extracellular	  
glutamate	  (Rothstein,	  Martin	  et	  al.	  1992).	  Abnormal	  editing	  of	  the	  mRNA	  coding	  for	  the	  
GluR2	  AMPA	  receptor	  subunit	  could	  compound	  this	  problem	  by	  increasing	  the	  sensitivity	  
of	  motor	  neurons	  to	  glutamate	  (Kwak,	  Hideyama	  et	  al.	  2010).	  Lastly,	  the	  fact	  that	  Riluzole	  
acts	  in	  part	  through	  the	  inhibition	  of	  glutamatergic	  neurotransmission	  is	  consistent	  with	  a	  
pathogenic	  role	  for	  excitotoxicity.	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Axonal	  Transport	  
	   One	  distinguishing	  feature	  of	  motor	  neurons	  is	  their	  exceptionally	  long	  axons,	  and	  
this	  may	  contribute	  to	  their	  vulnerability	  in	  ALS	  (Ferraiuolo,	  Kirby	  et	  al.	  2011).	  Indeed,	  
retraction	  of	  axons	  and	  muscle	  denervation	  is	  a	  very	  early	  event	  in	  disease	  pathogenesis.	  
Studies	  in	  SOD1G93A	  mice	  have	  revealed	  defects	  in	  axonal	  transport	  significantly	  before	  
symptom	  onset	  (Williamson	  and	  Cleveland	  1999,	  Bilsland,	  Sahai	  et	  al.	  2010).	  Mutant	  SOD1	  
binds	  to	  the	  dynein	  intermediate	  chain	  and	  this	  may	  be	  one	  mechanism	  through	  which	  it	  
can	  disrupt	  retrograde	  transport	  (Xie,	  Zhou	  et	  al.	  2015).	  Axonal	  transport	  is	  also	  intimately	  
linked	  to	  the	  axonal	  cytoskeleton,	  and	  genes	  encoding	  cytoskeletal	  components	  such	  as	  
peripherin	  (PRPH)	  and	  neurofilament	  heavy	  subunit	  (NEFH)	  are	  mutated	  in	  ALS	  patients	  
(Figlewicz,	  Krizus	  et	  al.	  1994,	  Gros-­‐Louis,	  Lariviere	  et	  al.	  2004).	  	  
	  
Neuroinflammation	  
	   A	  large	  body	  of	  work	  suggests	  that	  motor	  neuron	  degeneration	  in	  ALS	  is	  not	  strictly	  
cell-­‐autonomous	  and	  is	  mediated	  in	  part	  by	  activation	  of	  an	  inflammatory	  response	  in	  non-­‐
neuronal	  cells.	  Microglia,	  the	  resident	  immune	  cells	  of	  the	  nervous	  system,	  are	  key	  
mediators	  of	  neuroinflammation.	  Astrocytes,	  while	  not	  technically	  immune	  cells,	  can	  also	  
become	  activated	  in	  disease	  states	  and	  secrete	  pro-­‐inflammatory	  cytokines.	  Both	  microglia	  
and	  astrocytes	  undergo	  dramatic	  activation	  in	  the	  central	  nervous	  system	  of	  ALS	  patients	  
(Barres	  2008,	  Philips	  and	  Robberecht	  2011,	  Phatnani	  and	  Maniatis	  2015).	  	  
ALS	  disease	  models	  based	  on	  the	  expression	  of	  mutant	  SOD1	  have	  confirmed	  that	  
non-­‐neuronal	  cells	  contribute	  to	  disease	  progression.	  	  The	  directed	  differentiation	  of	  
mouse	  embryonic	  stem	  cells	  into	  motor	  neurons	  has	  made	  it	  possible	  to	  examine	  the	  
	   12	  
effects	  of	  non-­‐neuronal	  cells	  in	  vitro.	  	  This	  co-­‐culture	  system	  has	  revealed	  that	  primary	  glial	  
cells	  from	  SOD1G93A	  mice	  are	  directly	  toxic	  to	  motor	  neurons	  (Di	  Giorgio,	  Carrasco	  et	  al.	  
2007,	  Nagai,	  Re	  et	  al.	  2007).	  Follow-­‐up	  experiments	  have	  demonstrated	  that	  mutant	  
astrocytes	  also	  induce	  complex	  transcriptional	  changes	  in	  motor	  neurons	  (Phatnani,	  
Guarnieri	  et	  al.	  2013).	  Mice	  expressing	  a	  SODG37R	  transgene	  that	  can	  be	  deleted	  through	  
Cre-­‐Lox	  recombination	  have	  provided	  in	  vivo	  evidence	  for	  cell	  non-­‐autonomous	  
contributions	  to	  ALS	  pathogenesis.	  When	  the	  multicopy	  mutant	  SOD1	  transgene	  was	  
excised	  from	  motor	  neurons,	  disease	  onset	  was	  delayed	  but	  eventually	  the	  mice	  still	  
succumbed	  to	  paralysis	  (Boillee,	  Yamanaka	  et	  al.	  2006).	  In	  contrast,	  removal	  of	  mutant	  
SOD1	  from	  astrocytes	  and	  microglia	  did	  not	  affect	  disease	  onset	  but	  significantly	  slowed	  
disease	  progression	  leading	  to	  an	  extension	  of	  lifespan	  (Boillee,	  Yamanaka	  et	  al.	  2006,	  
Yamanaka,	  Chun	  et	  al.	  2008).	  Thus,	  astrocytes	  and	  microglia	  may	  become	  activated	  early	  in	  
disease	  and	  act	  to	  perpetuate	  neurodegeneration.	  	  	  
	  
ER	  Stress	  
	   Protein	  misfolding	  and	  aggregation,	  discussed	  below,	  are	  key	  features	  of	  ALS.	  
Misfolding	  can	  lead	  to	  ER	  stress,	  which	  subsequently	  activates	  a	  coordinated	  homeostatic	  
mechanism	  known	  as	  the	  unfolded	  protein	  response	  (UPR).	  The	  UPR	  involves	  the	  
upregulation	  of	  machinery	  involved	  in	  protein	  folding	  and	  quality	  control.	  However,	  
chronic	  activation	  of	  this	  pathway	  can	  be	  detrimental	  and	  leads	  to	  apoptosis	  (Ferraiuolo,	  
Kirby	  et	  al.	  2011).	  	  
	   In	  post-­‐mortem	  spinal	  cord	  samples	  from	  sALS	  patients,	  numerous	  UPR	  sensors	  
have	  been	  found	  to	  be	  upregulated	  including	  IRE1,	  ATF6,	  PERK	  (Atkin,	  Farg	  et	  al.	  2008).	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Mutant	  SOD1	  also	  activates	  the	  UPR.	  This	  has	  been	  proposed	  to	  occur	  through	  an	  abnormal	  
interaction	  of	  mutant	  SOD1	  with	  Derlin-­‐1,	  a	  component	  of	  the	  ER	  associated	  degradation	  
(ERAD)	  pathway.	  Inhibition	  of	  ERAD	  subsequently	  leads	  to	  ER	  stress	  (Homma,	  Fujisawa	  et	  
al.	  2013).	  Consistent	  with	  a	  pathogenic	  role	  for	  ER	  stress	  and	  UPR	  activation,	  
transcriptional	  profiling	  of	  SOD1G93A	  mice	  revealed	  that	  these	  pathways	  are	  selectively	  
activated	  in	  the	  most	  vulnerable	  motor	  neurons	  innervating	  fast-­‐twitch	  muscle	  fibers.	  
Furthermore,	  administration	  of	  the	  ER	  stress	  inhibitor	  salubrinal	  was	  able	  to	  attenuate	  
disease	  progression	  in	  vivo	  (Saxena,	  Cabuy	  et	  al.	  2009).	  	  It	  is	  interesting	  to	  note,	  however,	  
that	  in	  contrast	  to	  the	  occurrence	  of	  mutations	  in	  multiple	  genes	  involved	  in	  autophagy,	  




	   The	  formation	  of	  ubiquitinated	  protein	  aggregates	  is	  a	  hallmark	  of	  ALS	  and	  is	  likely	  
to	  serve	  as	  a	  primary	  insult	  that	  initiates	  many	  of	  the	  aforementioned	  disease	  mechanisms.	  
This	  theory	  is	  supported	  by	  the	  fact	  that	  many	  ALS-­‐causing	  mutations	  lead	  to	  protein	  
aggregation.	  Mutations	  in	  SOD1	  render	  it	  more	  likely	  to	  aggregate,	  and	  the	  aggregation	  
propensity	  of	  specific	  mutants	  shows	  a	  striking	  correlation	  with	  clinical	  disease	  severity	  
(Pratt,	  Shin	  et	  al.	  2014).	  Misfolding	  and	  aggregation	  of	  SOD1	  are	  detectable	  in	  SOD1G93A	  
mice	  as	  well	  as	  patients	  harboring	  SOD1	  mutations	  (Brotherton,	  Li	  et	  al.	  2012).	  The	  C9orf72	  
hexanucleotide	  repeat	  expansion	  also	  causes	  protein	  aggregation.	  Dipeptide-­‐repeat	  
proteins	  generated	  by	  RAN	  translation	  of	  the	  hexanucleotide	  expansion	  form	  insoluble	  
aggregates	  in	  the	  central	  nervous	  system	  of	  ALS	  patients	  (Mori,	  Weng	  et	  al.	  2013).	  Recently,	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it	  was	  demonstrated	  that	  viral	  delivery	  of	  the	  hexanucleotide	  repeats	  to	  the	  central	  
nervous	  system	  of	  mice	  also	  leads	  to	  aggregated	  dideptide-­‐repeat	  proteins	  and	  motor	  
dysfunction	  (Chew,	  Gendron	  et	  al.	  2015).	  
	   As	  mentioned	  earlier,	  RNABPs,	  including	  those	  that	  are	  mutated	  in	  ALS	  patients,	  are	  
especially	  prone	  to	  aggregation.	  Recent	  work	  has	  shown	  that	  RNABPs	  such	  as	  FUS	  and	  
hnRNPA2	  can	  form	  hydrogels	  spontaneously	  under	  the	  appropriate	  conditions	  (Kato,	  Han	  
et	  al.	  2012).	  At	  the	  ultrastuctural	  level,	  these	  hydrogels	  are	  composed	  of	  amyloid-­‐like	  
fibers.	  The	  phase	  transition	  depends	  on	  the	  low-­‐complexity,	  prion-­‐like	  domains	  and	  the	  
resulting	  higher-­‐order	  structures	  can	  trap	  other	  RNA-­‐binding	  proteins	  containing	  low-­‐
complexity	  domains.	  These	  results	  may	  provide	  a	  biophysical	  basis	  for	  the	  physiological	  
formation	  RNA	  granules,	  a	  heterogeneous	  group	  of	  ribonucleoprotein	  structures	  that	  were	  
originally	  identified	  in	  the	  late	  19th	  century.	  These	  structures	  play	  important	  roles	  in	  
embryonic	  development	  (germ	  cell	  granules),	  mRNA	  decay	  (processing	  bodies),	  adaptation	  
to	  cellular	  stress	  (stress	  granules)	  and	  local	  translation	  at	  synaptic	  terminals	  (neuronal	  
granules)	  (Anderson	  and	  Kedersha	  2006).	  
	   Controlled	  aggregation	  of	  RNABPs	  may	  play	  a	  role	  in	  their	  normal	  function,	  but	  ALS-­‐
associated	  mutations	  increase	  this	  aggregation	  beyond	  physiological	  levels.	  This	  principle	  
was	  elegantly	  demonstrated	  for	  hnRNPA1	  and	  hnRNPA2B1,	  which	  can	  both	  form	  self-­‐
seeding	  fibrils	  in	  vitro	  (Kim,	  Kim	  et	  al.	  2013).	  Fibril	  formation	  requires	  a	  specific	  region	  
within	  the	  prion-­‐like	  domains	  of	  these	  proteins,	  which	  is	  called	  a	  ‘steric	  zipper’	  for	  its	  
ability	  to	  fold	  into	  two	  complementary	  beta	  strands.	  ALS-­‐causing	  mutations	  in	  these	  
RNABPs	  are	  localized	  to	  the	  steric	  zipper	  motif	  and	  markedly	  enhance	  the	  speed	  of	  fibril	  
nucleation.	  In	  living	  cells,	  ALS-­‐causing	  mutations	  also	  enhanced	  the	  incorporation	  of	  these	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proteins	  into	  stress	  granules.	  Lastly,	  expression	  of	  mutant	  hnRNPA1	  and	  hnRNPA2B1	  in	  
Drosophila	  led	  to	  cytoplasmic	  aggregates	  and	  muscle	  degeneration,	  confirming	  the	  
pathogenic	  effects	  of	  RNABP	  aggregation	  (Kim,	  Kim	  et	  al.	  2013).	  Similar	  results	  have	  been	  
obtained	  for	  the	  prion-­‐like	  domain	  of	  TDP-­‐43,	  which	  also	  forms	  fibrils	  in	  vitro	  that	  are	  
exacerbated	  by	  ALS-­‐associated	  mutations	  (Guo,	  Chen	  et	  al.	  2011).	  
	   The	  mechanism	  through	  which	  aberrant	  RNABP	  aggregation	  contributes	  to	  disease	  
remains	  a	  topic	  of	  active	  investigation.	  In	  the	  majority	  of	  ALS	  cases,	  TDP-­‐43	  is	  the	  main	  
protein	  constituent	  of	  ubiquitinated	  protein	  aggregates.	  Primarily	  localized	  to	  the	  nucleus	  
of	  healthy	  cells,	  TDP-­‐43	  aggregation	  in	  ALS	  is	  also	  associated	  with	  its	  nuclear	  depletion	  
(Lee,	  Lee	  et	  al.	  2012).	  Thus,	  aggregate	  formation	  could	  cause	  toxicity	  through	  cytoplasmic	  
gain-­‐of-­‐function,	  nuclear	  loss-­‐of-­‐function,	  or	  a	  combination	  of	  these	  two	  mechanisms.	  A	  
loss-­‐of-­‐function	  mechanism	  is	  difficult	  to	  study	  in	  mice	  because	  complete	  deletion	  leads	  to	  
embryonic	  lethality	  (Wu,	  Cheng	  et	  al.	  2010).	  However,	  conditional	  deletion	  of	  TDP-­‐43	  from	  
motor	  neurons	  using	  the	  Hb9-­‐Cre	  transgene	  is	  sufficient	  to	  cause	  many	  features	  of	  motor	  
neuron	  disease,	  suggesting	  that	  some	  amount	  of	  TDP-­‐43	  is	  critical	  for	  motor	  neuron	  
viability	  (Wu,	  Cheng	  et	  al.	  2012).	  	  
	   Other	  genetic	  studies	  argue	  that	  mutations	  in	  RNABPs	  cause	  a	  toxic	  gain-­‐of-­‐function.	  
For	  instance,	  overexpression	  of	  wild-­‐type	  TDP-­‐43	  using	  the	  mouse	  prion	  promoter	  is	  
sufficient	  to	  cause	  toxicity	  without	  inducing	  nuclear	  depletion	  (Xu,	  Gendron	  et	  al.	  2010).	  
Expression	  of	  mutant	  FUS	  from	  the	  mouse	  Mapt	  locus	  is	  also	  sufficient	  to	  cause	  
neurodegeneration	  in	  mice	  (Sharma,	  Lyashchenko	  et	  al.	  2015).	  Another	  compelling	  
demonstration	  of	  toxic	  gain-­‐of-­‐function	  comes	  from	  a	  study	  in	  Drosophila,	  in	  which	  genetic	  
mutations	  associated	  with	  multisystem	  proteinopathy	  were	  introduced	  into	  the	  fly	  VCP	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homolog	  (Ritson,	  Custer	  et	  al.	  2010).	  These	  mutations	  led	  degenerative	  phenotype	  when	  
expressed	  in	  the	  fly	  eye	  and	  brain.	  In	  vitro,	  these	  same	  mutations	  were	  observed	  to	  cause	  
redistribution	  of	  TDP-­‐43	  from	  the	  nucleus	  to	  the	  cytoplasm.	  	  When	  an	  unbiased	  RNAi	  
screen	  was	  performed	  to	  search	  for	  modifiers	  of	  the	  degenerative	  phenotype,	  knockdown	  
of	  the	  Drosophila	  homolog	  of	  TDP-­‐43	  was	  found	  to	  suppress	  degeneration.	  This	  data	  
indicates	  that	  cytoplasmic	  TDP-­‐43	  accumulation	  contributes	  to	  the	  toxicity	  of	  pathogenic	  
VCP	  mutations	  (Ritson,	  Custer	  et	  al.	  2010).	  
	   The	  genetic	  interaction	  between	  VCP	  and	  TDP-­‐43	  also	  underscores	  the	  importance	  
of	  autophagy	  machinery	  in	  the	  clearance	  of	  aggregation	  prone	  proteins.	  If	  protein	  
aggregates	  are	  indeed	  toxic	  to	  cells,	  then	  autophagy	  may	  represent	  an	  important	  cellular	  
mechanism	  for	  mitigating	  this	  toxicity.	  Such	  a	  model	  is	  supported	  by	  the	  human	  genetic	  
data	  from	  ALS	  patients,	  which	  implicates	  genes	  encoding	  aggregation	  prone	  proteins	  along	  
with	  autophagy	  components	  as	  causative	  factors	  in	  disease	  pathogenesis.	  Thus,	  ALS-­‐
causing	  mutations	  may	  alter	  neuronal	  proteostasis	  –	  either	  by	  promoting	  the	  formation	  of	  
protein	  aggregates	  or	  by	  impeding	  their	  degradation.	  	  
	  
Nucleocytoplasmic	  transport	  
	   Research	  into	  the	  C9orf72	  hexanucleotide	  repeat	  expansion	  has	  revealed	  a	  role	  for	  
nucleocytoplasmic	  transport	  in	  ALS.	  Expression	  of	  the	  repeat	  expansion	  in	  Drosophila	  is	  
sufficient	  to	  cause	  a	  degenerative	  phenotype,	  and	  this	  has	  made	  it	  possible	  to	  screen	  for	  
genetic	  modifiers.	  Recently,	  two	  independent	  screens	  have	  revealed	  numerous	  genetic	  
modifiers	  that	  encode	  proteins	  involved	  in	  nucleocytoplasmic	  transport	  (Freibaum,	  Lu	  et	  
al.	  2015,	  Zhang,	  Donnelly	  et	  al.	  2015).	  A	  parallel	  screen	  in	  yeast	  expressing	  toxic	  dipeptide	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repeat	  proteins	  predicted	  to	  arise	  from	  RAN	  translation	  has	  also	  identified	  genes	  in	  this	  
pathway	  (Jovicic,	  Mertens	  et	  al.	  2015).	  Though	  it	  is	  not	  clear	  whether	  defects	  in	  
nucleocytoplasmic	  transport	  are	  mediated	  by	  the	  repeat-­‐containing	  RNA	  or	  the	  dipeptide	  
repeat	  proteins,	  it	  does	  appear	  that	  they	  are	  a	  pervasive	  feature	  of	  the	  disease	  since	  
markers	  for	  the	  nuclear	  pore	  are	  disrupted	  in	  post-­‐mortem	  tissue	  from	  sALS	  patients	  
(Kinoshita,	  Ito	  et	  al.	  2009).	  
	   RNABPs	  such	  as	  FUS	  and	  TDP-­‐43	  rely	  on	  nucleocytoplasmic	  transport	  for	  their	  
normal	  function.	  Accordingly,	  the	  Drosophila	  homolog	  of	  TDP-­‐43	  was	  mislocalized	  to	  the	  
cytoplasm	  in	  some	  cells	  expressing	  the	  C9orf72	  hexanucleotide	  repeat	  expansion.	  Similar	  
mislocalization	  was	  seen	  in	  neurons	  differentiated	  from	  patient-­‐derived	  induced	  
pluripotent	  stem	  cells	  (iPSCs)	  harboring	  the	  repeats,	  and	  antisense	  knockdown	  of	  the	  
repeat-­‐containing	  RNA	  was	  sufficient	  to	  restore	  nuclear	  localization	  (Zhang,	  Donnelly	  et	  al.	  
2015).	  Thus,	  defects	  in	  nucleocytoplasmic	  transport	  may	  hinder	  the	  nuclear	  import	  of	  
RNABPs	  such	  as	  TDP-­‐43	  and	  contribute	  to	  their	  cytoplasmic	  aggregation.	  
	  
RNA	  metabolism	  
	   As	  discussed	  above,	  aggregation	  of	  TDP-­‐43	  may	  impair	  its	  normal	  nuclear	  functions.	  
Furthermore,	  the	  identification	  of	  mutations	  in	  other	  RNABPs	  such	  as	  FUS	  and	  
HNRNPA1/A2B1	  have	  suggested	  that	  disruption	  of	  RNA	  processing	  may	  be	  a	  common	  
feature	  of	  ALS.	  The	  advent	  of	  high-­‐throughput	  sequencing	  of	  RNA	  isolated	  by	  crosslinking	  
immunoprecipitation	  (HITS-­‐CLIP)	  has	  made	  possible	  the	  unbiased	  identification	  of	  RNA	  
species	  directly	  bound	  by	  RNABPs	  (Licatalosi,	  Mele	  et	  al.	  2008).	  An	  initial	  study	  of	  TDP-­‐43	  
targets	  in	  the	  mouse	  brain	  revealed	  preferential	  binding	  to	  genes	  with	  long	  introns,	  which	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are	  particularly	  enriched	  among	  neuronal	  genes.	  Knockdown	  of	  TDP-­‐43	  was	  found	  to	  cause	  
decreased	  RNA	  levels	  of	  these	  genes	  (Polymenidou,	  Lagier-­‐Tourenne	  et	  al.	  2011).	  	  
	   A	  recent	  study	  has	  revealed	  a	  potential	  mechanism	  for	  this	  downregulation	  (Ling,	  
Pletnikova	  et	  al.	  2015).	  Genetic	  deletion	  of	  TDP-­‐43	  in	  stem	  cells	  was	  found	  to	  cause	  
derepression	  of	  nonconserved	  cryptic	  exons.	  These	  cryptic	  exons	  introduced	  premature	  
stop	  codons,	  leading	  to	  nonsense	  mediated	  decay	  and	  downregulation	  of	  specific	  
transcripts.	  Some	  genes	  that	  were	  affected	  by	  cryptic	  exons	  function	  in	  ALS-­‐relevant	  
pathways.	  These	  included,	  RANBP1,	  which	  is	  involved	  in	  nucleocytoplasmic	  transport,	  and	  
Atg4B,	  an	  important	  autophagy	  gene	  (Ling,	  Pletnikova	  et	  al.	  2015).	  This	  data	  must	  be	  
interpreted	  with	  caution,	  since	  the	  activation	  of	  cryptic	  exons	  may	  be	  an	  artifact	  of	  TDP-­‐43	  
deletion	  that	  is	  not	  relevant	  for	  human	  ALS.	  Moreover,	  it	  is	  not	  clear	  whether	  TDP-­‐43	  
directly	  controls	  splicing	  or	  whether	  it	  acts	  indirectly	  through	  its	  effects	  on	  other	  RNABPs.	  
Nonetheless,	  an	  independent	  study	  found	  that	  TDP-­‐43	  also	  regulates	  the	  level	  of	  another	  
critical	  autophagy	  gene,	  Atg7	  (Bose,	  Huang	  et	  al.	  2011).	  Thus,	  initial	  aggregation	  of	  TDP-­‐43	  
in	  the	  cytoplasm	  might	  lead	  to	  nuclear	  loss-­‐of-­‐function,	  which	  could	  then	  exacerbate	  
cytoplasmic	  aggregation	  in	  a	  feed-­‐forward	  fashion	  through	  downregulation	  of	  genes	  
involved	  in	  autophagy-­‐mediated	  degradation	  (Ling,	  Pletnikova	  et	  al.	  2015).	  While	  this	  is	  an	  
appealing	  model,	  it	  is	  highly	  speculative	  and	  requires	  further	  testing.	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1.3	  The	  autophagy	  pathway	  
Core	  Autophagy	  Machinery	  
Autophagy,	  which	  literally	  means	  self-­‐eating,	  is	  a	  process	  through	  which	  cellular	  
contents	  can	  be	  delivered	  to	  the	  lysosome	  for	  degradation.	  This	  delivery	  can	  occur	  through	  
three	  distinct	  routes	  (Figure	  1.3).	  In	  chaperone	  mediated	  autophagy	  (CMA)	  a	  chaperone	  
such	  as	  Hsc70	  recognizes	  a	  specific	  peptide	  sequence	  in	  substrate	  proteins	  and	  facilitates	  
their	  direct	  translocation	  across	  the	  lysosomal	  membrane.	  In	  microautophagy,	  the	  
lysosomal	  membrane	  invaginates	  to	  engulf	  substrates	  that	  are	  destined	  for	  degradation.	  
While	  these	  two	  mechanisms	  likely	  play	  important	  roles	  in	  the	  degradation	  of	  specific	  
substrates,	  it	  is	  the	  third	  form	  of	  autophagy,	  macroautophagy,	  that	  is	  thought	  to	  be	  the	  
primary	  mechanism	  for	  lysosomal	  delivery	  of	  a	  wide	  variety	  of	  cellular	  substrates.	  In	  this	  
form	  of	  autophagy,	  substrates	  are	  enclosed	  by	  a	  double	  membrane	  autophagosome	  that	  
subsequently	  fuses	  with	  the	  lysosome.	  Macroautophagy,	  henceforth	  autophagy,	  will	  be	  the	  
focus	  of	  the	  work	  presented	  here.	  
	   Seminal	  genetic	  studies	  in	  yeast	  identified	  a	  family	  of	  35	  autophagy-­‐related	  proteins	  
(Atg1-­‐35),	  many	  of	  which	  are	  essential	  for	  autophagosome	  formation.	  Subsequent	  research	  
has	  identified	  homologs	  for	  many	  of	  these	  proteins	  in	  mammals	  and	  clarified	  how	  they	  
interact	  with	  other	  key	  proteins	  to	  form	  discrete	  modules	  (Figure	  1.4).	  
	   One	  of	  the	  most	  upstream	  factors	  in	  the	  autophagy	  pathway,	  and	  the	  only	  kinase	  
among	  the	  Atg	  genes,	  is	  Atg1	  in	  yeast	  or	  ULK1	  in	  mammals.	  In	  mammals,	  ULK1	  forms	  a	  
complex	  with	  Atg13,	  FIP200	  and	  Atg101	  and	  translocates	  to	  sites	  of	  autophagosome	  
formation	  upon	  autophagy	  induction.	  A	  key	  regulator	  of	  ULK1	  activity	  is	  the	  mammalian	  
target	  of	  rapamycin	  (mTOR),	  a	  kinase	  that	  integrates	  information	  about	  nutrient	  conditions	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and	  growth	  factors	  to	  control	  anabolic	  and	  catabolic	  programs	  within	  the	  cell.	  	  As	  part	  of	  
the	  mTORC1	  complex,	  mTOR	  inhibits	  autophagy	  induction	  by	  phosphorylating	  ULK1	  and	  
Atg13	  under	  nutrient-­‐rich	  conditions.	  Rapamycin	  inhibits	  mTOR	  and	  is	  the	  most	  widely	  
used	  drug	  for	  upregulating	  the	  autophagy	  pathway	  (Mizushima,	  Yoshimori	  et	  al.	  2011).	  	  
	   Upon	  activation	  by	  stimuli	  such	  as	  starvation,	  ULK1	  phosphorylates	  Beclin-­‐1	  (Atg6	  
in	  yeast)	  (Russell,	  Tian	  et	  al.	  2013).	  Beclin-­‐1	  is	  part	  of	  a	  larger	  complex	  responsible	  for	  
generating	  phosphatidylinositol	  3-­‐phosphate	  (PI3P),	  an	  essential	  lipid	  for	  autophagosome	  
formation.	  The	  other	  components	  of	  this	  complex	  include	  Atg14L	  and	  the	  PI3-­‐kinase	  
hVps34.	  Upon	  activation	  by	  ULK1,	  this	  complex	  localizes	  to	  the	  omegasome,	  a	  cup-­‐shaped	  
specialization	  of	  the	  endoplasmic	  reticulum	  that	  gives	  rise	  to	  the	  isolation	  membrane.	  
Because	  PI3P	  is	  necessary	  for	  autophagosome	  formation,	  autophagy	  can	  be	  inhibited	  by	  the	  
activity	  of	  PI3	  phosphastases	  or	  by	  pharmacological	  inhibition	  of	  Vps34	  by	  drugs	  such	  as	  3-­‐
methyladenine	  (3-­‐MA)	  (Mizushima,	  Yoshimori	  et	  al.	  2011).	  
	   The	  presence	  of	  PI3P	  recruits	  downstream	  effectors	  such	  as	  the	  Atg2-­‐Atg18	  
complex	  in	  yeast.	  Mammals	  possess	  four	  Atg18	  homologs	  called	  WD-­‐repeat	  protein	  
interacting	  with	  phosphoinositides	  (WIPI1-­‐4).	  These	  proteins	  are	  involved	  in	  the	  formation	  
of	  the	  isolation	  membrane	  at	  the	  omegasome.	  Depletion	  of	  WIPI2	  leads	  to	  accumulation	  of	  
omegasomes,	  suggesting	  that	  WIPI-­‐containing	  complexes	  are	  critical	  for	  the	  transition	  from	  
omegasome	  to	  mature	  autophagosome	  (Polson,	  de	  Lartigue	  et	  al.	  2010).	  	  
	   In	  addition	  to	  activating	  the	  PI3K	  complex	  and	  thereby	  recruiting	  PI3P	  effectors,	  
yeast	  Atg1	  also	  phosphorylates	  the	  transmembrane	  protein	  Atg9	  (Atg9L	  in	  mammals).	  
Vesicles	  containing	  Atg9	  are	  thought	  to	  contribute	  additional	  factors	  necessary	  for	  the	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formation	  of	  the	  isolation	  membrane.	  Phosphorylation	  of	  Atg9	  by	  Atg1	  is	  also	  involved	  in	  
recruiting	  Atg8	  to	  the	  isolation	  membrane	  (Papinski,	  Schuschnig	  et	  al.	  2014).	  	  
	   Atg8	  is	  a	  small	  ubiquitin-­‐like	  protein	  with	  six	  mammalian	  homologues:	  LC3A,	  LC3B,	  
LC3C,	  GABARAP,	  GABARAPL1	  and	  GABARAPL2/GATE-­‐16.	  In	  order	  to	  function	  in	  
autophagy,	  Atg8	  must	  be	  sequentially	  processed	  by	  a	  number	  of	  additional	  Atg	  proteins	  
leading	  to	  its	  eventual	  conjugation	  to	  a	  lipid	  called	  phosphatidylethanolamine	  (PE).	  Atg4	  
cleaves	  Atg8	  to	  expose	  a	  C-­‐terminal	  glycine,	  which	  leads	  to	  its	  activation	  by	  the	  E1-­‐like	  
activity	  of	  Atg7	  and	  the	  E2-­‐like	  activity	  of	  Atg3.	  Finally,	  a	  complex	  composed	  of	  Atg12,	  Atg5	  
and	  Atg16	  acts	  as	  an	  E3-­‐ligase	  to	  transfer	  Atg8	  from	  Atg3	  to	  PE.	  Functionally,	  Atg8	  tethers	  
membranes	  to	  one	  another	  and	  facilitate	  membrane	  fusion	  events	  that	  may	  play	  a	  role	  in	  
expansion	  of	  the	  isolation	  membrane	  and	  its	  eventual	  closure.	  Consistent	  with	  this	  theory,	  
levels	  of	  Atg8	  correlate	  with	  the	  size	  of	  autophagosomes	  and	  blocking	  Atg8	  lipidation	  
prevents	  autophagosome	  closure.	  Because	  Atg8	  and	  its	  mammalian	  homologs	  persist	  on	  
the	  mature	  autophagosome	  membrane,	  they	  are	  widely	  used	  markers	  for	  the	  autophagy	  
pathway	  (Mizushima,	  Yoshimori	  et	  al.	  2011).	  
	   The	  complex	  of	  Atg12,	  Atg5	  and	  Atg16,	  which	  performs	  the	  final	  conjugation	  of	  Atg8	  
to	  PE,	  is	  itself	  the	  product	  of	  ubiquitin-­‐like	  conjugation	  reaction.	  While	  Atg16	  is	  merely	  
associated	  with	  the	  other	  two	  proteins,	  Atg12	  is	  covalently	  attached	  to	  Atg5	  through	  the	  
sequential	  E1-­‐like	  activity	  of	  Atg7	  and	  E2-­‐like	  activity	  of	  Atg10.	  Because	  it	  is	  required	  for	  
conjugation	  of	  Atg12	  to	  Atg5	  and	  Atg8	  to	  PE,	  Atg7	  is	  a	  critical	  enzyme	  for	  autophagosome	  
biogenesis	  (Mizushima,	  Yoshimori	  et	  al.	  2011).	  Although	  the	  complete	  loss	  of	  Atg7	  in	  mice	  
leads	  to	  postnatal	  lethality,	  many	  researchers	  use	  cell-­‐specific	  Atg7	  deletion	  to	  study	  the	  
effects	  of	  autophagy	  inhibition	  in	  vivo	  (Komatsu,	  Waguri	  et	  al.	  2005).	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Selective	  Autophagy	  
	   Autophagy	  likely	  evolved	  as	  general	  response	  to	  starvation,	  but	  it	  was	  subsequently	  
adapted	  for	  the	  degradation	  of	  specific	  substrates.	  In	  contrast	  to	  starvation-­‐induced	  
autophagy,	  selective	  autophagy	  occurs	  under	  nutrient-­‐rich	  conditions	  and	  only	  targets	  
specific	  substrates	  for	  degradation.	  Much	  of	  what	  we	  know	  about	  selective	  autophagy	  is	  
based	  on	  a	  biosynthetic	  pathway	  in	  yeast	  called	  cytoplasm	  to	  vacuole	  targeting	  (Cvt).	  
	   Ape1	  is	  a	  yeast	  aminopeptidase	  that	  is	  localized	  to	  the	  yeast	  vacuole,	  but	  it	  is	  
originally	  synthesized	  as	  a	  zymogen	  called	  prApe1	  that	  must	  be	  further	  cleaved	  by	  the	  
vacuolar	  protease	  pep4.	  Trafficking	  of	  prApe1	  to	  the	  vacuole	  relies	  on	  the	  autophagy	  
pathway.	  Aggregates	  of	  prApe1	  in	  the	  cytoplasm	  are	  recognized	  by	  Atg19	  and	  Atg34,	  which	  
act	  as	  selective	  autophagy	  receptors.	  These	  receptors	  also	  bind	  Atg11	  and	  Atg8,	  which	  in	  
turn	  recruit	  the	  machinery	  necessary	  for	  autophagosome	  formation.	  After	  engulfment	  
within	  a	  Cvt	  vesicle,	  prApe1	  may	  be	  delivered	  to	  the	  vacuole	  for	  the	  final	  processing	  steps	  
(Rogov,	  Dotsch	  et	  al.	  2014).	  
	   The	  first	  mammalian	  autophagy	  receptor	  to	  be	  discovered	  was	  SQSTM1/p62.	  
Previously	  characterized	  as	  a	  scaffold	  protein	  for	  NF-­‐kB	  signaling,	  it	  was	  subsequently	  
found	  to	  be	  involved	  in	  selective	  autophagy.	  The	  structure	  of	  p62	  reveals	  three	  domains	  
that	  are	  critical	  for	  its	  function	  as	  an	  autophagy	  receptor:	  1)	  an	  N-­‐terminal	  PB1	  domain	  that	  
mediates	  self-­‐oligomerization,	  2)	  an	  LC3	  interacting	  region	  (LIR)	  and	  3)	  a	  C-­‐terminal	  UBA	  
domain	  that	  preferentially	  binds	  Lys63	  poly-­‐ubiquitin	  chains.	  This	  architecture	  endows	  
p62	  with	  the	  ability	  bind	  ubiquitinated	  substrates	  and	  collect	  them	  into	  discrete	  aggregates	  
prior	  to	  recruiting	  LC3	  and	  associated	  autophagy	  machinery	  (Rogov,	  Dotsch	  et	  al.	  2014).	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When	  autophagy	  is	  inhibited	  by	  deletion	  of	  Atg7,	  aggregates	  containing	  p62	  and	  ubiquitin	  
accumulate.	  Importantly,	  loss	  of	  p62	  in	  Atg7-­‐deficient	  cells	  prevents	  the	  formation	  of	  
ubiquitinated	  aggregates,	  suggesting	  that	  p62	  is	  involved	  in	  aggregate	  formation	  in	  
addition	  to	  degradation	  (Komatsu,	  Waguri	  et	  al.	  2007).	  	  
	   Mammalian	  cells	  express	  a	  diverse	  repertoire	  of	  selective	  autophagy	  receptors	  	  
(Figure	  1.5).	  Though	  they	  differ	  in	  their	  affinity	  for	  specific	  substrates,	  they	  share	  core	  
structural	  features	  with	  p62,	  including	  a	  self-­‐association	  domain,	  an	  LC3-­‐interacting	  region,	  
and	  ubiquitin	  binding	  domains.	  Neighbor	  of	  BRCA1	  gene	  1	  (NBR1),	  which	  contains	  PB1,	  LIR	  
and	  UBA	  domains,	  is	  the	  most	  similar	  to	  p62.	  NBR1	  can	  interact	  with	  p62	  but	  its	  function	  is	  
not	  dependent	  on	  this	  association	  (Kirkin,	  Lamark	  et	  al.	  2009).	  Optineurin,	  discussed	  
earlier	  as	  an	  ALS-­‐causing	  gene	  when	  mutated,	  is	  similar	  to	  p62	  and	  NBR1	  but	  lacks	  a	  PB1	  
domain	  and	  instead	  uses	  a	  coiled	  coil	  domain	  for	  oligomerization.	  Optineurin	  has	  also	  been	  
characterized	  as	  an	  inhibitor	  of	  NFκB	  signaling	  (Zhu,	  Wu	  et	  al.	  2007).	  Nuclear	  dot	  protein	  
52	  kDa	  (NDP52)	  and	  Tax1	  Binding	  Protein	  1	  (TAX1BP1)	  are	  two	  additional	  selective	  
autophagy	  receptors	  that	  are	  highly	  homologous	  to	  each	  other	  (Rogov,	  Dotsch	  et	  al.	  2014).	  
The	  selective	  autophagy	  receptors	  described	  here	  function	  independently	  and	  in	  concert	  to	  
achieve	  lysosomal	  degradation	  of	  various	  substrates	  including	  mitochondria,	  intracellular	  
pathogens,	  endoplasmic	  reticulum,	  peroxisomes,	  and	  protein	  aggregates.	  	  
	   The	  selective	  degradation	  of	  defective	  mitochondria,	  or	  mitophagy,	  is	  mediated	  by	  
several	  autophagy	  receptors.	  A	  role	  for	  p62	  has	  been	  described,	  specifically	  with	  respect	  to	  
clustering	  of	  mitochondria	  prior	  to	  autophagosome	  engulfment	  (Narendra,	  Kane	  et	  al.	  
2010).	  However,	  a	  recent	  study	  utilizing	  CRISPR	  to	  combinatorially	  delete	  selective	  
autophagy	  receptors	  has	  revealed	  that	  optineurin	  and	  NDP52	  are	  the	  primary	  mediators	  of	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mitophagy	  (Lazarou,	  Sliter	  et	  al.	  2015).	  This	  study	  also	  clarified	  the	  roles	  of	  the	  kinase	  
PINK1	  the	  E3	  ubiquitin	  ligase	  PARKIN,	  two	  genes	  that	  have	  been	  implicated	  in	  familial	  
Parkinson’s	  Disease	  (PD).	  PINK1	  phosphorylates	  ubiquitin	  on	  defective	  mitochondria,	  and	  
this	  recruits	  optineurin	  and	  NDP52.	  Subsequent	  recruitment	  of	  PARKIN	  amplifies	  this	  
signal	  by	  adding	  more	  ubiquitin	  to	  the	  mitochondrial	  membrane,	  which	  can	  then	  be	  
phosphorylated	  by	  PINK1	  to	  recruit	  additional	  optineurin	  and	  NDP52	  (Lazarou,	  Sliter	  et	  al.	  
2015).	  In	  addition	  to	  autophagy	  receptors	  that	  bind	  mitochondria	  via	  phosphorylated	  
ubiquitin,	  the	  outer	  mitochondrial	  matrix	  harbors	  BNIP3	  and	  NIX,	  both	  of	  which	  contain	  
LIR	  motifs	  and	  play	  dedicated	  roles	  in	  mitophagy	  (Rogov,	  Dotsch	  et	  al.	  2014).	  
	   Mitochondria	  are	  not	  the	  only	  organelles	  that	  may	  be	  degraded	  via	  selective	  
autophagy.	  In	  addition	  to	  serving	  as	  a	  site	  of	  autophagosome	  biogenesis	  and	  a	  potential	  
source	  of	  autophagosome	  membrane,	  the	  ER	  can	  also	  undergo	  direct	  autophagic	  
degradation	  through	  a	  process	  called	  reticulophagy.	  A	  recent	  study	  revealed	  the	  existence	  
of	  an	  ER	  resident	  selective	  autophagy	  receptor	  (Khaminets,	  Heinrich	  et	  al.	  2015).	  The	  
reticulon-­‐homology-­‐domain-­‐containing	  protein	  FAM134B	  was	  found	  to	  interact	  with	  LC3	  
in	  a	  yeast	  two-­‐hybrid	  screen,	  and	  was	  subsequently	  shown	  to	  regulate	  ER	  abundance.	  Loss	  
of	  FAM134B	  promoted	  ER	  expansion,	  and	  this	  was	  especially	  pronounced	  in	  the	  periphery	  
of	  the	  cell.	  In	  contrast,	  overexpression	  of	  FAM134B	  led	  to	  ER	  fragmentation	  and	  
degradation	  in	  an	  Atg5-­‐dependent	  manner	  (Khaminets,	  Heinrich	  et	  al.	  2015).	  
	   Selective	  autophagy	  of	  intracellular	  pathogens,	  or	  xenophagy,	  is	  also	  mediated	  by	  
specific	  receptors.	  For	  instance,	  optineurin	  and	  NDP52	  are	  both	  required	  for	  autophagy-­‐
mediated	  degradation	  of	  Salmonella.	  Both	  of	  these	  autophagy	  receptors	  bind	  to	  ubiquitin	  
on	  the	  surface	  of	  Salmonella.	  NDP52	  also	  recruits	  the	  adaptor	  proteins	  Nap1	  and	  Sintbad,	  
	   25	  
which	  in	  turn	  recruit	  TBK1	  (Thurston,	  Ryzhakov	  et	  al.	  2009).	  TBK1	  phosphorylates	  
optineurin,	  which	  enhances	  its	  affinity	  for	  LC3	  and	  promotes	  autophagic	  clearance	  of	  
salmonella	  (Wild,	  Farhan	  et	  al.	  2011).	  	  Along	  with	  optineurin	  and	  NDP52,	  p62	  has	  also	  been	  
implicated	  xenophagy	  (Zheng,	  Shahnazari	  et	  al.	  2009).	  The	  same	  principles	  are	  likely	  
applicable	  to	  a	  wide	  variety	  of	  intracellular	  pathogens	  including	  Listeria	  and	  Shigella	  
(Rogov,	  Dotsch	  et	  al.	  2014).	  Thus,	  the	  autophagy	  pathway	  plays	  a	  key	  role	  in	  innate	  
immunity.	  
	   The	  accumulation	  of	  ubiquitinated	  protein	  aggregates	  is	  a	  common	  feature	  of	  many	  
neurodegenerative	  diseases.	  Because	  these	  are	  too	  large	  to	  be	  degraded	  by	  the	  proteasome,	  
autophagy	  may	  play	  a	  role	  in	  their	  clearance.	  Consistent	  with	  this	  hypothesis,	  selective	  
autophagy	  receptors	  are	  a	  common	  component	  of	  protein	  aggregates	  in	  a	  variety	  of	  
neurodegenerative	  diseases.	  In	  particular,	  both	  optineruin	  and	  p62	  have	  been	  found	  in	  PD-­‐
associated	  Lewy	  bodies,	  AD-­‐associated	  neurofibrillary	  tangles,	  HD-­‐associated	  
polyglutamine	  inclusions	  and	  ALS-­‐associated	  protein	  aggregates	  (Zatloukal,	  Stumptner	  et	  
al.	  2002,	  Nagaoka,	  Kim	  et	  al.	  2004,	  Mizuno,	  Amari	  et	  al.	  2006,	  Osawa,	  Mizuno	  et	  al.	  2011,	  
Schwab,	  Yu	  et	  al.	  2012).	  A	  functional	  role	  for	  selective	  autophagy	  in	  the	  clearance	  of	  these	  
aggregates	  has	  also	  been	  described.	  Reducing	  the	  level	  of	  p62	  interferes	  with	  autophagic	  
degradation	  of	  mutant	  SOD1	  and	  also	  makes	  cells	  more	  vulnerable	  to	  mutant	  huntingtin	  
(Bjorkoy,	  Lamark	  et	  al.	  2005,	  Gal,	  Strom	  et	  al.	  2009).	  	  Similarly,	  optineurin	  deficiency	  also	  
increases	  the	  aggregation	  these	  two	  disease-­‐associated	  proteins	  (Korac,	  Schaeffer	  et	  al.	  
2013).	  	  
	   Autophagy	  receptors	  are	  likely	  to	  play	  a	  key	  role	  in	  recruiting	  Atg8	  homologs	  to	  
protein	  aggregates,	  but	  complete	  engulfment	  by	  the	  autophagosome	  may	  require	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additional,	  local	  lipidation	  of	  Atg8	  homologs	  by	  the	  core	  autophagy	  machinery.	  The	  
autophagy-­‐linked	  FYVE	  protein	  (ALFY)	  accomplishes	  this	  by	  acting	  as	  a	  scaffold	  that	  
simultaneously	  binds	  p62-­‐positive	  protein	  aggregates	  and	  the	  Atg12-­‐Atg5-­‐Atg16L1	  
complex	  through	  a	  direct	  interaction	  with	  Atg5	  (Filimonenko,	  Isakson	  et	  al.	  2010).	  
Knockdown	  of	  ALFY	  impairs	  the	  autophagic	  degradation	  of	  HD-­‐associated	  polyglutamine	  
aggregates,	  but	  has	  no	  effect	  on	  starvation-­‐induced	  autophagy.	  Moreover,	  overexpression	  
of	  ALFY	  can	  alleviate	  the	  toxicity	  of	  these	  aggregates	  in	  vivo.	  Interestingly,	  ALFY	  is	  
expressed	  at	  the	  highest	  levels	  in	  the	  central	  nervous	  system,	  suggesting	  that	  post-­‐mitotic	  
neurons	  may	  be	  especially	  reliant	  on	  selective	  autophagy	  for	  adequate	  proteostasis	  
(Yamamoto	  and	  Simonsen	  2011).	  As	  we	  learn	  more	  about	  the	  molecular	  mechanisms	  of	  
aggrephagy,	  it	  seems	  likely	  that	  additional	  selective	  autophagy	  machinery	  will	  be	  revealed.	  
	  
Secretory	  autophagy	  
	   Classically,	  the	  autophagy	  pathway	  concludes	  when	  the	  autophagosome	  fuses	  with	  
the	  lysosome,	  leading	  to	  degradation	  of	  autophagosome	  contents	  (degradative	  autophagy).	  
However,	  the	  autophagy	  machinery	  may	  also	  be	  involved	  in	  the	  extracellular	  secretion	  of	  
specific	  substrates	  (secretory	  autophagy)	  (Ponpuak,	  Mandell	  et	  al.	  2015).	  The	  majority	  of	  
secreted	  proteins	  contain	  an	  N-­‐terminal	  signal	  peptide	  that	  destines	  them	  for	  transport	  
from	  the	  ER	  to	  Golgi	  followed	  by	  exocytosis.	  However,	  a	  subset	  of	  secreted	  proteins	  lack	  
this	  signal	  peptide	  and	  therefore	  rely	  on	  unconventional	  secretion	  mechanisms.	  The	  role	  of	  
autophagy	  in	  unconventional	  secretion	  was	  first	  identified	  in	  yeast.	  Upon	  starvation,	  yeast	  
secrete	  acetyl-­‐CoA	  binding	  protein	  Acb1.	  This	  process	  requires	  a	  number	  of	  Atg	  genes,	  the	  
Golgi-­‐resident	  protein	  Grh1,	  genes	  coding	  for	  the	  ESCRT	  complex	  involved	  in	  the	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biogenesis	  of	  multivesicular	  bodies	  (MVBs),	  as	  well	  as	  genes	  encoding	  SNARE	  proteins	  
(Duran,	  Anjard	  et	  al.	  2010).	  
	   Initial	  evidence	  for	  autophagy-­‐mediated	  unconventional	  secretion	  in	  mammalian	  
cells	  came	  from	  the	  observation	  that	  release	  of	  IL-­‐1β,	  which	  lacks	  a	  signal	  peptide,	  was	  
strongly	  upregulated	  by	  starvation	  (Dupont,	  Jiang	  et	  al.	  2011).	  Remarkably,	  this	  effect	  was	  
inhibited	  by	  depletion	  of	  the	  essential	  autophagy	  protein	  Atg5,	  as	  well	  as	  one	  of	  the	  
mammalian	  Grh1	  homologs	  (GRASP55).	  Furthermore,	  intracellular	  IL-­‐1β	  was	  found	  to	  
colocalize	  with	  LC3-­‐positive	  autophagic	  vacuoles	  prior	  to	  release.	  Importantly,	  similar	  
mechanisms	  were	  found	  to	  mediate	  unconventional	  secretion	  of	  other	  proteins	  such	  as	  IL-­‐
18	  and	  the	  alarmin	  HMGB1	  (Dupont,	  Jiang	  et	  al.	  2011).	  Thus,	  the	  autophagy	  machinery	  may	  
be	  common	  mechanism	  for	  the	  extracellular	  release	  of	  inflammatory	  mediators.	  
	   Recent	  work	  has	  also	  implicated	  secretory	  autophagy	  in	  the	  extracellular	  release	  of	  
proteins	  associated	  with	  neurodegeneration.	  Alpha-­‐synuclein	  undergoes	  extracellular	  
secretion	  and	  this	  is	  hypothesized	  to	  contribute	  to	  the	  stereotyped	  spread	  of	  the	  disease	  
pathology.	  A	  recent	  study	  determined	  that	  extracellular	  secretion	  from	  PC12	  cells	  could	  be	  
reduced	  by	  knockdown	  of	  Atg5	  or	  inhibition	  of	  PI3	  kinase	  activity	  by	  3-­‐MA	  (Ejlerskov,	  
Rasmussen	  et	  al.	  2013).	  Furthermore,	  secretion	  was	  dependent	  on	  Rab27a,	  which	  regulates	  
fusion	  of	  late	  endosomes	  with	  the	  plasma	  membrane.	  Interestingly,	  inhibition	  of	  
autophagosome-­‐lysosome	  fusion	  by	  Bafilomycin	  A1	  or	  HDAC6	  knockdown	  promoted	  
secretion.	  This	  data	  suggests	  that	  secretory	  autophagy	  may	  be	  upregulated	  upon	  
downstream	  inhibition	  of	  degradative	  autophagy.	  Manipulations	  that	  promoted	  secretion	  
also	  reduced	  cytotoxicity,	  suggesting	  that	  this	  could	  be	  a	  protective	  mechanism	  at	  the	  level	  
of	  individual	  cells	  (Ejlerskov,	  Rasmussen	  et	  al.	  2013).	  Nonetheless,	  the	  potentially	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deleterious	  consequences	  of	  secretory	  autophagy	  on	  the	  neighboring	  cellular	  milieu	  have	  
not	  been	  adequately	  explored.	  	  
	   Autophagy	  machinery	  has	  also	  been	  implicated	  in	  the	  extracellular	  secretion	  of	  
amyloid	  beta	  (Aβ),	  a	  pathological	  hallmark	  of	  AD.	  Transgenic	  mice	  overexpressing	  amyloid	  
precursor	  protein	  (APP)	  normally	  recapitulate	  this	  pathology.	  However,	  genetic	  disruption	  
Atg7	  in	  the	  neurons	  of	  these	  mice	  was	  found	  to	  reduce	  the	  formation	  of	  extracellular	  Aβ	  
plaques	  (Nilsson,	  Loganathan	  et	  al.	  2013).	  This	  was	  associated	  with	  a	  concomitant	  increase	  
in	  the	  intracellular	  accumulation	  of	  Aβ,	  consistent	  with	  reduced	  secretion.	  These	  results	  
were	  complemented	  by	  in	  vitro	  experiments	  showing	  that	  Aβ	  secretion	  could	  be	  modulated	  
by	  manipulations	  that	  affect	  the	  autophagy	  pathway	  (Nilsson,	  Loganathan	  et	  al.	  2013).	  
Thus,	  in	  vitro	  and	  in	  vivo	  data	  support	  a	  role	  for	  autophagy	  machinery	  in	  the	  extracellular	  
secretion	  of	  proteins	  associated	  with	  neurodegeneration.	  
	   The	  role	  of	  autophagy	  machinery	  in	  the	  secretion	  of	  ALS-­‐associated	  proteins	  has	  not	  
been	  explored,	  despite	  the	  fact	  that	  mutant	  SOD1	  has	  been	  shown	  to	  undergo	  extracellular	  
secretion	  (Basso,	  Pozzi	  et	  al.	  2013,	  Grad,	  Yerbury	  et	  al.	  2014).	  This	  secretion	  is	  thought	  to	  
depend	  on	  chromogranin	  proteins,	  which	  work	  together	  with	  Atg16L1	  in	  other	  contexts	  
(Urushitani,	  Sik	  et	  al.	  2006,	  Ishibashi,	  Uemura	  et	  al.	  2012).	  While	  the	  role	  of	  secretory	  
autophagy	  in	  ALS	  remains	  unclear,	  it	  may	  play	  an	  important	  role	  in	  the	  genetically	  
associated	  Paget’s	  disease	  of	  bone	  (PDB).	  In	  PDB,	  osteocleast	  activity	  is	  upregulated	  leading	  
to	  excessive	  bone	  remodeling.	  The	  process	  of	  bone	  resorption	  involves	  the	  fusion	  of	  
lysosomes	  with	  the	  plasma	  membrane,	  and	  this	  requires	  several	  autophagy	  proteins	  
including	  Atg7,	  Atg5,	  Atg4B	  and	  LC3	  (DeSelm,	  Miller	  et	  al.	  2011).	  Further	  research	  is	  
	   29	  
needed	  in	  order	  to	  elucidate	  whether	  genetic	  mutations	  that	  predispose	  patients	  to	  both	  
PDB	  and	  ALS	  alter	  the	  secretory	  autophagy	  pathway.	  	  
	  
Role	  of	  autophagy	  in	  neurons	  	  
Autophagy	  may	  play	  specialized	  roles	  in	  neurons.	  In	  one	  of	  the	  first	  attempts	  to	  
address	  this	  issue,	  Nestin-­‐Cre	  mice	  were	  crossed	  to	  Atg7	  conditional	  mice	  to	  achieve	  pan-­‐
neuronal	  autophagy	  inhibition	  (Komatsu,	  Waguri	  et	  al.	  2006).	  Though	  these	  mice	  were	  
viable,	  autophagy	  inhibition	  caused	  neuronal	  degeneration	  in	  the	  brain	  and	  overt	  
behavioral	  changes	  such	  as	  limb-­‐clasping.	  Autophagy	  inhibition	  also	  led	  to	  premature	  
death	  of	  these	  animals	  by	  28	  weeks	  of	  age.	  Thus,	  widespread	  inhibition	  of	  autophagy	  in	  the	  
CNS	  is	  not	  compatible	  with	  life	  (Komatsu,	  Waguri	  et	  al.	  2006).	  
More	  targeted	  manipulations	  have	  revealed	  that	  some	  neuronal	  subtypes	  can	  
survive	  in	  the	  absence	  of	  Atg7,	  and	  this	  has	  made	  it	  possible	  to	  investigate	  the	  role	  of	  basal	  
autophagy	  in	  neurons.	  Specifically,	  a	  number	  of	  studies	  have	  implicated	  autophagy	  in	  the	  
regulation	  of	  axons	  and	  presynaptic	  terminals.	  Eliminating	  Atg7	  from	  dopaminergic	  
neurons	  resulted	  in	  dramatic	  hypertrophy	  of	  presynaptic	  terminals,	  which	  was	  
accompanied	  by	  increased	  neurotransmitter	  release	  (Hernandez,	  Torres	  et	  al.	  2012,	  Inoue,	  
Rispoli	  et	  al.	  2013).	  When	  Atg7	  was	  deleted	  from	  Purkinje	  neurons,	  axon	  terminals	  became	  
swollen	  and	  eventually	  degenerated	  altogether	  (Komatsu,	  Wang	  et	  al.	  2007).	  These	  results	  
suggest	  that	  autophagy	  may	  serve	  as	  an	  important	  mechanism	  for	  recycling	  presynaptic	  
components.	  The	  mechanistic	  basis	  for	  such	  recycling	  was	  revealed	  by	  live	  imaging	  of	  
neurons	  expressing	  LC3	  fused	  to	  green	  fluorescent	  protein	  (GFP-­‐LC3).	  In	  these	  neurons,	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autophagosomes	  formed	  at	  distal	  regions	  of	  the	  axon	  and	  were	  retrogradely	  trafficked	  back	  
to	  the	  cell	  soma	  for	  degradation	  (Figure	  1.6)	  (Maday,	  Wallace	  et	  al.	  2012).	  	  
In	  addition	  to	  maintaining	  mature	  synapses,	  autophagy	  may	  dynamically	  regulate	  
synaptic	  structure	  during	  development	  and	  disease	  states.	  A	  recent	  study	  revealed	  that	  
autophagy	  participates	  in	  pruning	  of	  synapses	  during	  the	  maturation	  of	  cortical	  circuitry	  
(Tang,	  Gudsnuk	  et	  al.	  2014).	  In	  autistic	  patients,	  spine	  density	  is	  elevated	  and	  this	  may	  be	  
secondary	  to	  defects	  in	  autophagy.	  Consistent	  with	  this	  hypothesis,	  activating	  autophagy	  by	  
rapamycin	  administration	  was	  able	  to	  restore	  normal	  synaptic	  pruning	  and	  behavior	  in	  a	  
mouse	  model	  of	  autism	  (Tang,	  Gudsnuk	  et	  al.	  2014).	  
	   The	  aforementioned	  studies	  have	  revealed	  an	  unexpected	  role	  for	  autophagy	  in	  the	  
regulation	  of	  synaptic	  structure	  and	  function.	  Do	  these	  principles	  apply	  to	  other	  neuronal	  
subtypes?	  Because	  the	  autophagy	  pathway	  has	  been	  implicated	  in	  ALS,	  the	  role	  of	  
autophagy	  in	  motor	  neurons	  is	  of	  special	  interest.	  In	  Drosophila,	  autophagy	  is	  a	  potent	  
regulator	  of	  neuromuscular	  junction	  (NMJ)	  morphology	  (Shen	  and	  Ganetzky	  2009),	  but	  it	  is	  
not	  clear	  whether	  similar	  mechanisms	  operate	  at	  the	  mammalian	  NMJ.	  In	  mice,	  selective	  
deletion	  of	  Atg7	  in	  motor	  neurons	  does	  not	  lead	  to	  overt	  neurodegeneration,	  suggesting	  
that	  autophagy	  in	  not	  required	  for	  the	  survival	  of	  these	  cells	  (Tashiro,	  Urushitani	  et	  al.	  
2012).	  However,	  the	  role	  of	  motor	  neuron	  autophagy	  at	  the	  mammalian	  neuromuscular	  
junction	  has	  not	  been	  addressed	  to	  date.	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1.4	  Role	  of	  autophagy	  in	  ALS	  patients	  and	  model	  systems	  
Evidence	  for	  autophagy	  activation	  in	  ALS	  patients	  
	   While	  the	  genetic	  evidence	  for	  a	  role	  of	  autophagy	  in	  ALS	  pathogenesis	  is	  
compelling,	  immunohistochemical	  and	  ultrastructural	  studies	  specifically	  examining	  the	  
autophagy	  pathway	  in	  ALS	  patients	  are	  lacking.	  Nonetheless,	  one	  relatively	  thorough	  
evaluation	  of	  post-­‐mortem	  sALS	  spinal	  cords	  has	  revealed	  significant	  upregulation	  of	  the	  
autophagy	  pathway	  (Sasaki	  2011).	  Neurons	  in	  the	  anterior	  horn	  of	  control	  subjects	  did	  not	  
display	  pronounced	  staining	  for	  p62	  or	  LC3.	  In	  contrast,	  neurons	  from	  ALS	  patients	  
contained	  round	  bodies	  and	  skein	  inclusions	  that	  were	  immunoreactive	  for	  p62.	  While	  a	  
subset	  of	  round	  bodies	  exhibited	  LC3	  immunoreactivity,	  this	  was	  never	  observed	  for	  skein	  
inclusions.	  Bunina	  bodies	  were	  negative	  for	  both	  p62	  and	  LC3.	  Ultrastructural	  examination	  
of	  motor	  neurons	  by	  electron	  microscopy	  revealed	  little	  evidence	  of	  autophagy	  in	  control	  
patients,	  but	  ALS	  patients	  exhibited	  autophagosomes	  in	  motor	  neuron	  somata.	  
Autophagosome-­‐like	  structures	  were	  more	  common	  in	  patients	  with	  short	  clinical	  courses,	  
suggesting	  that	  upregulation	  of	  autophagy	  may	  occur	  early	  in	  disease	  progression.	  
Additionally,	  autophagosomes	  were	  identified	  in	  association	  with	  inclusion	  bodies.	  Round	  
bodies	  usually	  colocalized	  with	  autophagosomes,	  and	  some	  smaller	  skein	  inclusions	  were	  
observed	  to	  be	  membrane	  bound	  as	  well.	  Collectively,	  these	  data	  suggest	  that	  the	  
autophagy	  pathway	  is	  upregulated	  in	  ALS	  patient	  motor	  neurons	  and	  likely	  participates	  in	  
the	  degradation	  of	  a	  subset	  of	  disease-­‐associated	  inclusion	  bodies	  (Sasaki	  2011).	  
A	  recent	  study	  explored	  the	  phosphorylation	  of	  p62	  in	  neurodegenerative	  diseases	  
and	  found	  that	  phosphorylation	  was	  particularly	  pronounced	  in	  ALS	  patients	  (Kurosawa,	  
Matsumoto	  et	  al.	  2015).	  This	  phosphorylation	  is	  especially	  interesting	  given	  the	  fact	  that	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TBK1,	  a	  recently	  discovered	  ALS	  gene,	  encodes	  a	  kinase	  that	  directly	  phosphorylates	  p62	  
(Pilli,	  Arko-­‐Mensah	  et	  al.	  2012).	  Consistent	  with	  previous	  neuropathological	  findings,	  a	  
subset	  of	  aggregates	  that	  stained	  positive	  for	  phosphorylated	  p62	  also	  colocalized	  with	  
LC3.	  Interestingly,	  phosphorylated	  p62	  also	  colocalized	  with	  skein-­‐like	  TDP-­‐43	  inclusions	  
(Kurosawa,	  Matsumoto	  et	  al.	  2015).	  This	  suggests	  that	  aggregated	  TDP-­‐43	  is	  recognized	  by	  
the	  selective	  autophagy	  machinery,	  though	  it	  may	  not	  be	  successfully	  degraded.	  	  
	  
Role	  of	  autophagy	  in	  cell-­‐based	  ALS	  model	  systems	  
Autophagy	  has	  also	  been	  implicated	  in	  ALS	  model	  systems	  based	  on	  the	  expression	  
of	  mutant	  SOD1.	  In	  vitro	  studies	  suggest	  that	  aggregates	  composed	  of	  mutant	  SOD1	  are	  
substrates	  for	  autophagic	  degradation.	  Treating	  cells	  with	  the	  PI3K	  inhibitor	  3-­‐MA	  or	  
siRNA-­‐mediated	  knockdown	  of	  Beclin-­‐1	  and	  Atg7	  increases	  the	  half-­‐life	  of	  mutant	  SOD1	  
significantly	  (Kabuta,	  Suzuki	  et	  al.	  2006).	  This	  degradation	  appears	  to	  rely	  on	  selective	  
autophagy,	  since	  p62	  specifically	  binds	  to	  mutant	  but	  not	  wild-­‐type	  SOD1	  both	  in	  vitro	  and	  
in	  vivo	  (Gal,	  Strom	  et	  al.	  2007).	  Consistent	  with	  a	  functional	  role	  in	  aggrephagy,	  depletion	  of	  
p62	  reduces	  the	  amount	  of	  SOD1	  that	  reaches	  the	  lysosome	  (Gal,	  Strom	  et	  al.	  2009).	  
Nonetheless,	  autophagy	  is	  not	  the	  only	  cellular	  mechanism	  for	  degrading	  mutant	  SOD1,	  
since	  the	  proteasome	  has	  also	  been	  shown	  to	  participate	  (Kabuta,	  Suzuki	  et	  al.	  2006).	  
Cell-­‐based	  models	  have	  also	  implicated	  autophagy	  in	  the	  degradation	  of	  TDP-­‐43.	  In	  
one	  of	  the	  first	  such	  studies,	  it	  was	  demonstrated	  that	  TDP-­‐43	  C-­‐terminal	  fragments	  form	  
aggregates	  that	  recruit	  p62	  and	  LC3.	  Treatment	  with	  3-­‐MA	  or	  knockdown	  of	  Atg5	  increased	  
the	  number	  of	  cells	  with	  aggregates,	  though	  proteasome	  inhibition	  had	  a	  similar	  albeit	  
milder	  effect.	  Interestingly,	  overexpression	  of	  p62	  was	  sufficient	  to	  reduce	  the	  amount	  of	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aggregation,	  and	  this	  reduction	  was	  mediated	  by	  both	  autophagy	  and	  the	  proteasome	  
(Brady,	  Meng	  et	  al.	  2011).	  A	  more	  recent	  study	  clarified	  the	  relative	  contributions	  of	  these	  
degradative	  pathways.	  In	  this	  study,	  proteasome	  inhibition	  was	  found	  to	  induce	  
aggregation	  of	  full-­‐length	  TDP-­‐43.	  Although	  inhibition	  of	  the	  autophagy	  pathway	  alone	  was	  
not	  sufficient	  to	  recapitulate	  this	  phenotype,	  it	  did	  impair	  aggregate	  clearance	  after	  
proteasome	  inhibition.	  Thus,	  the	  proteasome	  may	  degrade	  soluble	  TDP-­‐43,	  whereas	  
autophagy	  is	  required	  for	  degradation	  of	  larger	  aggregates	  (Scotter,	  Vance	  et	  al.	  2014).	  
Although	  these	  studies	  were	  conducted	  in	  immortalized	  cell	  lines,	  autophagy	  induction	  was	  
also	  found	  to	  reduce	  TDP-­‐43	  aggregation	  and	  toxicity	  in	  primary	  mouse	  neurons	  as	  well	  as	  
human	  stem	  cell	  derived	  neurons	  and	  astrocytes	  (Barmada,	  Serio	  et	  al.	  2014).	  
Though	  autophagy	  may	  be	  protective	  in	  many	  contexts,	  it	  is	  possible	  that	  
autophagosome	  formation	  could	  be	  detrimental	  if	  downstream	  autophagic	  flux	  is	  impaired.	  
This	  appears	  to	  be	  the	  case	  in	  a	  cell	  culture	  model	  of	  FTD	  based	  on	  expression	  of	  mutant	  
CHMP2B,	  which	  prevents	  MVB	  formation.	  Neurons	  expressing	  mutant	  CHMP2B	  
accumulated	  autophagosomes,	  likely	  because	  MVBs	  are	  involved	  in	  late	  steps	  of	  
autophagosome	  maturation	  and	  cargo	  degradation	  (Filimonenko,	  Stuffers	  et	  al.	  2007,	  Lee,	  
Beigneux	  et	  al.	  2007).	  	  These	  autophagy	  abnormalities	  were	  accompanied	  by	  neuronal	  cell	  
death.	  Strikingly,	  treatment	  of	  these	  cells	  with	  PI3K	  inhibitors	  3-­‐MA	  and	  wortmannin	  
reduced	  this	  cell	  death	  phenotype.	  Knockdown	  of	  Atg7	  or	  knockout	  of	  Atg5	  was	  also	  
sufficient	  to	  confer	  protection	  against	  mutant	  CHMP2B	  (Lee	  and	  Gao	  2009).	  These	  data	  
indicate	  that	  inhibiting	  autophagosome	  biogenesis	  might	  be	  neuroprotective	  when	  
autophagic	  flux	  is	  compromised.	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Evidence	  for	  autophagy	  dysregulation	  in	  SOD1	  mouse	  models	  
	  	   In	  vitro	  models	  of	  ALS	  are	  invaluable	  for	  studying	  autophagy	  in	  a	  controlled	  setting,	  
but	  it	  they	  may	  not	  fully	  recapitulate	  the	  disease	  mechanisms	  that	  occur	  in	  vivo.	  	  For	  
instance,	  the	  timescale	  of	  cell-­‐based	  experiments	  is	  usually	  a	  few	  weeks	  at	  most,	  whereas	  
human	  patients	  usually	  develop	  ALS	  over	  the	  course	  of	  decades.	  Additionally,	  cell	  based	  
models	  typically	  model	  one	  or	  at	  most	  two	  different	  cell	  types,	  whereas	  animal	  models	  
preserve	  the	  cellular	  complexity	  and	  heterogeneity	  of	  the	  central	  nervous	  system.	  
Autophagy	  activation	  in	  one	  cell	  type	  might	  have	  non-­‐cell	  autonomous	  effects	  that	  cannot	  
be	  accurately	  modeled	  in	  vitro.	  For	  these	  reasons,	  it	  is	  crucial	  to	  understand	  the	  role	  of	  
autophagy	  in	  animal	  models	  of	  ALS.	  Mice	  expressing	  mutant	  SOD1	  are	  the	  most	  widely	  
used	  ALS	  mouse	  model	  and	  they	  have	  yielded	  valuable	  insights	  into	  the	  role	  of	  autophagy	  
in	  disease	  pathogenesis.	  
	   Several	  groups	  have	  suggested	  that	  autophagy	  is	  upregulated	  in	  the	  spinal	  cord	  of	  
SOD1G93A	  mice.	  Levels	  of	  LC3-­‐II	  were	  found	  to	  be	  increased	  at	  disease	  endstage,	  suggesting	  
increased	  number	  of	  autophagosomes	  (Morimoto,	  Nagai	  et	  al.	  2007,	  Li,	  Zhang	  et	  al.	  2008).	  
This	  conclusion	  was	  supported	  by	  immunofluorescence	  experiments	  demonstrating	  
punctate	  neuronal	  LC3	  staining.	  Analysis	  of	  SOD1G93A	  spinal	  cords	  by	  electron	  microscopy	  
analyses	  also	  revealed	  ultrastructural	  evidence	  for	  autophagosomes	  late	  in	  disease	  
progression	  (Li,	  Zhang	  et	  al.	  2008).	  In	  a	  follow	  up	  study,	  GFP-­‐LC3	  transgenic	  mice	  were	  
crossed	  to	  the	  SOD1G93A	  mouse	  model.	  The	  authors	  observed	  a	  global	  increase	  in	  spinal	  
cord	  fluorescence	  that	  they	  attribute	  to	  autophagosome	  accumulation	  in	  motor	  neurons	  
(Tian,	  Morimoto	  et	  al.	  2011).	  However,	  like	  many	  studies	  purporting	  to	  show	  increased	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autophagy	  in	  the	  SOD1G93A	  mouse	  model,	  it	  is	  not	  entirely	  clear	  which	  cell	  types	  are	  
involved.	  
	   The	  accumulation	  of	  autophagosomes	  in	  the	  SOD1G93A	  mice	  could	  be	  due	  to	  
increased	  formation	  of	  autophagosomes	  or	  impaired	  degradation.	  Phosphorylation	  of	  
mTOR	  at	  Serine	  2448	  was	  found	  to	  be	  reduced	  in	  motor	  neurons	  from	  SOD1G93A	  mice,	  
suggesting	  mTOR	  inactivation	  (Morimoto,	  Nagai	  et	  al.	  2007).	  This	  would	  be	  predicted	  to	  
induce	  autophagosome	  biogenesis	  through	  disinhibition	  of	  the	  ULK1	  complex.	  Consistent	  
with	  this	  possibility,	  motor	  neurons	  from	  SOD1G85R	  mice	  were	  found	  to	  exhibit	  decreased	  
levels	  of	  ULK1	  phosphorylation	  at	  Serine	  757	  (Bandyopadhyay,	  Nagy	  et	  al.	  2014).	  This	  
phosphorylation	  state	  promotes	  autophagy	  and	  may	  help	  explain	  the	  accumulation	  of	  
autophagosomes	  in	  mice	  expressing	  mutant	  SOD1.	  	  
Alternatively,	  autophagosome	  accumulation	  might	  be	  due	  to	  impaired	  
autophagosome-­‐lysosome	  fusion	  or	  other	  defects	  in	  lysosomal	  function.	  A	  recent	  study	  
investigated	  this	  possibility	  by	  monitoring	  the	  abundance	  of	  lysosomal	  marker	  Cathepsin	  D	  
(Xie,	  Zhou	  et	  al.	  2015).	  Marked	  reduction	  in	  Cathepsin	  D	  was	  observed	  in	  motor	  neurons	  
during	  disease	  progression,	  and	  cells	  exhibiting	  this	  deficiency	  were	  more	  likely	  to	  
accumulate	  p62-­‐positive	  autophagosomes	  containing	  damaged	  mitochondria.	  Lysosome	  
biogenesis	  depends	  on	  late	  endosomes,	  and	  the	  authors	  found	  that	  retrograde	  trafficking	  of	  
endosomes	  was	  impaired	  by	  mutant	  SOD1.	  Overexpression	  Snapin,	  an	  adaptor	  that	  links	  
late	  endosomes	  to	  dynein	  motors,	  was	  able	  to	  rescue	  retrograde	  transport	  of	  late	  
endosomes	  in	  vitro.	  	  Likewise,	  adenovirus-­‐mediated	  overexpression	  of	  snapin	  in	  SOD1G93A	  
mice	  enhanced	  mitophagy	  and	  slightly	  extended	  survival	  (Xie,	  Zhou	  et	  al.	  2015).	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Despite	  these	  studies,	  the	  exact	  nature	  of	  the	  autophagy	  dysregulation	  in	  the	  
SOD1G93A	  mouse	  model	  remains	  unclear.	  Both	  autophagy	  induction	  and	  decreased	  
autophagosome	  turnover	  may	  contribute	  to	  autophagosome	  accumulation	  in	  motor	  
neurons.	  There	  may	  also	  be	  heterogeneity	  in	  the	  regulation	  of	  autophagy	  between	  different	  
motor	  neuron	  subtypes,	  or	  even	  over	  time	  within	  the	  same	  motor	  neuron.	  To	  better	  
understand	  the	  role	  of	  autophagy	  in	  SOD1G93A	  mice	  and	  the	  therapeutic	  potential	  of	  
autophagy	  modulators,	  many	  efforts	  have	  been	  made	  to	  manipulate	  autophagy	  in	  vivo	  
(summarized	  in	  Table	  1.1).	  	  	  
	  
Autophagy	  manipulations	  in	  the	  SOD1	  mouse	  model	  
	   One	  of	  the	  first	  attempts	  to	  manipulate	  autophagic	  activity	  in	  an	  SOD1	  mouse	  model	  
used	  lithium,	  which	  had	  been	  shown	  to	  inhibit	  inositol	  monophosphatase,	  activate	  
autophagy	  and	  promote	  the	  clearance	  of	  mutant	  huntingtin	  and	  a-­‐synuclein	  in	  vitro	  
(Sarkar,	  Floto	  et	  al.	  2005).	  The	  initial	  study	  found	  that	  lithium	  administration	  increased	  
lifespan	  in	  SOD1G93A	  transgenic	  mice	  (Fornai,	  Longone	  et	  al.	  2008).	  This	  study	  also	  
examined	  the	  effects	  of	  lithium	  administration	  in	  human	  ALS	  patients,	  and	  reported	  that	  
lithium	  reduced	  mortality	  and	  delayed	  the	  progression	  of	  symptoms	  such	  as	  pulmonary	  
dysfunction.	  Despite	  these	  promising	  results,	  two	  subsequent	  studies	  failed	  to	  replicate	  the	  
survival	  effect	  in	  mice	  expressing	  mutant	  SOD1	  (Gill,	  Kidd	  et	  al.	  2009,	  Pizzasegola,	  Caron	  et	  
al.	  2009).	  Additional	  clinical	  trials	  also	  failed	  to	  replicate	  the	  protective	  effect	  of	  lithium	  in	  
ALS	  patients	  (Chio,	  Borghero	  et	  al.	  2010,	  Group,	  Morrison	  et	  al.	  2013).	  
Another	  pharmacological	  study	  manipulated	  autophagy	  in	  SOD1G93A	  mice	  using	  the	  
mTOR	  inhibitor	  rapamycin	  (Zhang,	  Li	  et	  al.	  2011).	  While	  rapamycin	  treatment	  in	  wild-­‐type	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mice	  did	  not	  cause	  detectable	  neurodegeneration,	  it	  exacerbated	  the	  SOD1G93A	  disease	  
phenotype	  by	  accelerating	  disease	  onset	  and	  shortening	  lifespan.	  The	  overall	  disease	  
duration	  was	  faster	  in	  rapamycin-­‐treated	  animals	  suggesting	  that	  autophagy	  induction	  
enhanced	  the	  speed	  of	  disease	  progression.	  This	  was	  accompanied	  by	  increased	  neuronal	  
cell	  death	  in	  the	  spinal	  cord	  and	  enhanced	  accumulation	  of	  autophagic	  vacuoles	  as	  
determined	  by	  LC3-­‐II	  levels	  and	  electron	  microscopy.	  Thus,	  despite	  upregulating	  
autophagy	  induction,	  rapamycin	  probably	  did	  little	  to	  correct	  downstream	  defects	  in	  
autophagic	  flux.	  Paradoxically,	  autophagy	  upregulation	  led	  to	  increased	  levels	  of	  oligomeric	  
SOD1,	  suggesting	  that	  autophagy	  promotes	  aggregate	  formation	  in	  the	  spinal	  cord.	  The	  
authors	  indicate	  that	  increased	  SOD1	  aggregation	  occurred	  in	  motor	  neurons,	  but	  they	  did	  
not	  examine	  aggregation	  in	  other	  cell	  types	  (Zhang,	  Li	  et	  al.	  2011).	  A	  second	  study	  
examined	  the	  effect	  of	  rapamycin	  in	  SOD1G93A	  and	  SOD1H46R/H48Q	  mice	  but	  found	  no	  
significant	  effects	  on	  disease	  onset	  or	  survival	  (Bhattacharya,	  Bokov	  et	  al.	  2012).	  	  
The	  failure	  of	  rapamycin	  to	  improve	  the	  phenotype	  of	  mice	  expressing	  mutant	  SOD1	  
led	  to	  increased	  interest	  in	  mTOR-­‐independent	  autophagy	  activation.	  One	  mTOR-­‐
independent	  autophagy	  enhancer	  is	  trehalose,	  a	  dissacharide	  present	  in	  non-­‐mammalian	  
species	  that	  protects	  against	  cellular	  stress	  and	  may	  act	  as	  a	  chaperone	  to	  promote	  proper	  
protein	  folding.	  Trehalose	  promotes	  the	  autophagic	  clearance	  of	  mutant	  huntingtin	  and	  α-­‐
synuclein	  aggregates,	  suggesting	  that	  it	  might	  have	  broad	  utility	  in	  neurodegenerative	  
disease	  (Sarkar,	  Davies	  et	  al.	  2007).	  Based	  on	  these	  findings,	  several	  groups	  have	  tested	  the	  
efficacy	  of	  trehalose	  in	  SOD1	  mouse	  models.	  An	  initial	  study	  found	  that	  trehalose	  
administration	  could	  induce	  autophagy	  and	  reduce	  SOD1	  aggregation,	  leading	  to	  an	  
extension	  of	  lifespan	  and	  reduced	  neuronal	  cell	  death	  in	  SOD1G86R	  transgenic	  mice	  (Castillo,	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Nassif	  et	  al.	  2013).	  The	  mechanism	  through	  which	  trehalose	  increases	  autophagic	  flux	  is	  
not	  understood,	  but	  the	  authors	  find	  that	  that	  it	  promotes	  nuclear	  translocation	  of	  the	  
transcription	  factor	  FOXO1	  and	  increased	  transcription	  of	  autophagy	  related	  genes	  
including	  LC3,	  Beclin-­‐1,	  Sqstm1	  and	  Atg5	  (Castillo,	  Nassif	  et	  al.	  2013).	  Follow	  up	  studies	  
utilizing	  SOD1G93A	  transgenic	  mice	  yielded	  conflicting	  results.	  The	  first	  study	  replicated	  the	  
beneficial	  effect	  of	  trehalose	  on	  lifespan	  (Zhang,	  Chen	  et	  al.	  2014),	  but	  a	  second	  found	  that	  
trehalose	  only	  delayed	  disease	  onset	  and	  did	  not	  alter	  lifespan	  (Li,	  Guo	  et	  al.	  2015).	  	  
Pharmacological	  approaches	  have	  shed	  some	  light	  on	  the	  role	  of	  autophagy	  in	  SOD1	  
mouse	  models,	  but	  the	  interpretation	  of	  these	  studies	  is	  hampered	  by	  potentially	  
nonspecific	  drug	  effects.	  In	  contrast,	  genetic	  manipulations	  constitute	  a	  more	  targeted	  
approach.	  One	  of	  the	  first	  studies	  to	  employ	  such	  a	  genetic	  approach	  examined	  the	  effect	  of	  
Beclin-­‐1	  downregulation	  on	  the	  SOD1G86R	  mouse	  model	  (Nassif,	  Valenzuela	  et	  al.	  2014).	  
Though	  complete	  deletion	  of	  Beclin-­‐1	  is	  lethal	  in	  mice,	  the	  authors	  examined	  its	  function	  by	  
generating	  SOD1G86R	  mice	  that	  are	  heterozygous	  for	  a	  Beclin-­‐1	  null	  allele.	  Unexpectedly,	  
they	  find	  that	  that	  these	  mice	  live	  longer	  than	  control	  SOD1G86R	  mice.	  Despite	  this	  survival	  
effect,	  phenotypic	  analysis	  of	  these	  mice	  revealed	  no	  change	  in	  neuronal	  cell	  death	  relative	  
to	  controls.	  Nonetheless,	  Beclin-­‐1	  heterozygous	  mice	  accumulate	  less	  oligomeric	  SOD1	  and	  
there	  is	  a	  trend	  toward	  reduced	  astrogliosis.	  Through	  a	  series	  of	  in	  vitro	  experiments,	  the	  
authors	  propose	  that	  mutant,	  but	  not	  wild-­‐type,	  SOD1	  binds	  BCL2	  and	  disrupts	  its	  
interaction	  with	  Beclin-­‐1.	  They	  propose	  that	  the	  loss	  of	  this	  inhibitory	  interaction	  causes	  
aberrant	  upregulation	  of	  autophagy,	  and	  that	  reduction	  in	  Beclin-­‐1	  levels	  restores	  normal	  
autophagy	  levels	  in	  SOD1	  mice	  leading	  to	  improved	  survival	  (Nassif,	  Valenzuela	  et	  al.	  
2014).	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   In	  summary,	  the	  existing	  data	  from	  mice	  expressing	  mutant	  SOD1	  leaves	  many	  
unresolved	  questions.	  Fundamentally,	  we	  still	  do	  not	  understand	  whether	  autophagy	  is	  
playing	  a	  protective	  or	  detrimental	  role	  in	  ALS.	  Part	  of	  this	  confusion	  stems	  from	  
methodological	  shortcomings	  of	  these	  in	  vivo	  studies,	  which	  often	  utilize	  crude	  
manipulations	  that	  hamper	  interpretation	  of	  the	  results.	  Moreover,	  autophagy	  may	  play	  
counteracting	  roles	  during	  disease	  progression.	  It	  is	  possible	  that	  authophagy	  could	  be	  
protective	  early	  in	  disease	  by	  limiting	  the	  accumulation	  of	  aggregated	  protein,	  but	  promote	  
the	  later	  stages	  of	  disease	  progression	  in	  combination	  with	  neuroinflammation.	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1.5	  Summary	  and	  aims	  of	  thesis	  
Mice	  expressing	  mutant	  SOD1	  present	  an	  attractive	  model	  system	  for	  interrogating	  
the	  role	  of	  autophagy	  in	  ALS	  because	  they	  recapitulate	  the	  autophagy	  dysregulation	  that	  is	  
seen	  in	  human	  patients.	  A	  common	  feature	  of	  the	  human	  disease	  and	  the	  SOD1G93A	  mouse	  
model	  is	  the	  aggregation	  of	  p62	  in	  motor	  neurons.	  However,	  the	  functional	  significance	  of	  
these	  aggregates	  remains	  unclear.	  
Despite	  tremendous	  efforts	  to	  modulate	  autophagy	  in	  SOD1G93A	  mice,	  these	  studies	  
have	  yielded	  conflicting	  results.	  Attempts	  to	  manipulate	  autophagy	  by	  pharmacological	  
means	  are	  difficult	  to	  interpret	  because	  these	  drugs	  have	  nonspecific	  effects.	  Another	  
limitation	  of	  these	  studies	  is	  that	  autophagy	  is	  often	  manipulated	  in	  the	  entire	  organism	  
rather	  than	  in	  defined	  cell	  populations.	  	  This	  is	  problematic	  because	  autophagy	  might	  be	  
playing	  positive	  or	  negative	  roles	  in	  different	  cell	  types.	  Lastly,	  autophagic	  activity	  may	  
differ	  early	  and	  late	  in	  disease	  pathogenesis,	  so	  greater	  attention	  must	  be	  paid	  to	  the	  role	  of	  
autophagy	  as	  a	  function	  of	  time.	  	  
In	  this	  thesis	  I	  will	  present	  our	  work	  on	  characterizing	  autophagy	  abnormalities	  in	  
SOD1G93A	  mice	  and	  determining	  the	  functional	  importance	  of	  this	  pathway	  in	  diseases	  
pathogenesis.	  
• Chapter	  2:	  I	  will	  characterize	  p62	  aggregates	  in	  the	  SOD1G93A	  mouse	  model	  and	  
determine	  whether	  genetic	  deletion	  of	  p62	  alters	  disease	  progression.	  
• Chapter	  3:	  I	  will	  present	  the	  generation	  and	  characterization	  of	  Atg7	  cKO	  mice	  in	  
which	  autophagy	  is	  specifically	  inhibited	  in	  motor	  neurons.	  
• Chapter	  4:	  I	  will	  determine	  the	  effect	  of	  motor	  neuron-­‐specific	  autophagy	  
inhibition	  on	  disease	  progression	  in	  the	  SOD1G93A	  mouse.	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• Chapter	  5:	  I	  will	  draw	  conclusions	  from	  the	  findings	  presented	  in	  this	  thesis.	  
• Chapter	  6:	  I	  will	  describe	  the	  experimental	  methods	  used	  in	  this	  work	  
	  





































Figure	  1.1:	  Genetics	  of	  ALS	  
	  
(A)	  A	  timeline	  of	  major	  discoveries	  in	  ALS	  genetics	  (adapted	  from	  alstdi.org).	  (B)	  The	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Figure	  1.2:	  ALS	  disease	  mechanisms	  
	  
Illustration	  of	  various	  cellular	  mechanisms	  thought	  to	  contribute	  to	  motor	  neuron	  
degeneration.	  Protein	  misfolding	  and	  aggregation	  within	  motor	  neurons	  is	  likely	  to	  serve	  
as	  a	  trigger	  that	  initiates	  secondary	  pathogenic	  mechanisms.	  Some	  of	  these	  mechanisms	  
occur	  strictly	  within	  motor	  neurons,	  whereas	  others	  involve	  other	  cell	  types	  (Ferraiuolo,	  
Kirby	  et	  al.	  2011).

































Figure	  1.3:	  Different	  forms	  of	  autophagy	  
	  
Autophagy	  can	  lead	  to	  lysosomal	  degradation	  of	  cellular	  substrates	  through	  three	  distinct	  
routes.	  In	  macroautophagy,	  substrates	  are	  engulfed	  by	  an	  autophagosome	  intermediate	  
prior	  to	  fusion	  with	  the	  lysosome.	  In	  microautophagy,	  substrates	  are	  engulfed	  by	  
invagination	  of	  the	  lysosomal	  membrane.	  In	  chaperone-­‐mediated	  autophagy,	  substrates	  are	  
recognized	  by	  Hsc70	  and	  translocated	  across	  the	  lysosome	  membrane	  via	  Lamp-­‐2a	  
(Mizushima	  and	  Komatsu	  2011).
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Figure	  1.4:	  Core	  autophagy	  machinery	  
	  
Autophagosome	  biogenesis	  depends	  on	  a	  multitude	  of	  specialized	  proteins	  that	  form	  
discrete	  complexes.	  The	  ULK1	  complex	  is	  the	  most	  upstream	  and	  activates	  the	  PI3K	  
complex.	  The	  local	  generation	  of	  PI3P	  recruits	  downstream	  effectors	  including	  WIPI	  
proteins,	  which	  are	  involved	  in	  the	  generation	  of	  the	  isolation	  membrane.	  Another	  PI3P	  
effector	  is	  ALFY	  (not	  shown),	  which	  recruits	  the	  Atg12-­‐Atg5-­‐Atg16L1	  complex	  through	  
direct	  interaction	  with	  Atg5.	  The	  Atg12-­‐Atg5-­‐Atg16L1	  complex	  is	  critical	  for	  the	  lipidation	  
of	  LC3	  and	  its	  localization	  to	  the	  autophagosome	  membrane.	  Lipidation	  of	  LC3	  requires	  
direct	  interaction	  with	  Atg7,	  as	  well	  as	  Atg7-­‐dependent	  formation	  of	  the	  Atg12-­‐Atg5-­‐
Atg16L1	  complex	  (Mizushima	  and	  Komatsu	  2011).	  




































Figure	  1.5:	  Mammalian	  autophagy	  receptors	  
	  
(A)	  Autophagy	  receptors	  bind	  cargo,	  often	  via	  a	  ubiquitin	  tag,	  and	  direct	  it	  to	  nascent	  
autophagosomes	  through	  interactions	  with	  LC3	  and	  other	  Atg8	  homologs.	  (B)	  Mammalian	  
selective	  autophagy	  receptors	  share	  core	  structural	  features	  including	  oligomerization	  
domains,	  ubiquitin	  or	  substrate	  binding	  domains,	  and	  LC3-­‐interacting	  regions	  (Stolz,	  Ernst	  
et	  al.	  2014).	  	  
	  




Figure	  1.6:	  Retrograde	  trafficking	  of	  autophagosomes	  from	  synapse	  to	  cell	  body.	  
	  
A	  model	  for	  neuronal	  autophagy	  in	  which	  autophagosome	  form	  distally	  and	  then	  undergo	  
retrograde	  transport	  toward	  the	  cell	  body.	  During	  this	  process,	  they	  become	  progressively	  
acidified	  and	  begin	  to	  take	  on	  additional	  characteristics	  of	  lysosomes	  such	  as	  bidirectional	  
movement	  (Maday,	  Wallace	  et	  al.	  2012).	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Manipulation Mouse Model Strain Findings Reference 
Lithium SOD1G93A B6SJL 
Delayed disease onset, 
extended lifespan, decreased 
motor neuron cell death, 
reduced accumulation of 
ubiquitin and SOD1 
(Fornai, Longone et 
al. 2008) 
  SOD1G93A B6SJL 
No effect on disease onset or 
lifespan 
(Gill, Kidd et al. 
2009) 
  SOD1G93A 129S2/Sv 
Accelerated disease onset and 
decreased lifespan  
(Pizzasegola, Caron 
et al. 2009) 
  SOD1G93A C57BL/6J 
No effect on disease onset or 
lifespan 
(Pizzasegola, Caron 
et al. 2009) 
Rapamycin SOD1G93A B6SJL 
Accelerated disease onset and 
decreased lifespan, increased 
motor neuron cell death, 
increased oligomeric SOD1 
(Zhang, Li et al. 
2011) 
  SOD1G93A B6SJL 
Trend towards accelerated 
disease onset, no effect on 
lifespan 
(Bhattacharya, 
Bokov et al. 2012) 
  SOD1H46R/H48Q  C57BL/6J 
No effect on disease onset or 
lifespan 
(Bhattacharya, 
Bokov et al. 2012) 
Trehalose SOD1G86R C57BL/6 
Delayed disease onset, 
extended lifespan, decreased 
motor neuron cell death, 
reduced oligomeric SOD1 
(Castillo, Nassif et al. 
2013) 
  SOD1G93A B6SJL 
Delayed disease onset, 
extended lifespan, decreased 
motor neuron cell death, 
reduced SOD1 and p62 
aggregation 
(Zhang, Chen et al. 
2014) 
  SOD1G93A B6SJL 
Delayed disease onset but no 
change in lifespan, reduced 
SOD1 and p62 levels early in 
disease but not late (Li, Guo et al. 2015) 
Beclin-1 
haploinsufficiency SOD1G86R C57BL/6 
Delayed disease onset, 
extended lifespan, no change in 
neuronal cell death, reduced 
oligomeric SOD1 
(Nassif, Valenzuela 
et al. 2014) 
	  
	  
Table	  1.1:	  	  Autophagy	  manipulations	  in	  mutant	  SOD1	  mice	  
	  
Summary	  of	  published	  studies	  that	  have	  attempted	  to	  directly	  manipulate	  autophagy	  
through	  pharmacological	  or	  genetic	  means.	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Chapter	  2:	  Autophagy	  dysregulation	  in	  the	  SOD1G93A	  mouse	  model	  of	  ALS	  
	  
2.1	  Introduction	  
A	  common	  feature	  of	  ALS	  is	  the	  formation	  of	  ubiquitinated	  protein	  aggregates	  
within	  affected	  cells	  in	  the	  central	  nervous	  system.	  Despite	  serving	  as	  hallmarks	  of	  the	  
disease,	  it	  is	  not	  currently	  known	  whether	  these	  aggregates	  are	  toxic,	  inert,	  or	  potentially	  
beneficial.	  Further	  research	  is	  needed	  in	  order	  to	  better	  define	  the	  heterogeneous	  
composition	  of	  protein	  aggregates,	  the	  cells	  in	  which	  they	  develop	  over	  the	  course	  of	  
disease	  and	  their	  relationship	  to	  protein	  degradation	  machinery.	  	  
Some	  components	  of	  ALS	  aggregates	  are	  known,	  and	  these	  have	  served	  as	  useful	  
markers	  for	  disease	  pathology.	  For	  instance,	  immunohistochemistry	  for	  TDP-­‐43	  is	  
considered	  to	  be	  the	  gold	  standard	  for	  detecting	  these	  aggregates	  in	  post-­‐mortem	  tissue	  
samples.	  	  However,	  TDP-­‐43	  pathology	  is	  not	  entirely	  specific	  for	  ALS,	  since	  it	  is	  also	  
observed	  in	  some	  cases	  of	  Alzheimer’s	  disease	  (Cook,	  Zhang	  et	  al.	  2008).	  	  Moreover,	  TDP-­‐
43	  pathology	  is	  not	  observed	  in	  ALS	  patients	  harboring	  SOD1	  mutations	  (Mackenzie,	  Bigio	  
et	  al.	  2007).	  This	  is	  problematic	  because	  mice	  expressing	  mutant	  SOD1	  continue	  to	  serve	  as	  
the	  leading	  model	  system	  for	  exploring	  ALS	  disease	  mechanisms	  in	  vivo.	  	  In	  contrast,	  
aggregation	  of	  p62	  has	  been	  observed	  in	  essentially	  all	  types	  of	  human	  ALS	  and	  is	  
recapitulated	  in	  mice	  expressing	  mutant	  SOD1	  (Mizuno,	  Amari	  et	  al.	  2006,	  Gal,	  Strom	  et	  al.	  
2007,	  Maekawa,	  Leigh	  et	  al.	  2009,	  Al-­‐Sarraj,	  King	  et	  al.	  2011).	  	  
The	  established	  role	  of	  p62	  in	  the	  autophagy	  pathway	  may	  provide	  clues	  into	  the	  
functional	  significance	  of	  the	  protein	  aggregates	  of	  which	  it	  is	  a	  component.	  As	  discussed	  in	  
Chapter	  1,	  several	  groups	  have	  demonstrated	  that	  autophagy	  is	  dysregulated	  in	  the	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SOD1G93A	  spinal	  cord,	  but	  further	  research	  is	  needed	  in	  order	  to	  clarify	  the	  function	  of	  
autophagy	  in	  disease	  pathogenesis.	  In	  this	  chapter,	  I	  will	  characterize	  the	  p62	  aggregates	  
that	  form	  in	  these	  mice	  and	  determine	  when	  and	  where	  they	  develop	  over	  the	  course	  of	  
disease	  progression.	  I	  will	  also	  determine	  the	  relationship	  between	  p62	  and	  other	  
components	  of	  the	  autophagy	  machinery	  including	  additional	  receptors	  and	  Atg8	  
homologues.	  
The	  presence	  of	  p62	  in	  protein	  aggregates	  could	  reflect	  functional	  involvement	  of	  
this	  protein	  in	  disease	  pathogenesis,	  or	  p62	  could	  simply	  be	  a	  surrogate	  marker	  for	  
ubiquitinated	  aggregates.	  As	  described	  in	  the	  Chapter	  1,	  downregulation	  of	  p62	  impairs	  
aggrephagy	  in	  several	  in	  vitro	  systems,	  suggesting	  a	  functional	  role.	  Perhaps	  the	  most	  
compelling	  evidence	  is	  human	  genetic	  data	  demonstrating	  SQSTM1	  mutations	  in	  ALS	  
patients.	  Nonetheless,	  it	  is	  not	  clear	  whether	  these	  mutations	  are	  sufficient	  to	  cause	  
neurodegeneration.	  To	  date,	  no	  fALS	  pedigrees	  have	  been	  described	  in	  which	  SQSTM1	  
mutations	  segregate	  with	  disease.	  Most	  patients	  with	  SQSTM1	  mutations	  only	  harbor	  one	  
mutant	  allele,	  and	  complete	  deletion	  of	  p62	  in	  mice	  does	  not	  result	  in	  overt	  motor	  neuron	  
disease	  (Duran,	  Serrano	  et	  al.	  2004).	  Other	  autophagy	  receptors	  such	  as	  NBR1	  share	  
remarkable	  homology	  with	  p62,	  suggesting	  genetic	  redundancy.	  Thus,	  p62	  loss-­‐of-­‐function	  
alone	  seems	  like	  an	  unlikely	  disease	  mechanism.	  	  	  
It	  is	  possible	  that	  SQSTM1	  mutations	  could	  increase	  susceptibility	  to	  ALS	  without	  
themselves	  being	  sufficient	  to	  cause	  disease.	  Under	  this	  scenario,	  complete	  or	  partial	  loss	  of	  
function	  could	  conspire	  with	  other	  mutations	  that	  impair	  proteostasis	  to	  cause	  
neurodegeneration.	  In	  this	  chapter,	  I	  will	  test	  this	  hypothesis	  through	  the	  generation	  of	  
	   51	  
SOD1G93A	  mice	  that	  are	  also	  deficient	  for	  p62.	  This	  will	  allow	  us	  to	  test	  whether	  loss	  of	  p62	  
modulates	  disease	  progression	  in	  a	  well-­‐established	  mouse	  model	  of	  ALS.	  
	  
2.2	  Results	  
Aggregation	  of	  p62	  in	  SOD1G93A	  motor	  neurons	  
We	  first	  sought	  to	  characterize	  dysregulation	  of	  the	  autophagy	  pathway	  in	  the	  
SOD1G93A	  mouse	  model.	  Given	  the	  ubiquitious	  presence	  of	  p62	  in	  ALS	  protein	  aggregates,	  
we	  set	  out	  to	  determine	  whether	  similar	  p62	  pathology	  was	  present	  in	  in	  the	  SOD1G93A	  
spinal	  cord.	  Indeed,	  we	  found	  that	  p62	  aggregated	  in	  motor	  neurons	  throughout	  disease	  
progression.	  While	  wild-­‐type	  motor	  neurons	  showed	  a	  diffuse	  cytoplasmic	  distribution,	  a	  
subset	  of	  motor	  neurons	  from	  SOD1G93A	  mice	  showed	  dramatic	  aggregation	  of	  p62	  as	  early	  
as	  early	  as	  50	  days	  postnatal,	  long	  before	  symptom	  onset	  (Figure	  2.1A).	  	   	  
Analysis	  of	  p62	  aggregates	  at	  the	  P50	  timepoint	  revealed	  the	  presence	  of	  two	  
distinct	  types	  of	  inclusions.	  In	  6.17%	  of	  motor	  neurons,	  p62	  labeled	  round	  bodies	  (RBs)	  in	  
the	  cell	  soma	  that	  measured	  over	  3	  µm	  in	  diameter	  (Figure	  2.1A,	  arrowheads).	  The	  percent	  
of	  SOD1G93A	  motor	  neurons	  exhibiting	  RBs	  decreased	  with	  age	  and	  they	  were	  never	  
observed	  in	  wild-­‐type	  mice	  (Figure	  2.1B,	  two-­‐way	  ANOVA,	  effect	  of	  genotype:	  F	  (1,	  14)	  =	  
10.84,	  p	  =	  0.0053;	  effect	  of	  age:	  F	  (2,	  14)	  =	  3.811,	  p	  =	  0.0477;	  genotype	  ×	  age	  interaction:	  F	  
(2,	  14)	  =	  3.811,	  p	  =	  0.0477).	  In	  contrast,	  0.85%	  of	  motor	  neurons	  in	  P50	  SOD1G93A	  mice	  
exhibited	  skein-­‐like	  inclusions	  (SLIs)	  that	  occupied	  the	  cell	  soma	  and	  dendrites	  (Figure	  
2.1A,	  arrow).	  SLIs	  were	  never	  observed	  in	  wild-­‐type	  motor	  neurons,	  while	  the	  percent	  of	  
SOD1G93A	  motor	  neurons	  exhibiting	  SLIs	  increased	  dramatically	  with	  age,	  reaching	  10.05%	  
at	  P150	  (Figure	  2.1B,	  two-­‐way	  ANOVA,	  effect	  of	  genotype:	  F	  (1,	  14)	  =	  38.16,	  P	  <	  0.0001;	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effect	  of	  age:	  F	  (2,	  14)	  =	  14.56,	  p	  =	  0.0004;	  genotype	  ×	  age	  interaction:	  F	  (2,	  14)	  =	  14.56,	  p	  =	  
0.0004).	  
	  
Round	  bodies	  form	  in	  vulnerable	  motor	  neurons	  
	   A	  key	  feature	  of	  p62	  aggregation	  in	  SOD1G93A	  mice	  is	  that	  only	  a	  subset	  of	  motor	  
neurons	  are	  affected	  at	  a	  given	  timepoint.	  We	  sought	  to	  characterize	  the	  features	  that	  
distinguish	  these	  motor	  neurons	  from	  neighboring	  cells.	  We	  began	  with	  cell	  size,	  which	  can	  
serve	  as	  a	  proxy	  for	  functional	  characteristics.	  Alpha	  motor	  neurons	  that	  innervate	  skeletal	  
muscle	  are	  large,	  whereas	  gamma	  motor	  neurons	  that	  innervate	  muscle	  spindles	  are	  small	  
(Shneider,	  Brown	  et	  al.	  2009).	  Alpha	  motor	  neurons	  can	  be	  further	  subdivided	  by	  size:	  the	  
largest	  alpha	  motor	  neurons	  innervate	  fast-­‐twitch	  muscle	  fibers	  while	  smaller	  alpha	  motor	  
neurons	  innervate	  slow-­‐twitch	  fibers.	  	  These	  categories	  also	  correlate	  with	  differential	  
vulnerability:	  fast	  alpha	  motor	  neurons	  are	  the	  first	  to	  degenerate	  in	  both	  ALS	  and	  normal	  
aging,	  slow	  motor	  neurons	  are	  more	  resistant	  and	  gamma	  motor	  neurons	  are	  generally	  the	  
last	  to	  degenerate	  (Kanning,	  Kaplan	  et	  al.	  2010).	  Based	  on	  these	  well-­‐defined	  differences,	  
we	  proceeded	  to	  compare	  the	  relative	  size	  of	  motor	  neurons	  with	  RBs,	  SLIs	  and	  those	  with	  
no	  p62	  aggregates	  across	  disease	  progression.	  We	  found	  that	  aggregate	  status	  was	  a	  
significant	  predictor	  of	  cell	  size	  (Figure	  2.2A,	  two-­‐way	  ANOVA,	  effect	  of	  aggregate	  status:	  F	  
(2,	  20)	  =	  14.14,	  p	  =	  0.0001;	  effect	  of	  age:	  F	  (2,	  20)	  =	  2.966,	  p	  =	  0.0745;	  genotype	  ×	  age	  
interaction:	  F	  (4,	  20)	  =	  0.6645,	  p	  =	  0.6240).	  Motor	  neurons	  with	  RBs	  were	  some	  of	  the	  
largest	  in	  the	  ventral	  horn,	  whereas	  cells	  containing	  SLIs	  were	  similar	  in	  size	  to	  unaffected	  
cells.	  This	  data	  suggested	  that	  RBs	  but	  not	  SLIs	  preferentially	  formed	  in	  fast,	  vulnerable	  
motor	  neurons.	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The	  tibialis	  anterior	  is	  innervated	  primarily	  by	  fast	  motor	  neurons,	  while	  the	  soleus	  
is	  innervated	  by	  a	  mixture	  of	  fast	  and	  slow	  motor	  neurons.	  We	  used	  fluorescently	  
conjugated	  Cholera	  Toxin	  B	  subunit	  (CTB)	  to	  retrogradely	  label	  motor	  neurons	  innervating	  
the	  tibialis	  anterior	  or	  the	  soleus	  muscle	  of	  P50	  SOD1G93A	  mice.	  We	  found	  that	  motor	  
neurons	  innervating	  both	  muscles	  developed	  RBs,	  but	  a	  greater	  fraction	  of	  motor	  neurons	  
innervating	  the	  tibialis	  anterior	  exhibited	  this	  pathology	  compared	  to	  those	  innervating	  the	  
soleus	  (Figure	  2.2B	  and	  2.2C).	  	  
The	  results	  of	  our	  retrograde	  labeling	  experiment	  were	  consistent	  with	  the	  idea	  that	  
fast	  motor	  neurons	  preferentially	  develop	  RBs.	  Finally,	  we	  sought	  to	  confirm	  this	  using	  a	  
molecular	  marker	  for	  fast	  motor	  neurons.	  Matrix	  metalloprotease-­‐9	  (MMP-­‐9)	  was	  recently	  
identified	  as	  one	  such	  marker	  (Kaplan,	  Spiller	  et	  al.	  2014).	  When	  we	  quantified	  the	  percent	  
of	  motor	  neurons	  exhibiting	  RBs,	  we	  found	  that	  they	  were	  highly	  specific	  for	  MMP-­‐9-­‐
positive	  cells	  (Figure	  2.2D	  and	  2.2E,	  mean	  ±	  SEM:	  0.42	  ±	  0.42%	  of	  MMP-­‐9-­‐negative	  motor	  
neurons	  versus	  15.47	  ±	  4.43%	  of	  MMP-­‐9-­‐positive	  motor	  neurons,	  p	  =	  0.0148	  two	  tailed	  t-­‐
test).	  Taken	  together	  with	  the	  large	  size	  of	  these	  cells,	  we	  conclude	  that	  RBs	  specifically	  
develop	  in	  fast	  motor	  neurons	  in	  SOD1G93A	  mice.	  
	  
Interneurons	  develop	  skein-­‐like	  inclusions	  late	  in	  disease	  progression	  
To	  determine	  whether	  p62	  aggregation	  was	  specific	  to	  motor	  neurons,	  we	  tested	  
whether	  p62	  colocalized	  with	  additional	  cell	  type	  markers.	  We	  did	  not	  observe	  
colocalization	  of	  p62	  with	  the	  astrocyte	  marker	  GFAP,	  nor	  did	  we	  observe	  colocalization	  
with	  microglial	  marker	  Iba1	  (Figure	  2.3A	  and	  2.3B).	  However,	  we	  did	  observe	  the	  
formation	  of	  SLIs	  outside	  of	  the	  ventral	  horn	  late	  in	  disease	  progression.	  We	  found	  that	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these	  cells	  stained	  positive	  for	  Nissl	  substance	  but	  negative	  for	  ChAT,	  indicating	  that	  they	  
were	  interneurons	  (Figure	  2.1C).	  Quantification	  of	  interneuron	  SLIs	  revealed	  a	  progressive	  
accumulation	  that	  became	  especially	  prominent	  at	  the	  P150	  timepoint	  (Figure	  2.1D).	  
Because	  calcium	  binding	  proteins	  are	  differentially	  expressed	  by	  spinal	  interneurons	  
(Alvarez,	  Jonas	  et	  al.	  2005),	  we	  stained	  spinal	  sections	  with	  antibodies	  against	  
parvalbumin,	  calbindin	  and	  calretinin	  to	  determine	  if	  SLIs	  were	  specific	  to	  one	  of	  these	  
populations.	  	  We	  found	  that	  SLIs	  colocalized	  with	  all	  three	  calcium	  binding	  proteins	  (Figure	  
2.4).	  Thus,	  while	  RBs	  are	  specific	  to	  motor	  neurons,	  SLIs	  first	  appear	  in	  motor	  neurons	  and	  
eventually	  spread	  to	  a	  diverse	  group	  of	  spinal	  interneurons.	  	  
	  
Molecular	  Characterization	  of	  p62	  aggregates	  
We	  sought	  to	  identify	  additional	  protein	  components	  of	  these	  inclusions	  in	  order	  to	  
better	  understand	  their	  role	  in	  disease.	  First,	  we	  asked	  whether	  any	  other	  autophagy	  
receptors	  were	  present	  in	  these	  aggregates.	  NBR1	  is	  the	  most	  closely	  related	  autophagy	  
receptor	  and	  may	  serve	  partially	  overlapping	  functions	  with	  p62	  (Kirkin,	  Lamark	  et	  al.	  
2009).	  We	  found	  that	  NBR1	  accumulated	  in	  both	  RBs	  and	  SLIs,	  consistent	  with	  a	  shared	  
functional	  role	  (Figure	  2.5A).	  Because	  both	  p62	  and	  NBR1	  contain	  ubiquitin-­‐associated	  
domains,	  we	  stained	  for	  ubiquitin	  and	  found	  high	  enrichment	  in	  both	  RBs	  and	  SLIs	  (Figure	  
2.5B).	  	  
Previous	  work	  has	  demonstrated	  that	  p62	  interacts	  with	  mutant	  SOD1	  in	  the	  
SOD1G93A	  spinal	  cord	  (Gal,	  Strom	  et	  al.	  2007).	  However,	  this	  study	  did	  not	  address	  
differential	  association	  of	  SOD1	  with	  distinct	  types	  of	  p62	  aggregates.	  We	  found	  that	  SOD1	  
preferentially	  localized	  to	  SLIs,	  but	  not	  RBs	  (Figure	  2.5C).	  Through	  co-­‐immunoprecipitation	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of	  mutant	  SOD1	  with	  p62,	  we	  were	  able	  to	  confirm	  this	  interaction	  at	  the	  biochemical	  level	  
(Figure	  2.5D).	  	  Consistent	  with	  the	  specific	  association	  of	  p62	  with	  SOD1	  in	  SLIs,	  we	  were	  
only	  able	  to	  detect	  robust	  association	  of	  these	  proteins	  at	  disease	  endstage,	  when	  SLI	  
pathology	  predominates.	  	  
	   Next	  we	  asked	  whether	  autophagy	  receptors	  successfully	  recruit	  Atg8	  homologues	  
to	  ubiquitinated	  aggregates	  in	  SOD1G93A	  motor	  neurons,	  which	  would	  be	  prerequisite	  for	  
their	  autophagic	  degradation.	  LC3	  is	  the	  most	  commonly	  used	  Atg8	  homolog	  for	  labeling	  
autophagosomes,	  and	  we	  were	  able	  to	  identify	  weak	  LC3	  immunoreactivity	  on	  the	  
periphery	  of	  RBs	  (Figure	  2.6A).	  To	  circumvent	  limitations	  associated	  with	  antibody	  
labeling,	  we	  bred	  SOD1G93A	  mice	  to	  GFP-­‐LC3	  transgenic	  mice	  (Mizushima,	  Yamamoto	  et	  al.	  
2004).	  Using	  this	  genetically	  encoded	  reporter,	  we	  found	  that	  RBs	  were	  surrounded	  by	  LC3	  
whereas	  SLIs	  were	  devoid	  of	  this	  marker	  (Figure	  2.6B).	  This	  data	  suggests	  that	  RBs	  
correspond	  to	  autophagosomes,	  whereas	  SLIs	  may	  represent	  aggregates	  that	  are	  
recalcitrant	  to	  autophagic	  degradation.	  This	  is	  consistent	  with	  human	  ALS	  pathology,	  
where	  RBs	  but	  not	  SLIs	  are	  found	  to	  colocalize	  with	  LC3	  (Sasaki	  2011).	  
Despite	  the	  widespread	  use	  of	  LC3	  as	  an	  autophagosome	  marker,	  other	  Atg8	  
homologues	  may	  be	  equally	  important.	  In	  particular,	  GABARAPL1	  is	  expressed	  at	  high	  
levels	  in	  spinal	  motor	  neurons	  (Wang,	  Dun	  et	  al.	  2006,	  Le	  Grand,	  Bon	  et	  al.	  2013).	  We	  
confirmed	  that	  GABARAPL1	  protein	  is	  expressed	  in	  motor	  neurons	  found	  that	  it	  forms	  
small	  punctate	  structures	  in	  wild-­‐type	  mice.	  In	  contrast,	  GABARAPL1	  robustly	  labeled	  p62-­‐
positive	  RBs	  in	  motor	  neurons	  from	  SOD1G93A	  mice	  and	  this	  labeling	  was	  even	  more	  
pronounced	  than	  LC3	  (Figure	  2.1E).	  Nonetheless,	  consistent	  with	  LC3	  localization,	  
GABARAPL1	  was	  not	  observed	  to	  engulf	  SLIs	  (Figure	  2.1E).	  Based	  on	  the	  differential	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labeling	  of	  RBs	  and	  SLIs	  with	  two	  different	  Atg8	  homologues,	  we	  conclude	  that	  the	  former	  
but	  not	  the	  latter	  correspond	  to	  mature	  autophagosomes.	  	  
	  
Activation	  of	  a	  neuronal	  stress	  response	  in	  neurons	  with	  SLIs	  
We	  reasoned	  that	  the	  motor	  neurons	  with	  p62	  pathology	  might	  activate	  stress	  
response	  pathways.	  In	  particular,	  upregulation	  of	  phosphorylated	  c-­‐Jun	  has	  been	  described	  
in	  the	  nuclei	  of	  both	  motor	  neurons	  and	  interneurons	  containing	  ubiquitinated	  aggregates	  
in	  SOD1G93A	  mice	  (Vlug,	  Teuling	  et	  al.	  2005).	  We	  asked	  whether	  this	  transcription	  factor	  
was	  differentially	  regulated	  in	  motor	  neurons	  with	  RBs	  versus	  SLIs.	  We	  found	  that	  p62	  
aggregation	  in	  motor	  neurons	  was	  a	  significant	  predictor	  of	  p-­‐c-­‐Jun	  levels	  (Figure	  2.1F,	  
one-­‐way	  ANOVA,	  F	  =	  43.39,	  p	  =	  0.0003).	  Nuclear	  p-­‐c-­‐Jun	  was	  specifically	  upregulated	  in	  
motor	  neurons	  with	  SLIs,	  but	  not	  RBs.	  A	  similar	  correlation	  between	  SLI	  pathology	  and	  p-­‐c-­‐
Jun	  upregulation	  was	  also	  observed	  in	  spinal	  interneurons	  (see	  chapter	  4).	  	  These	  data	  
indicate	  that	  SLI	  pathology	  is	  associated	  with	  the	  activation	  of	  a	  neuronal	  stress	  response.	  	  
	  
Genetic	  deletion	  of	  p62	  in	  SOD1G93A	  mice	  
	   The	  aggregation	  of	  p62	  in	  the	  form	  of	  RBs	  and	  SLIs	  suggested	  that	  it	  might	  play	  a	  
functional	  role	  in	  disease	  pathogenesis.	  To	  address	  this	  question,	  we	  obtained	  p62	  
knockout	  mice	  (Kwon,	  Han	  et	  al.	  2012)	  and	  crossed	  them	  to	  SOD1G93A	  mice	  to	  generate	  p62-­‐
/-­‐;	  SOD1G93A	  double	  mutant	  mice.	  	  First	  we	  asked	  whether	  loss	  of	  p62	  affected	  aggregate	  
formation	  in	  these	  mice.	  To	  do	  this,	  we	  utilized	  NBR1	  as	  a	  marker	  for	  ubiquitinated	  
aggregates.	  We	  found	  that	  NBR1-­‐positive	  RBs	  and	  SLIs	  still	  formed	  in	  p62-­‐/-­‐;	  SOD1G93A	  
motor	  neurons	  (Figure	  2.7A	  and	  2.7B).	  This	  result	  indicates	  that	  p62	  is	  not	  required	  for	  the	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formation	  of	  these	  structures.	  Moreover,	  the	  continued	  presence	  of	  NBR1	  in	  RBs	  and	  SLIs	  
suggests	  that	  there	  may	  be	  functional	  redundancy	  among	  the	  autophagy	  receptors.	  
Though	  p62	  is	  dispensable	  for	  aggregate	  formation,	  it	  may	  still	  be	  important	  for	  
downstream	  recruitment	  of	  autophagy	  machinery	  and/or	  intracellular	  signaling.	  We	  asked	  
whether	  p62	  was	  required	  for	  recruitment	  of	  GABARAPL1	  to	  RBs.	  We	  found	  that	  
GABARAPL1	  was	  still	  recruited	  to	  RBs	  in	  p62-­‐/-­‐;	  SOD1G93A	  mice	  (Figure	  2.7C),	  suggesting	  
that	  NBR1	  and	  potentially	  other	  autophagy	  receptors	  are	  sufficient	  to	  recruit	  Atg8	  
homologues	  to	  ubiquitinated	  aggregates	  in	  SOD1G93A	  motor	  neurons.	  We	  also	  tested	  the	  
necessity	  of	  p62	  for	  upregulation	  of	  p-­‐c-­‐Jun	  in	  motor	  neuron	  nuclei.	  We	  found	  that	  p-­‐c-­‐Jun	  
still	  accumulated	  in	  the	  nuclei	  of	  SLI-­‐containing	  motor	  neurons	  in	  p62-­‐/-­‐;	  SOD1G93A	  mice	  
(Figure	  2.7D),	  indicating	  that	  p62	  is	  not	  required	  for	  activating	  this	  stress	  response.	  	  
Finally,	  we	  asked	  whether	  loss	  of	  p62	  affected	  lifespan	  in	  SOD1G93A	  mice.	  We	  tested	  
mice	  for	  the	  ability	  to	  right	  themselves	  after	  being	  placed	  on	  their	  side,	  and	  lifespan	  was	  
determined	  as	  the	  age	  at	  which	  a	  mouse	  could	  no	  longer	  return	  to	  a	  standing	  posture	  
within	  15	  seconds	  (disease	  endstage).	  Consistent	  with	  the	  lack	  of	  an	  effect	  on	  aggregate	  
formation,	  genetic	  deletion	  of	  p62	  had	  no	  significant	  effect	  on	  the	  lifespan	  of	  SOD1G93A	  mice	  
(Figure	  2.7E,	  Median	  age	  of	  disease	  endstage	  in	  p62+/+	  ;	  SOD1G93A,	  p62+/-­‐	  ;	  SOD1G93A,	  and	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In	  this	  chapter,	  we	  demonstrate	  that	  motor	  neurons	  in	  SOD1G93A	  mice	  develop	  two	  
distinct	  types	  of	  p62	  aggregates.	  Early	  in	  disease,	  a	  subset	  of	  motor	  neurons	  develop	  round	  
bodies	  that	  correspond	  to	  LC3-­‐positive,	  GABARAPL1-­‐positive	  autophagosomes	  containing	  
ubiquitinated	  cargo.	  These	  wane	  with	  disease	  progression,	  while	  another	  subset	  of	  motor	  
neurons	  begins	  to	  accumulate	  p62	  in	  skein-­‐like	  inclusions.	  SLIs	  also	  contain	  high	  levels	  of	  
ubiquitin,	  but	  in	  contrast	  to	  RBs,	  they	  are	  not	  engulfed	  by	  Atg8	  homologs	  suggesting	  that	  
they	  are	  resistant	  to	  autophagic	  degradation.	  Our	  analysis	  reveals	  unexpected	  diversity	  in	  
the	  regulation	  of	  autophagy	  in	  motor	  neurons.	  	  
Analysis	  of	  the	  cells	  containing	  p62	  aggregates	  revealed	  that	  RBs	  accumulated	  in	  
cells	  with	  characteristics	  of	  fast	  motor	  neurons.	  They	  had	  extremely	  large	  cell	  somas,	  they	  
were	  enriched	  among	  motor	  neurons	  innervating	  the	  tibialis	  anterior	  muscle	  and	  they	  
expressed	  MMP-­‐9.	  These	  motor	  neurons	  are	  known	  to	  degenerate	  early	  in	  both	  human	  ALS	  
patients	  and	  the	  SOD1G93A	  mouse	  model.	  In	  contrast,	  SLIs	  formed	  in	  smaller	  motor	  neurons	  
and	  a	  diverse	  group	  of	  spinal	  interneurons.	  Thus,	  RB	  pathology	  is	  unique	  to	  a	  small	  
population	  of	  vulnerable	  motor	  neurons	  whereas	  SLI	  pathology	  is	  less	  specific.	  We	  never	  
observed	  cells	  containing	  both	  types	  of	  p62	  aggregates,	  suggesting	  that	  they	  represent	  two	  
mutually	  exclusive	  fates.	  
What	  mechanisms	  might	  be	  responsible	  for	  this	  seemingly	  binary	  choice,	  and	  what	  
are	  the	  consequences	  for	  neuronal	  viability?	  One	  clue	  comes	  from	  our	  observation	  that	  
cells	  with	  SLI	  pathology	  preferentially	  upregulate	  p-­‐c-­‐Jun	  in	  their	  nuclei.	  Phosphorylation	  
of	  c-­‐Jun	  leads	  to	  transcription	  of	  a	  number	  of	  pro-­‐apoptotic	  genes	  including	  Mkp1,	  Dp5,	  Bim	  
and	  PUMA	  and	  is	  required	  for	  neuronal	  cell	  death	  induced	  by	  diverse	  stressors	  such	  as	  
excitotoxic	  damage	  and	  axotomy	  (Coffey	  2014).	  	  As	  their	  name	  implies,	  Jun	  terminal	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kinases	  (JNKs)	  are	  required	  for	  phosphorylation	  of	  c-­‐Jun.	  	  When	  all	  three	  JNK	  enzymes	  
were	  simultaneously	  deleted	  from	  mouse	  cortical	  neurons,	  autophagy	  was	  found	  to	  be	  
upregulated	  as	  a	  pro-­‐survival	  mechanism	  (Xu,	  Das	  et	  al.	  2011).	  This	  suggests	  that	  the	  JNK	  
enzymes	  act	  to	  suppress	  autophagy	  in	  neurons.	  Based	  on	  these	  results,	  it	  seems	  likely	  that	  
activation	  of	  the	  JNK	  pathway	  and	  downstream	  phosphorylation	  of	  c-­‐Jun	  may	  suppress	  
autophagy	  in	  SOD1G93A	  neurons	  exhibiting	  SLI	  pathology.	  Conversely,	  the	  absence	  of	  p-­‐c-­‐
Jun	  in	  the	  nuclei	  of	  motor	  neurons	  with	  RBs	  may	  reflect	  low	  JNK	  activity,	  which	  permits	  a	  
protective	  autophagic	  program.	  	  
	  
Functional	  role	  of	  p62	  in	  SOD1G93A	  mouse	  model	  
The	  pronounced	  aggregation	  of	  p62	  in	  both	  motor	  neurons	  and	  interneurons	  in	  the	  
SOD1G93A	  mouse	  led	  us	  to	  ask	  whether	  p62	  is	  functionally	  involved	  in	  disease	  pathogenesis.	  
In	  particular,	  we	  hypothesized	  that	  p62	  might	  be	  necessary	  for	  the	  recruitment	  Atg8	  
homologs	  to	  ubiquitinated	  aggregates.	  However,	  we	  found	  p62-­‐/-­‐	  	  ;	  SOD1G93A	  mice	  were	  still	  
able	  capable	  of	  forming	  GABARAPL1-­‐positive	  autophagosomes.	  We	  also	  observed	  SLI	  
pathology	  and	  p-­‐c-­‐Jun	  upregulation	  in	  p62-­‐/-­‐	  ;	  SOD1G93A	  mice,	  suggesting	  that	  p62	  is	  not	  
required	  for	  these	  processes	  either.	  Consistent	  with	  these	  shared	  pathological	  features,	  we	  
found	  that	  p62-­‐/-­‐	  ;	  SOD1G93A	  mice	  showed	  no	  difference	  in	  survival	  from	  p62-­‐/-­‐	  ;	  SOD1G93A	  
controls.	  Thus,	  p62	  is	  neither	  a	  critical	  mediator	  nor	  critical	  suppressor	  of	  the	  
neurodegenerative	  phenotype	  in	  this	  mouse	  model.	  
This	  result	  may	  be	  explained	  by	  the	  great	  genetic	  redundancy	  that	  exists	  among	  
selective	  autophagy	  receptors.	  Indeed,	  we	  find	  that	  NBR1	  is	  still	  recruited	  to	  both	  RBs	  and	  
SLIs	  in	  the	  absence	  of	  p62.	  	  Since	  they	  are	  highly	  homologous	  proteins,	  it	  seems	  likely	  that	  
	   60	  
NBR1	  and	  is	  able	  to	  compensate	  for	  loss	  of	  p62,	  perhaps	  in	  concert	  with	  additional	  
autophagy	  receptors.	  This	  result	  suggests	  that	  human	  SQSTM1	  mutations	  are	  unlikely	  to	  
contribute	  to	  disease	  through	  a	  loss-­‐of-­‐function	  mechanism.	  Instead,	  as	  is	  the	  case	  with	  
many	  ALS-­‐causing	  mutations,	  mutations	  to	  p62	  may	  lead	  to	  a	  toxic-­‐gain	  of	  function	  that	  is	  
not	  observed	  for	  the	  wild-­‐type	  protein.	  For	  instance,	  the	  P392L	  mutation	  that	  is	  associated	  
with	  PDB	  and	  ALS	  has	  been	  shown	  to	  positively	  regulate	  NFκB	  signaling	  (Chamoux,	  
Couture	  et	  al.	  2009).	  It	  is	  possible	  that	  other	  SQSTM1	  mutations	  also	  lead	  to	  the	  acquisition	  
of	  novel	  toxic	  functions.	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Figure 2.1 
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Figure 2.1 Autophagy dysregulation in the SOD1G93A mouse model 
 
A. Immunofluorescent labeling of ChAT (green) and p62 (red) reveals selective 
aggregation of p62 in SOD1G93A motor neurons. A subset of motor neurons shows p62 
aggregation in round bodies (arrowheads) while another subset shows p62 aggregation 
in skein-like inclusions (arrow). Scale bar, 100 µm. 
 
B. Quantification of motor neuron p62 aggregates reveals a decline in RB abundance 
over disease progression and an increase in SLI abundance. **p < 0.01, ***p < 0.001, 
****p < 0.0001 (two-way ANOVA, Tukey post hoc test). 
 
C. Nissl stain (blue) combined with immunofluorescent labeling of ChAT (green) and 
p62 (red) showing skein-like inclusion in an interneuron. Scale bar, 20 µm. 
 
D. Quantification of interneuron p62 aggregates reveals an absence of RBs and 
formation of SLIs late in disease. ***p < 0.001 (two-way ANOVA, Tukey post hoc test). 
 
E. Immunofluorescence labeling of p62 (red) and GABARAPL1 (green) in wild-type and 
SOD1G93A motor neurons reveals selective engulfment of RBs and not SLIs (ChAT 
labeling not shown). Scale bar, 10 µm. 
 
F. Immunofluorescence labeling of p62 (red) and p-c-Jun (green) in wild-type and 
SOD1G93A motor neurons reveals selective activation of nuclear stress response in cells 
with SLIs (ChAT labeling not shown). Scale bar, 10 µm. 
 
G. Quantification of normalized p-c-Jun fluorescence intensity in motor neurons with 
RBs, SLIs, and no p62 aggregates. ***p < 0.001 (one-way ANOVA, Tukey post hoc 
test).
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Figure 2.2 Round bodies preferentially form in vulnerable motor neurons. 
 
A. Motor neurons with RBs are significantly larger than motor neurons with SLIs and 
those without p62 aggregates. n = 3-4 animals per timepoint. *p < 0.05, **p < 0.01, ***p 
< 0.001 (two-way ANOVA, Tukey post hoc test). 
 
B. Immunofluorescent labeling of p62 (red) in motor neurons labeled by CTB (green) 
injections into the tibialis anterior (TA) or soleus (SOL). Scale bar, 20 µm. Collaboration 
with Juan Carlos Tapia. 
 
C. Quantification of p62 pathology in CTB labeled motor neurons reveals that motor 
neurons innervating the TA are more likely to develop RBs than motor neurons 
innervating the SOL. n = 1 animal 
 
D. Immunofluorescent labeling of p62 (red) and MMP-9 (green). Motor neurons 
identified by Nissl and VAChT staining (not shown) are outlined in white. Scale bar, 50 
µm. 
 
E. Quantification of RBs reveals that they selectively form in MMP-9 positive motor 
neurons. n = 4 animals. *p < 0.05 (two-tailed t-test)
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Figure 2.3 Aggregation of p62 is not present in astrocytes or microglia. 
 
A. Immunofluorescent labeling of p62 aggregates (red) and GFAP-positive astrocytes 
(green) does not show colocalization. Scale bar, 20 µm. 
 
B. Immunofluorescent labeling of p62 aggregates (red) and Iba1-positive microglia 
(green) does not show colocalization. Scale bar, 20 µm. 
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Figure 2.4 
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Figure 2.4 SLIs form in diverse interneuron subtypes. 
 
A. Immunofluorescent labeling of p62 (red) reveals skein-like inclusions in parvalbumin, 
calretinin and calbindin (green) positive interneurons. Scale bar, 10 µm. 
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Figure 2.5 NBR1, Ubiquitin and SOD1 are differentially recruited to p62 aggregates in 
SOD1G93A mice. 
 
A-B. Immunofluorescent labeling (A) NBR1 or (B) Ubiquitin (green) in SOD1WT and 
SOD1G93A mice shows that both of these proteins colocalize with p62 (red) in RBs and 
SLIs. Motor neurons outlined in white, ChAT labeling not shown. Scale bar, 10 µm. 
 
C. Immunofluorescent labeling hSOD1 (green) in SOD1WT and SOD1G93A mice reveals 
hSOD1 immunoreactivity in SLIs but not RBs. Motor neurons outlined in white, ChAT 
labeling not shown. Scale bar, 10 µm. 
 
D. Immunoprecipitation of p62 from lumbar spinal cord lysates reveals selective 
interaction with mutant hSOD1 during the later stages of SOD1G93A disease 
progression. Age is represented in weeks. 
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Figure 2.6 LC3 engulfs round bodies but not skein-like inclusions. 
 
A. Immunofluorescent labeling of p62 (red) and LC3 (green) in WT and SOD1G93A motor 
neurons reveals recruitment of LC3 to RBs but not SLIs. ChAT labeling not shown. 
Scale bar, 10 µm. 
 
B. Immunofluorescent labeling of p62 (red) in WT ; GFP-LC3 and SOD1G93A ; GFP-LC3 
mice. Endogenous fluorescence was enhanced through the use of an anti-GFP 
antibody (green). The resulting images reveal selective recruitment of LC3 to RBs but 
not SLIs. ChAT labeling not shown. Scale bar, 10 µm
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Figure 2.7 
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Figure 2.7 Loss of p62 does not block aggregate formation or alter survival in SOD1G93A 
mice. 
 
A-B. Immunofluorescent labeling of NBR1 (green) and p62 (red) in p62+/+ ; SOD1G93A 
and p62-/- ; SOD1G93A motor neurons reveals that RBs (A) and SLIs (B) still form in the 
absence of p62. ChAT labeling not shown. Scale bar, 20 µm. 
 
C. Immunofluorescent labeling of NBR1 (green) and GABARAPL1 (red) in p62+/+ ; 
SOD1G93A and p62-/- ; SOD1G93A mice shows that GABARAPL1 is still recruited to RBs 
in the absence of p62. ChAT labeling not shown. Scale bar, 20 µm. 
 
D. Immunofluorescent labeling of NBR1 (green) and p-c-Jun (red) in p62+/+ ; SOD1G93A 
and p62-/- ; SOD1G93A mice shows that p-c-Jun is still upregulated in the nuclei of SLI-
containing motor neurons in the absence of p62. ChAT labeling not shown. Scale bar, 
20 µm. 
 
E. Kaplan-Meier plot showing time to disease endstage in p62+/+ ; SOD1G93A (black) 
p62+/- ; SOD1G93A (grey) and p62-/- ; SOD1G93A (red) mice. Genotype does not 
significantly affect lifespan. Log-rank test = 0.6032; p = 0.7397. n = 9 animals per 
genotype. 
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Chapter	  3:	  Characterization	  of	  mice	  with	  autophagy	  inhibition	  in	  motor	  neurons	  
	  
3.1	  Introduction	  
	   In	  Chapter	  2,	  I	  characterized	  autophagy	  dysregulation	  in	  the	  SOD1G93A	  mouse	  model.	  
This	  revealed	  two	  forms	  of	  p62	  pathology	  in	  spinal	  motor	  neurons.	  In	  one	  subset	  of	  motor	  
neurons,	  p62	  is	  engulfed	  within	  LC3	  and	  GABARAPL1-­‐positive	  autophagosomes	  (RBs).	  In	  
another	  subset	  of	  motor	  neurons,	  p62	  fails	  to	  be	  engulfed	  within	  autophagosomes	  and	  
instead	  accumulates	  in	  somatodendritic	  compartments	  along	  with	  mutant	  SOD1	  (SLIs).	  
While	  RBs	  are	  specific	  to	  motor	  neurons	  in	  the	  early	  stages	  of	  SOD1G93A	  disease	  
progression,	  SLIs	  becomes	  more	  prominent	  in	  the	  later	  stages	  of	  disease	  and	  eventually	  
spread	  to	  spinal	  interneurons.	  While	  SLIs	  are	  associated	  with	  activation	  of	  a	  nuclear	  stress	  
response,	  RBs	  are	  not,	  suggesting	  that	  autophagy	  may	  be	  acting	  as	  a	  protective	  mechanism	  
in	  vulnerable	  motor	  neurons.	  These	  data	  implicate	  autophagy	  in	  SOD1G93A	  disease	  
pathogenesis,	  but	  the	  functional	  significance	  of	  this	  pathway	  in	  motor	  neurons	  remains	  
poorly	  understood.	  	  
Characterizing	  the	  role	  of	  basal	  autophagy	  in	  motor	  neuron	  biology	  is	  prerequisite	  
for	  understanding	  its	  role	  in	  ALS.	  Because	  of	  the	  enormous	  genetic	  redundancy	  among	  
autophagy	  receptors,	  depletion	  of	  specific	  proteins	  such	  as	  p62	  will	  not	  be	  sufficient	  
address	  this	  question.	  As	  I	  have	  shown,	  autophagosomes	  still	  form	  in	  the	  absence	  of	  this	  
protein.	  Concurrent	  deletion	  of	  multiple	  autophagy	  receptors	  is	  an	  attractive	  strategy,	  but	  
it	  is	  impractical	  because	  the	  list	  of	  such	  receptors	  continues	  to	  grow	  and	  it	  is	  likely	  that	  
many	  remain	  to	  be	  discovered.	  Therefore,	  alternative	  genetic	  approaches	  are	  required	  to	  
address	  the	  role	  of	  autophagy	  in	  motor	  neurons.	  In	  contrast	  to	  the	  autophagy	  receptors,	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individual	  Atg	  genes	  are	  required	  for	  autophagosome	  formation.	  Genetic	  deletion	  of	  Atg7	  is	  
a	  widely	  used	  strategy	  for	  inhibiting	  autophagy	  because	  it	  is	  required	  for	  two	  different	  
conjugation	  steps	  in	  autophagosome	  biogenesis	  (Atg12-­‐Atg5	  and	  Atg8-­‐PE).	  Furthermore,	  
the	  generation	  of	  conditional	  Atg7	  knockout	  mice	  has	  made	  it	  possible	  to	  inhibit	  autophagy	  
in	  specific	  cell	  populations	  (Komatsu,	  Waguri	  et	  al.	  2005).	  
To	  date,	  only	  one	  published	  study	  has	  deleted	  Atg7	  from	  motor	  neurons	  (Tashiro,	  
Urushitani	  et	  al.	  2012).	  These	  experiments	  revealed	  that	  autophagy	  inhibition	  in	  motor	  
neurons	  is	  not	  sufficient	  to	  cause	  overt	  neurological	  dysfunction.	  However,	  this	  study	  
neglected	  to	  pursue	  more	  in-­‐depth	  analysis	  of	  motor	  neuron	  structure	  and	  function.	  Loss	  of	  
autophagy	  has	  been	  reported	  to	  cause	  both	  neuronal	  death	  and	  synaptic	  abnormalities	  
(Komatsu,	  Wang	  et	  al.	  2007,	  Hernandez,	  Torres	  et	  al.	  2012,	  Inoue,	  Rispoli	  et	  al.	  2013),	  but	  
neither	  of	  these	  of	  these	  were	  examined	  mice	  with	  motor	  neuron-­‐specific	  autophagy	  




Genetic	  inhibition	  of	  autophagy	  in	  motor	  neurons	  
	   We	  generated	  motor	  neuron-­‐specific	  autophagy	  deficient	  mice	  by	  crossing	  
Atg7flox/flox	  mice	  to	  ChAT-­‐Cre	  mice	  (Atg7	  cKO)	  and	  compared	  them	  to	  littermate	  controls	  
with	  intact	  Atg7	  expression	  (Atg7	  cWT).	  Autophagy	  deficiency	  was	  confirmed	  by	  Western	  
blot	  analysis	  of	  p62,	  Atg5	  and	  LC3	  (Figure	  3.1A	  and	  3.1B).	  We	  observed	  dramatic	  
accumulation	  of	  p62,	  which	  is	  normally	  a	  substrate	  for	  autophagic	  degradation.	  We	  also	  
found	  accumulation	  of	  monomeric	  Atg5,	  which	  is	  normally	  conjugated	  to	  Atg12	  through	  the	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enzymatic	  activity	  of	  Atg7.	  Lastly,	  Atg7-­‐dependent	  conversion	  of	  LC3	  I	  to	  LC3	  II	  was	  also	  
reduced	  in	  Atg7	  cKO	  spinal	  cord	  lysates.	  	  Autophagy	  inhibition	  was	  further	  confirmed	  by	  
immunofluorescence	  analysis,	  which	  revealed	  p62	  accumulation	  within	  Atg7	  cKO	  motor	  
neurons	  (Figure	  3.1C).	  	  
	   Atg7	  cKO	  mice	  were	  viable	  and	  born	  at	  Mendelian	  ratios.	  Consistent	  with	  previous	  
reports,	  they	  did	  not	  display	  overt	  neurological	  defects	  (Tashiro,	  Urushitani	  et	  al.	  2012).	  
Analysis	  motor	  neuron	  size	  revealed	  a	  bimodal	  distribution,	  consistent	  with	  two	  distinct	  
populations	  of	  alpha	  and	  gamma	  motor	  neurons	  (Figure	  3.1D).	  However,	  this	  distribution	  
was	  shifted	  to	  larger	  sizes	  in	  Atg7	  cKO	  mice	  relative	  to	  Atg7	  cWT	  controls	  and	  mean	  motor	  
neuron	  size	  was	  significantly	  larger	  in	  Atg7	  cKO	  mice	  (Figure	  3.1E,	  mean	  ±	  SEM:	  698.6	  ±	  
27.07	  µm2	  versus	  510.5	  ±	  27.93	  µm2,	  p	  =	  0.0084	  two-­‐tailed	  t-­‐test).	  Despite	  this	  pronounced	  
morphological	  change,	  motor	  neuron	  number	  was	  unchanged	  in	  the	  L4-­‐L5	  lumbar	  spinal	  
segments	  (Figure	  3.1F,	  mean	  ±	  SEM:	  45.05	  ±	  0.88	  per	  70 µm	  section	  versus	  47.33	  ±	  0.81	  
per	  70 µm	  section,	  p	  =	  0.1289	  two-­‐tailed	  t-­‐test).	  These	  results	  indicate	  that	  autophagy	  in	  
motor	  neurons	  is	  dispensable	  for	  cell	  survival	  and	  negatively	  regulates	  cell	  size.	  
	   	  
Altered	  neuromuscular	  junction	  morphology	  in	  Atg7	  cKO	  mice	  
Loss	  of	  Atg7	  in	  dopaminergic	  neurons	  leads	  to	  dramatic	  expansion	  of	  presynaptic	  
terminals	  (Hernandez,	  Torres	  et	  al.	  2012,	  Inoue,	  Rispoli	  et	  al.	  2013).	  Based	  on	  this	  data,	  we	  
asked	  whether	  cholinergic	  innervation	  of	  muscle	  fibers	  by	  motor	  neurons	  was	  similarly	  
affected	  by	  autophagy	  inhibition.	  To	  do	  this,	  we	  crossed	  Atg7	  cKO	  and	  Atg7	  cWT	  mice	  to	  
transgenic	  mice	  expressing	  yellow	  fluorescent	  protein	  in	  motor	  neuron	  presynaptic	  
terminals	  (YFP-­‐16)	  (Feng,	  Mellor	  et	  al.	  2000).	  Then	  we	  stained	  the	  tibialis	  anterior	  from	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these	  mice	  with	  fluorescent	  α-­‐bungarotoxin	  conjugates	  to	  label	  postsynaptic	  motor	  
endplates.	  In	  Atg7	  cWT	  controls,	  neuromuscular	  junctions	  from	  the	  tibialis	  anterior	  muscle	  
exhibited	  stereotyped	  apposition	  between	  presynaptic	  terminals	  and	  motor	  endplates	  
(Figure	  3.2A).	  In	  contrast,	  we	  found	  that	  NMJs	  from	  Atg7	  cKO	  mice	  were	  highly	  
heterogeneous.	  A	  subset	  of	  NMJs	  appeared	  to	  be	  partly	  or	  completely	  denervated.	  
Meanwhile,	  another	  subset	  of	  NMJs	  showed	  an	  unusual	  morphology	  marked	  by	  presynaptic	  
swellings	  that	  often	  extended	  beyond	  the	  boundaries	  of	  the	  postsynaptic	  endplate	  (Figure	  
3.2A).	  Notably,	  some	  motor	  endplates	  also	  exhibited	  defects	  such	  as	  patchy	  α-­‐bungarotoxin	  
labeling,	  suggesting	  that	  presynaptic	  abnormalities	  in	  Atg7	  cKO	  mice	  can	  lead	  to	  non-­‐cell	  
autonomous	  effects	  on	  postsynaptic	  acetylcholine	  receptor	  content.	  This	  is	  consistent	  with	  
a	  well-­‐established	  role	  for	  nerve-­‐muscle	  crosstalk	  in	  sculpting	  NMJ	  morphology	  (Sanes	  and	  
Lichtman	  1999).	  
To	  objectively	  quantify	  presynaptic	  abnormalities	  in	  Atg7	  cKO	  mice,	  we	  developed	  a	  
custom	  image	  analysis	  suite	  for	  Comprehensive	  Analysis	  of	  Neuromuscular	  Junction	  
Innervation	  (CANJI).	  This	  software	  automatically	  segments	  α-­‐bungarotoxin	  labeled	  muscle	  
images	  into	  regions	  of	  interest	  (ROIs)	  corresponding	  to	  individual	  endplates.	  Then	  CANJI	  
measures	  the	  fraction	  of	  each	  ROI	  that	  is	  occupied	  by	  presynaptic	  marker	  and	  generates	  
histograms	  of	  NMJ	  percent	  occupancy.	  We	  compared	  percent	  occupancy	  measurements	  
determined	  by	  YFP	  labeling	  in	  YFP-­‐16	  mice	  with	  standard	  synaptophysin	  immunolabeling	  
and	  found	  them	  to	  be	  highly	  correlated	  (r	  =	  0.93,	  p	  <0.0001).	  Therefore,	  we	  proceeded	  to	  
use	  synaptophysin	  as	  our	  presynaptic	  marker	  for	  subsequent	  experiments.	  Analysis	  of	  
tibialis	  anterior	  muscles	  with	  CANJI	  revealed	  that	  NMJ	  percent	  occupancy	  distributions	  
were	  significantly	  different	  in	  Atg7	  cKO	  mice	  and	  Atg7	  cWT	  controls	  (p	  <	  2.2	  ×	  10-­‐16,	  two-­‐
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sample	  Kolmogorov-­‐Smirnov	  test).	  The	  distribution	  for	  control	  NMJs	  was	  bell-­‐shaped	  and	  
peaked	  at	  70%	  percent	  occupancy	  (Figure	  3.2B).	  This	  result	  was	  consistent	  with	  previous	  
analyses	  of	  NMJ	  morphology	  on	  Type	  II	  muscle	  fibers,	  which	  compose	  the	  majority	  of	  the	  
tibialis	  anterior	  (Prakash,	  Miller	  et	  al.	  1996).	  In	  contrast,	  the	  distribution	  for	  Atg7	  cKO	  NMJs	  
was	  U-­‐shaped,	  revealing	  a	  greater	  preponderance	  of	  NMJs	  with	  low	  percent	  occupancy	  and	  
NMJs	  that	  were	  fully	  occupied	  (Figure	  3.2B).	  We	  defined	  innervated	  NMJs	  as	  those	  with	  
>10%	  occupancy	  and	  found	  that	  there	  was	  a	  trend	  toward	  denervation	  in	  the	  tibialis	  
anterior	  of	  Atg7	  cKO	  mice	  relative	  to	  controls	  (Figure	  3.2C,	  mean	  ±	  SEM:	  91.4	  ±	  2.1%	  
versus	  97.2	  ±	  1.4%,	  p	  =	  0.0619	  two-­‐tailed	  t-­‐test).	  	  
Next	  we	  set	  out	  to	  quantify	  presynaptic	  swellings	  in	  Atg7	  cKO	  mice.	  We	  used	  CANJI	  
to	  define	  additional	  ROIs	  corresponding	  to	  a	  6	  µm-­‐wide	  extrasynaptic	  band	  surrounding	  
each	  motor	  endplate	  and	  measured	  the	  percent	  of	  NMJs	  with	  synaptophysin	  staining	  in	  this	  
region.	  We	  found	  that	  the	  percent	  of	  NMJs	  with	  presynaptic	  swellings	  was	  significantly	  
larger	  in	  Atg7	  cKO	  mice	  relative	  to	  Atg7	  cWT	  controls	  (Figure	  3.2D,	  mean	  ±	  SEM:	  12.2	  ±	  
0.9%	  versus	  3.4	  ±	  1.3%,	  p	  =	  0.0017	  two-­‐tailed	  t-­‐test).	  	  
	   	  Hindlimb	  muscles	  differ	  in	  their	  fiber	  subtypes	  and	  vulnerability	  to	  denervation	  in	  
motor	  neuron	  disease.	  The	  tibialis	  anterior	  is	  composed	  of	  primarily	  of	  fast-­‐twitch	  Type	  II	  
muscle	  fibers	  whereas	  the	  soleus	  is	  has	  a	  much	  larger	  fraction	  of	  slow-­‐twitch	  Type	  I	  muscle	  
fibers	  (Kammoun,	  Cassar-­‐Malek	  et	  al.	  2014).	  The	  tibialis	  anterior	  is	  denervated	  early	  in	  
SOD1G93A	  disease	  progression	  whereas	  the	  soleus	  is	  protected	  from	  denervation	  until	  late	  
stages	  of	  disease	  (Pun,	  Santos	  et	  al.	  2006,	  Valdez,	  Tapia	  et	  al.	  2012).	  We	  used	  CANJI	  to	  
generate	  NMJ	  percent	  occupancy	  distributions	  for	  the	  soleus	  muscles	  of	  Atg7	  cKO	  mice	  and	  
Atg7	  cWT	  controls	  (Figure	  3.2E).	  This	  revealed	  very	  high	  levels	  of	  NMJ	  occupancy	  in	  both	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genotypes,	  which	  was	  also	  consistent	  with	  previous	  measurements	  of	  NMJ	  morphology	  on	  
Type	  I	  muscle	  fibers	  (Prakash,	  Miller	  et	  al.	  1996).	  Unlike	  the	  tibialis	  anterior,	  there	  was	  no	  
trend	  towards	  denervation	  in	  Atg7	  cKO	  mice	  compared	  to	  Atg7	  cWT	  controls	  (Figure	  3.2F,	  
mean	  ±	  SEM:	  99.1	  ±	  0.9%	  versus	  97.3	  ±	  2.3%,	  p	  =	  0.5451	  two-­‐tailed	  t-­‐test).	  We	  also	  
compared	  the	  degree	  of	  presynaptic	  swellings	  in	  the	  soleus	  from	  Atg7	  cKO	  mice	  and	  Atg7	  
cWT	  controls.	  In	  contrast	  to	  the	  tibialis	  anterior,	  we	  found	  that	  a	  substantial	  fraction	  of	  
soleus	  NMJs	  from	  control	  mice	  exhibited	  presynaptic	  swellings,	  though	  autophagy	  
inhibition	  still	  increased	  their	  frequency	  dramatically	  in	  Atg7	  cKO	  mice	  (Figure	  3.2G,	  mean	  
±	  SEM:	  46.8	  ±	  11.9%	  versus	  13.9	  ±	  1.8%,	  p	  =	  0.0229	  two-­‐tailed	  t-­‐test).	  	  	  
	  
Ultrastructural	  analysis	  of	  motor	  axons	  and	  presynaptic	  terminals	  in	  Atg7	  cKO	  mice.	  
	   As	  described	  above,	  immunofluorescent	  labeling	  of	  neuromuscular	  junctions	  from	  
Atg7	  cKO	  mice	  revealed	  dramatic	  morphological	  changes.	  To	  determine	  the	  subcellular	  
basis	  of	  these	  morphological	  changes,	  we	  investigated	  the	  ultrastucture	  of	  these	  synapses	  
by	  electron	  microscopy.	  We	  first	  examined	  motor	  neuron	  axons	  from	  the	  tibialis	  anterior	  
muscle,	  which	  are	  easily	  identifiable	  because	  they	  are	  surrounded	  by	  electron-­‐dense	  
myelin.	  In	  control	  animals,	  we	  observed	  normal	  axons	  that	  contained	  mitochondria	  and	  
sparse	  endoplasmic	  reticulum.	  	  In	  contrast,	  we	  observed	  numerous	  axonal	  swellings	  in	  
Atg7	  cKO	  mice	  that	  were	  absent	  from	  controls.	  These	  are	  likely	  to	  correlate	  with	  the	  axonal	  
swellings	  that	  we	  identified	  by	  immunofluorescence.	  In	  contrast	  to	  the	  relatively	  
unobstructed	  axonal	  lumen	  in	  control	  animals,	  Atg7	  cKO	  mice	  exhibited	  dramatic	  
accumulation	  of	  ER	  in	  motor	  axons	  (Figure	  3.3A,	  right	  panel).	  	  This	  ER	  was	  noticeably	  
thicker	  and	  more	  electron	  dense	  than	  the	  sparse	  endoplasmic	  reticulum	  observed	  in	  motor	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axons	  from	  control	  animals.	  We	  quantified	  the	  percent	  of	  the	  axon	  lumen	  that	  was	  occupied	  
by	  endoplasmic	  reticulum	  and	  confirmed	  that	  this	  was	  significantly	  elevated	  in	  Atg7	  cKO	  
mice	  relative	  to	  Atg7	  cWT	  controls	  (Figure	  XB,	  mean	  ±	  SEM:	  12.3	  ±	  1.9%	  versus	  2.9	  ±	  0.5%,	  
p	  =	  0.0004	  two-­‐tailed	  t-­‐test).	  
Next	  we	  turned	  our	  attention	  to	  the	  neuromuscular	  junction	  itself.	  In	  control	  
animals	  we	  found	  normal	  apposition	  of	  the	  presynaptic	  terminal	  and	  motor	  endplate,	  
which	  was	  easily	  identifiable	  by	  elaborate	  junctional	  folds	  (Figure	  3.3C,	  left	  panel).	  
Presynaptic	  mitochondria	  and	  synaptic	  vesicles	  were	  found	  with	  the	  expected	  distribution.	  
In	  contrast	  to	  the	  control	  animals,	  we	  found	  several	  abnormalities	  in	  the	  ultrastucture	  of	  
Atg7	  cKO	  neuromuscular	  junctions.	  A	  subset	  of	  motor	  endplates	  showed	  complete	  or	  
partial	  denervation	  (Figure	  3.3C,	  middle	  panel).	  	  In	  addition,	  we	  observed	  a	  subset	  of	  
synapses	  where	  the	  presynaptic	  terminal	  contained	  abnormally	  high	  density	  of	  synaptic	  
vesicles	  (Figure	  3.3C,	  right	  panel).	  These	  neuromuscular	  junctions	  were	  also	  defined	  by	  
small	  junctional	  folds	  that	  lacked	  the	  pronounced	  branching	  that	  is	  normally	  observed	  in	  
controls.	  Thus,	  it	  appears	  that	  the	  presynaptic	  terminal	  is	  overdeveloped	  relative	  to	  motor	  
endplate,	  which	  may	  correspond	  to	  areas	  of	  overgrowth	  that	  were	  visualized	  by	  
immunofluorescence.	  In	  summary,	  ultrastuctural	  analysis	  of	  Atg7	  cKO	  mice	  confirmed	  that	  
NMJs	  in	  the	  tibialis	  anterior	  were	  highly	  heterogeneous	  and	  marked	  by	  poor	  apposition	  
between	  presynaptic	  terminals	  and	  motor	  endplates.	  
	  
Electrophysiological	  analysis	  of	  neuromuscular	  junctions	  in	  Atg7	  cKO	  mice	  
	   Because	  immunofluorescence	  and	  ultrastructural	  analyses	  of	  autophagy	  deficient	  
NMJs	  revealed	  gross	  morphological	  abnormalities,	  we	  hypothesized	  that	  this	  might	  be	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associated	  with	  altered	  synaptic	  function.	  To	  investigate	  functional	  changes,	  we	  employed	  
patch	  clamp	  recordings	  from	  acutely	  isolated	  tibialis	  anterior	  muscles.	  	  We	  began	  by	  
examining	  spontaneous	  release	  of	  individual	  synaptic	  vesicles,	  which	  can	  be	  detected	  as	  
miniature	  endplate	  currents	  (mEPCs).	  	  In	  Atg7	  cKO	  NMJs,	  there	  was	  no	  change	  in	  the	  
frequency	  of	  spontaneous	  mEPCs	  compared	  to	  controls	  (mean	  ±	  SEM:	  3.19	  ±	  0.44	  Hz	  
versus	  2.94	  ±	  0.47	  Hz,	  p	  =	  0.693).	  	  There	  was,	  however,	  a	  reduction	  in	  mEPC	  amplitude	  
relative	  to	  control	  NMJs	  (Figure	  3.4A	  and	  3.4C,	  mean	  ±	  SEM:	  1.20	  ±	  0.03	  nA	  versus	  1.52	  ±	  
0.03	  nA,	  p	  <	  0.01).	  	  Reduction	  in	  mEPC	  amplitude	  can	  be	  due	  to	  a	  reduction	  in	  the	  amount	  
of	  acetylcholine	  contained	  in	  a	  single	  vesicle,	  reduction	  in	  the	  density	  of	  postsynaptic	  
acetylcholine	  receptors	  or	  impaired	  coupling	  between	  presynaptic	  and	  postsynaptic	  
terminals.	  Though	  we	  cannot	  definitively	  discriminate	  between	  these	  possibilities,	  
immunofluorescence	  and	  ultrastructural	  data	  provide	  support	  for	  the	  two	  latter	  
explanations.	  
Next	  we	  stimulated	  the	  nerve	  to	  the	  tibialis	  anterior	  to	  measure	  neurotransmitter	  
release	  evoked	  by	  action	  potentials.	  	  The	  number	  of	  synaptic	  vesicles	  that	  are	  released	  
upon	  nerve	  stimulation	  depends	  on	  both	  the	  number	  of	  releasable	  vesicles	  and	  the	  
probability	  of	  vesicle	  release.	  	  To	  analyze	  both	  of	  these	  parameters,	  we	  recorded	  from	  NMJs	  
in	  external	  solutions	  containing	  either	  normal	  external	  calcium	  and	  magnesium	  (2	  mM	  
Ca2+,	  0.7	  mM	  Mg2+)	  or	  low	  external	  calcium	  and	  elevated	  magnesium	  (1	  mM	  Ca2+,	  8	  mM	  
Mg2+).	  	  When	  external	  calcium	  is	  low	  and	  magnesium	  is	  elevated,	  probability	  of	  release	  is	  
the	  limiting	  factor.	  	  When	  external	  calcium	  and	  magnesium	  are	  normal,	  probability	  of	  
release	  is	  near	  1	  at	  the	  NMJ	  so	  the	  number	  of	  releasable	  vesicles	  is	  the	  limiting	  factor	  
(Wang,	  Wang	  et	  al.	  2010).	  	  The	  number	  of	  vesicles	  released	  (quantal	  content,	  QC)	  was	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calculated	  by	  dividing	  the	  peak	  amplitude	  of	  endplate	  currents	  (EPCs)	  by	  the	  amplitude	  of	  
mEPCs.	  	  	  
When	  external	  calcium	  was	  normal,	  there	  was	  a	  statistically	  significant	  reduction	  in	  
endplate	  current	  in	  Atg7	  cKO	  NMJs	  that	  was	  due	  to	  both	  reduction	  in	  mEPC	  amplitude	  and	  
QC	  (Figure	  3.4A-­‐3.4D).	  The	  reduction	  in	  QC	  was	  not	  uniform	  across	  NMJs	  (Figure	  3.4E).	  	  
Some	  NMJs	  had	  normal	  or	  even	  elevated	  QC,	  while	  other	  NMJs	  had	  greatly	  reduced	  QC.	  We	  
also	  used	  repetitive	  stimulation	  at	  50	  Hz	  to	  examine	  the	  rate	  of	  vesicle	  mobilization	  (Wang	  
2004)	  and	  found	  significantly	  more	  depression	  in	  Atg7	  cKO	  NMJs	  (Figure	  3.4F	  and	  3.4G).	  
As	  expected,	  EPC	  amplitude	  was	  lower	  in	  both	  genotypes	  when	  external	  calcium	  
was	  reduced.	  Surprisingly,	  when	  the	  genotypes	  were	  compared,	  EPC	  amplitude	  was	  found	  
to	  be	  higher	  in	  Atg7	  cKO	  mice	  relative	  to	  controls,	  and	  this	  was	  due	  to	  an	  increase	  in	  QC	  
that	  more	  than	  made	  up	  for	  the	  reduction	  in	  mEPC	  amplitude	  (Figure	  3.4H-­‐3.4K).	  
Therefore,	  the	  observed	  decrease	  in	  QC	  at	  a	  subset	  of	  Atg7	  cKO	  NMJs	  under	  normal	  calcium	  
conditions	  cannot	  be	  explained	  by	  a	  reduction	  in	  the	  probability	  of	  release.	  Instead,	  it	  is	  
likely	  that	  the	  number	  of	  releasable	  vesicles	  is	  reduced	  at	  the	  affected	  NMJs.	  Increased	  
depression	  upon	  repetitive	  stimulation	  suggests	  that	  a	  reduction	  in	  vesicle	  mobilization	  
may	  be	  a	  contributing	  factor.	  In	  summary,	  these	  data	  suggest	  that	  autophagy	  inhibition	  
causes	  multiple	  abnormalities	  in	  NMJ	  function	  that	  are	  particularly	  severe	  in	  a	  subset	  of	  
NMJs.	  	  	  
	  
Altered	  morphology	  of	  motor	  neuron-­‐Renshaw	  cell	  synapse	  in	  Atg7	  cKO	  mice	  
	   In	  addition	  to	  innervating	  skeletal	  muscle	  in	  the	  periphery,	  motor	  neurons	  also	  
make	  synapses	  onto	  inhibitory	  interneurons.	  Motor	  neuron	  axons	  bifurcate	  as	  they	  exit	  the	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ventral	  horn	  and	  send	  fine	  axon	  collaterals	  to	  a	  small	  group	  of	  calbindin-­‐positive	  
interneurons	  called	  Renshaw	  cells.	  In	  turn,	  these	  cells	  make	  inhibitory	  synapses	  back	  onto	  
motor	  neurons,	  and	  this	  negative	  feedback	  loop	  is	  thought	  to	  limit	  motor	  neuron	  
excitability	  (Bhumbra,	  Bannatyne	  et	  al.	  2014).	  Moreover,	  this	  circuit	  is	  disrupted	  in	  the	  
SOD1G93A	  mouse	  model	  of	  ALS	  (Wootz,	  Fitzsimons-­‐Kantamneni	  et	  al.	  2013).	  Based	  on	  the	  
morphological	  abnormalities	  we	  observed	  at	  the	  NMJ	  in	  Atg7	  cKO	  mice,	  we	  asked	  whether	  
the	  motor	  neuron-­‐Renshaw	  cell	  synapse	  was	  similarly	  affected	  by	  autophagy	  inhibition.	  
We	  stained	  spinal	  cord	  sections	  with	  antibodies	  against	  the	  vesicular	  acetylcholine	  
transporter	  (VAChT)	  and	  calbindin	  to	  visualize	  cholinergic	  presynaptic	  terminals	  and	  
Renshaw	  cells,	  respectively.	  We	  found	  a	  striking	  enhancement	  of	  VAChT	  immunoreactivity	  
in	  a	  region	  corresponding	  to	  the	  Renshaw	  cell	  area	  (Figure	  3.5A).	  Visualizing	  this	  area	  
under	  higher	  magnification	  revealed	  numerous	  enlarged	  presynaptic	  terminals	  (Figure	  
3.5B).	  To	  quantify	  these	  changes,	  we	  reconstructed	  the	  dendritic	  trees	  of	  Renshaw	  cells	  
from	  three-­‐dimensional	  confocal	  images	  and	  measured	  the	  size	  and	  density	  of	  VAChT	  
positive	  presynaptic	  terminals.	  We	  found	  that	  many	  VAChT-­‐positive	  terminals	  from	  Atg7	  
cKO	  mice	  were	  similar	  in	  size	  to	  control	  animals,	  but	  a	  subset	  of	  synapses	  were	  markedly	  
enlarged	  (Figure	  3.5C).	  When	  we	  compared	  the	  mean	  cross-­‐sectional	  area	  of	  VAChT-­‐
positive	  terminals,	  we	  found	  that	  they	  were	  significantly	  enlarged	  in	  Atg7	  cKO	  mice	  relative	  
to	  controls	  (Figure	  3.5D,	  mean	  ±	  SEM:	  4.51	  ±	  0.17	  µm2	  versus	  2.76	  ±	  0.22	  µm2,	  p	  =	  0.0033	  
two-­‐tailed	  t-­‐test).	  By	  dividing	  the	  number	  of	  VAChT-­‐positive	  terminals	  by	  the	  length	  of	  
reconstructed	  dendrites,	  we	  calculated	  the	  linear	  density	  of	  these	  synapses.	  However,	  we	  
did	  not	  observe	  any	  difference	  in	  this	  parameter	  between	  Atg7	  cKO	  mice	  and	  Atg7	  cWT	  
controls	  (Figure	  3.5E,	  mean	  ±	  SEM:	  9.85	  ±	  1.07	  terminals/100	  µm	  versus	  9.04	  ±	  0.58	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terminals/100	  µm,	  p	  =	  0.5453	  two-­‐tailed	  t-­‐test).	  In	  summary,	  these	  data	  indicate	  that	  
autophagy	  inhibition	  alters	  the	  size	  but	  not	  the	  number	  of	  motor	  neuron-­‐Renshaw	  cell	  
synapses.	  	  Taken	  together	  with	  our	  observations	  at	  the	  NMJ,	  these	  results	  show	  that	  
autophagy	  is	  a	  critical	  regulator	  of	  presynaptic	  morphology	  in	  both	  the	  central	  and	  
peripheral	  nervous	  system.	  
	  
3.3	  Discussion	  
	   In	  Chapter	  2,	  I	  showed	  that	  autophagy	  is	  dysregulated	  during	  SOD1G93A	  disease	  
progression.	  In	  this	  chapter,	  I	  describe	  our	  studies	  on	  the	  role	  of	  autophagy	  in	  normal	  
motor	  neuron	  biology.	  We	  generated	  Atg7	  cKO	  mice	  and	  confirmed	  that	  this	  manipulation	  
led	  to	  loss	  of	  autophagy	  in	  motor	  neurons.	  Moreover	  we	  identified	  autophagy	  as	  a	  critical	  
regulator	  of	  synaptic	  structure	  and	  function	  in	  these	  cells.	  	  
	  
Autophagy	  is	  dispensable	  for	  motor	  neuron	  survival	  and	  negatively	  regulates	  cell	  size	  
	   It	  has	  been	  proposed	  that	  disrupted	  autophagy	  may	  be	  a	  contributing	  factor	  in	  the	  
pathogenesis	  of	  neurodegenerative	  diseases	  (Menzies,	  Fleming	  et	  al.	  2015).	  Here	  we	  show	  
loss	  of	  autophagy	  in	  motor	  neurons	  is	  not	  sufficient	  to	  cause	  an	  overt	  neurological	  
phenotype	  in	  mice.	  Moreover,	  the	  number	  of	  motor	  neurons	  in	  the	  lumbar	  spinal	  cord	  
remains	  unchanged	  in	  Atg7	  cKO	  mice,	  indicating	  that	  autophagy	  is	  not	  required	  for	  motor	  
neuron	  survival.	  These	  results	  show	  that	  autophagy	  inhibition	  in	  motor	  neurons	  is	  not	  
sufficient	  to	  recapitulate	  ALS-­‐associated	  neurodegeneration.	  Nonetheless,	  it	  is	  possible	  that	  
autophagy	  serves	  as	  a	  protective	  response	  to	  toxic	  insults,	  and	  that	  the	  detrimental	  effects	  
of	  autophagy	  inhibition	  on	  motor	  neuron	  viability	  are	  only	  exposed	  in	  the	  presence	  of	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disease-­‐relevant	  stressors	  such	  as	  mutations	  to	  aggregation-­‐prone	  proteins.	  We	  will	  test	  
this	  possibility	  in	  Chapter	  4.	  
	   Although	  autophagy	  inhibition	  did	  not	  affect	  motor	  neuron	  number,	  it	  did	  cause	  a	  
substantial	  increase	  in	  motor	  neuron	  size.	  This	  is	  consistent	  with	  a	  substantial	  body	  of	  
work	  implicating	  autophagy	  in	  the	  control	  of	  cell	  growth	  and	  cell	  size	  (Neufeld	  2012).	  In	  
one	  of	  the	  first	  reported	  examples	  of	  such	  regulation,	  Drosophila	  fat	  body	  cells	  were	  
observed	  to	  shrink	  in	  size	  dramatically	  upon	  starvation	  (Butterworth,	  Bodenstein	  et	  al.	  
1965).	  Conversely,	  induction	  of	  autophagy	  by	  overexpression	  of	  Atg1	  is	  sufficient	  to	  
decrease	  the	  size	  of	  these	  cells	  (Scott,	  Juhasz	  et	  al.	  2007).	  In	  dopaminergic	  neurons,	  
inhibition	  of	  autophagy	  by	  deletion	  of	  Atg7	  has	  been	  shown	  to	  increase	  cell	  size,	  and	  this	  
effect	  can	  be	  potentiated	  by	  concurrent	  loss	  PTEN,	  suggesting	  coordinate	  regulation	  
neuronal	  size	  by	  these	  two	  pathways	  (Inoue,	  Rispoli	  et	  al.	  2013).	  Thus,	  our	  result	  is	  
consistent	  with	  a	  generalized	  role	  for	  autophagy	  in	  the	  control	  of	  cell	  size.	  
	  
Loss	  of	  autophagy	  alters	  the	  structure	  and	  function	  of	  motor	  neuron	  presynaptic	  terminals	  
	   In	  addition	  to	  controlling	  cell	  size,	  we	  find	  that	  autophagy	  regulates	  presynaptic	  
morphology	  at	  the	  mammalian	  neuromuscular	  junction.	  In	  the	  tibialis	  anterior,	  these	  
effects	  appear	  to	  be	  highly	  heterogeneous.	  While	  some	  synapses	  became	  engorged	  and	  
overgrew	  the	  motor	  endplate,	  others	  became	  partially	  or	  completely	  denervated.	  These	  
results	  are	  consistent	  with	  recent	  studies	  illustrating	  a	  role	  for	  autophagy	  in	  regulating	  
presynaptic	  structure	  in	  Purkinje	  cells	  and	  dopaminergic	  neurons	  (Komatsu,	  Wang	  et	  al.	  
2007,	  Hernandez,	  Torres	  et	  al.	  2012,	  Inoue,	  Rispoli	  et	  al.	  2013).	  Thus,	  autophagy	  appears	  to	  
be	  a	  conserved	  regulator	  of	  presynaptic	  structure	  in	  a	  variety	  of	  neuronal	  cell	  types.	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The	  effects	  of	  autophagy	  inhibition	  on	  synaptic	  morphology	  were	  confirmed	  by	  
electron	  microscopy,	  which	  revealed	  similar	  heterogeneity	  at	  the	  ultrastructural	  level.	  
These	  experiments	  also	  indicated	  that	  accumulation	  of	  ER	  membranes	  might	  contribute	  to	  
presynaptic	  swellings.	  	  This	  is	  consistent	  with	  a	  role	  for	  selective	  autophagy	  in	  regulating	  
ER	  abundance,	  especially	  at	  the	  cell	  periphery	  (Khaminets,	  Heinrich	  et	  al.	  2015).	  
To	  test	  whether	  morphological	  abnormalities	  were	  associated	  with	  functional	  
changes,	  we	  used	  patch	  clamp	  electrophysiology	  to	  measure	  neurotransmission	  at	  mutant	  
NMJs.	  These	  experiments	  revealed	  a	  reduction	  in	  mEPC	  amplitude	  relative	  to	  control	  NMJs,	  
which	  likely	  reflects	  alterations	  in	  postsynaptic	  acetylcholine	  receptor	  content	  and	  
impaired	  apposition	  between	  pre	  and	  postsynaptic	  terminals	  in	  Atg7	  cKO	  mice.	  When	  we	  
stimulated	  neurotransmitter	  release	  by	  evoking	  presynaptic	  action	  potentials,	  we	  found	  
that	  EPC	  amplitude	  was	  also	  reduced	  in	  Atg7	  cKO	  mice.	  This	  was	  due	  to	  decreased	  mEPC	  
amplitude	  as	  well	  as	  an	  overall	  reduction	  in	  quantal	  content.	  The	  effect	  of	  autophagy	  
inhibition	  on	  individual	  NMJs	  was	  highly	  variable,	  mirroring	  the	  morphological	  
heterogeneity	  that	  we	  observed	  by	  immunofluorescent	  and	  ultrastructural	  analyses.	  	  A	  
subset	  of	  NJMs	  exhibited	  dramatic	  reductions	  in	  quantal	  content,	  indicating	  that	  these	  
synapses	  were	  especially	  dependent	  on	  autophagy	  for	  their	  function.	  	  
The	  effects	  of	  autophagy	  inhibition	  on	  NMJ	  structure	  and	  function	  in	  the	  tibialis	  
anterior	  muscle	  are	  notable	  for	  their	  heterogeneity.	  Similar	  heterogeneity	  was	  also	  
observed	  at	  motor	  neuron-­‐Renshaw	  cell	  synapses.	  Why	  does	  autophagy	  exert	  different	  
effects	  on	  different	  synapses?	  One	  possibility	  is	  that	  the	  effects	  of	  autophagy	  inhibition	  are	  
simply	  stochastic.	  However,	  an	  alternative	  possibility	  is	  that	  differences	  in	  synaptic	  
responses	  to	  autophagy	  inhibition	  are	  a	  reflection	  of	  motor	  neuron	  diversity.	  It	  is	  well	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established	  that	  motor	  neurons	  differ	  in	  their	  anatomical	  and	  molecular	  properties,	  and	  it	  
is	  possible	  that	  they	  also	  differ	  in	  their	  relative	  dependence	  on	  autophagy	  for	  maintaining	  
synaptic	  integrity.	  This	  is	  idea	  is	  reminiscent	  of	  the	  subtype-­‐specific	  differences	  in	  the	  
regulation	  of	  autophagy	  in	  SOD1G93A	  motor	  neurons	  described	  in	  Chapter	  2.	  	  
The	  soleus	  muscle	  differs	  from	  the	  tibialis	  anterior	  both	  in	  fiber	  type	  composition	  
and	  in	  terms	  of	  the	  motor	  neurons	  by	  which	  it	  is	  innervated.	  	  Unlike	  the	  tibialis	  anterior,	  we	  
did	  not	  observe	  any	  trend	  toward	  denervation	  upon	  autophagy	  inhibition.	  	  This	  data	  
suggests	  that	  motor	  neurons	  innervating	  the	  soleus	  muscle	  are	  less	  dependent	  on	  
autophagy	  for	  the	  maintenance	  of	  neuromuscular	  innervation	  than	  those	  innervating	  the	  
tibialis	  anterior.	  The	  disparate	  effects	  of	  autophagy	  inhibition	  on	  the	  innervation	  of	  these	  
two	  muscles	  may	  help	  explain	  their	  differential	  vulnerability	  in	  the	  context	  of	  ALS.	  	  Though	  
disruption	  of	  autophagy	  in	  Atg7	  cKO	  mice	  is	  not	  sufficient	  to	  recapitulate	  the	  widespread	  
deneveration	  observed	  in	  ALS	  patients	  and	  animal	  models,	  elevated	  sensitivity	  to	  
autophagy	  inhibition	  may	  still	  be	  a	  contributing	  factor	  in	  the	  specific	  vulnerability	  of	  a	  
subset	  of	  NMJs.	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Figure 3.1 Autophagy inhibition in motor neurons increases cell size and does not lead 
to cell death.    
 
A. Western blot analysis of autophagy markers in lumbar spinal cord homogenates from 
P150 Atg7 cKO mice and Atg7 cWT controls. Loss of autophagy was indicated by 
increased p62 levels, the presence of monomeric Atg5 not conjugated to Atg12 and 
decreased LC3 II/I ratio. 
 
B. Quantification of p62 levels normalized to actin and the LC3 II/I ratio. n = 3 animals 
per genotype. **p < 0.01, ***p < 0.001 (two-tailed t-test). 
 
C. Immunofluorescent labeling of ChAT (green) and p62 (red) in motor neurons from 
Atg7 cKO mice and Atg7 cWT controls. Scale bar, 25 µm. 
 
D. Size distribution of motor neuron cross-sectional areas. n = 3 animals per genotype. 
Bars correspond to 50 µm2 bins. Sum of two gaussians non-linear fit is superimposed 
(r2 = 0.9462 and 0.9561 for Atg7 cWT and Atg7 cKO, respectively). 
 
E. Mean cross-sectional area of motor neurons was significantly larger in P150 Atg7 
cKO mice relative to Atg7 cWT controls. n = 3 animals per genotype. **p < 0.01 (two-
tailed t-test). 
 
F. No difference in the average number of motor neurons per 70 µm section from P150 
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Figure 3.2 Autophagy inhibition alters neuromuscular innervation. 
  
A. Visualization of α-bungarotoxin-labeled motor endplates (red) and YFP labeled 
presynaptic terminals (green) from the tibialis anterior muscles of Atg7 cWT ; YFP-16 
and Atg7 cKO ; YFP-16 mice. Scale bar, 20 µm. 
 
B. Distributions of NMJ percent occupancy in the tibialis anterior muscles of Atg7 cWT 
(grey) and Atg7 cKO (red) mice are significantly different. n = 4 animals per genotype. p 
< 2.2 × 10-16 (two-sample Kolmogorov-Smirnov test). 
 
C. Quantification of the percent of tibialis anterior NMJs with at least partial presynaptic 
occupancy reveals a trend towards reduced innervation in Atg7 cKO (red) mice relative 
to Atg7 cWT (grey) controls. n = 4 animals per genotype. p = 0.0619 (two-tailed t-test). 
 
D. Quantification of the percent of tibialis anterior NMJs with presynaptic terminals that 
extend beyond motor endplates reveals increased overgrowth in Atg7 cKO (red) mice 
relative to Atg7 cWT (grey) controls. n = 4 animals per genotype. **p < 0.01 (two-tailed 
t-test). 
 
E. Distributions of NMJ percent occupancy in the soleus muscles of Atg7 cWT (grey) 
and Atg7 cKO (red) mice are significantly different. n = 4 animals per genotype. p < 2.2 
× 10-16 (two-sample Kolmogorov-Smirnov test). 
 
F. Quantification of the percent of soleus NMJs with at least partial presynaptic 
occupancy shows no difference between Atg7 cKO (red) mice and Atg7 cWT (grey) 
controls. n = 3-4 animals per genotype. p = 0.5451 (two-tailed t-test). 
 
G. Quantification of the percent of soleus NMJs with presynaptic terminals that extend 
beyond motor endplates reveals increased overgrowth in Atg7 cKO (red) mice relative 
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Figure 3.3 Ultrastructure of motor axons and presynaptic terminals in Atg7 cKO mice. 
 
A. Electron micrographs reveal increased ER content in motor axons from the tibialis 
anterior muscle of P150 Atg7 cKO mice relative to Atg7 cWT controls. Scale bar, 1 µm. 
 
B. Quantification of the percent of axon lumen occupied by ER in motor axons from 
Atg7 cKO mice and Atg7 cWT controls. n = 8-9 axons per genotype. 
 
C. Electron micrographs of neuromuscular junctions from Atg7 cKO mice and Atg7 cWT 
controls. Presynaptic terminals and muscle have been pseudocolored green and red, 
respectively. Scale bar, 0.5 µm. 
 
Collaboration with Juan Carlos Tapia 
	   95	  
Figure 3.4 
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Figure 3.4 Altered neurotransmission in Atg7 cKO mice 
 
A. EPC and mEPC traces from tibialis anterior NMJs in Atg7 cWT (grey) and Atg7 cKO 
(red) mice. Each trace is an average of 6 NMJs.  
 
B-D. Mean EPC amplitude, mEPC amplitude and QC are significantly decreased in 
Atg7 cKO (red) mice relative to Atg7 cWT (grey) controls. n = 5 animals per genotype. 
*p < 0.05, **p < 0.01 
 
E. Distribution of QC measurements from individual NMJs reveals greater variability in 
Atg7 cKO (red) mice relative to Atg7 cWT (grey) controls. n = 109 and 99 NMJs, 
respectively. 
 
F. EPCs evoked by a train of 10 pulses (P1-P10) delivered at 50 Hz. Each trace is an 
average of 6 NMJs. 
 
G. Ratio of EPC amplitude evoked by P10 compared to P1. Greater depression in Atg7 
cKO (red) mice relative to Atg7 cWT controls (grey). n = 5 animals per genotype. *p < 
0.05 
 
H. EPC and mEPC traces from tibialis anterior NMJs in Atg7 cWT (grey) and Atg7 cKO 
(red) mice under low calcium conditions. Each trace is an average of 6 NMJs. 
 
I-K. Under low calcium conditions, EPC amplitude and QC are significantly elevated in 
Atg7 cKO (red) mice compared to Atg7 cWT (grey) controls while mEPC amplitude is 
still reduced. n = 4 animals per genotype. **p < 0.01 
 
Collaboration with Mark Rich and Xueyong Wang 
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Figure 3.5 Autophagy inhibition increases the size of motor neuron-Renshaw cell 
synapses without affecting synapse number. 
 
A. Immunofluorescent labeling of calbindin-positive Renshaw cells (red) and VAChT-
positive cholinergic presynaptic terminals (green) in the ventral horn of Atg7 cWT and 
Atg7 cKO mice at P150. Scale bar, 100 µm. 
 
B. High magnification images of individual calbindin-positive Renshaw cell dendrites 
(red) and associated VAChT-positive terminals (green) in Atg7 cWT and Atg7 cKO mice 
at P150. Scale bar, 5 µm. 
 
C. Size distribution of VAChT-positive terminals contacting Renshaw cell dendrites in 
Atg7 cWT and Atg7 cKO mice at P150. Each dot represents one terminal. n = 200 
terminals per genotype. 
 
D. Mean cross-sectional area of VAChT-positive terminals in Atg7 cWT and Atg7 cKO 
mice at P150. n = 3 animals per genotype. 
 
E. Quantification of VAChT-positive terminals per 100 µm of linear Renshaw cell 
dendrite did not show a difference between Atg7 cKO mice and Atg7 cWT controls. n = 
3 animals per genotype. 
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   In	  Chapter	  3,	  I	  presented	  the	  generation	  and	  characterization	  of	  Atg7	  cKO	  mice,	  in	  
which	  autophagy	  is	  specifically	  inhibited	  in	  motor	  neurons.	  I	  showed	  that	  inhibition	  of	  
autophagy	  did	  not	  result	  in	  motor	  neuron	  cell	  death,	  but	  rather	  an	  increase	  in	  motor	  
neuron	  size.	  Furthermore,	  I	  showed	  that	  autophagy	  inhibition	  caused	  structural	  changes	  to	  
motor	  neuron	  presynaptic	  terminals	  in	  the	  peripheral	  and	  central	  nervous	  system.	  At	  the	  
neuromuscular	  junction,	  I	  showed	  that	  that	  the	  effects	  of	  autophagy	  inhibition	  were	  
heterogeneous	  such	  that	  some	  synapses	  were	  innervated	  weakly	  or	  not	  at	  all,	  whereas	  
others	  showed	  large	  presynaptic	  swellings	  that	  extended	  beyond	  the	  motor	  endplate.	  I	  
presented	  ultrastructural	  evidence	  for	  both	  of	  these	  morphological	  abnormalities	  and	  
demonstrated	  that	  autophagy	  inhibition	  led	  to	  presynaptic	  accumulation	  of	  ER	  membranes.	  
Lastly,	  I	  described	  how	  neuromuscular	  function	  was	  impaired	  by	  autophagy	  inhibition.	  
	   Despite	  these	  morphological	  and	  functional	  changes	  in	  Atg7	  cKO	  mice,	  they	  still	  
survive	  beyond	  2	  years	  of	  age	  and	  do	  not	  show	  any	  overt	  neurological	  abnormalities.	  
Therefore,	  autophagy	  inhibition	  is	  not	  sufficient	  to	  cause	  motor	  neuron	  disease.	  However,	  
as	  I	  showed	  in	  Chapter	  2,	  the	  autophagy	  pathway	  is	  clearly	  dysregulated	  in	  the	  SOD1G93A	  
mouse	  model.	  This	  data,	  combined	  with	  a	  wealth	  of	  human	  genetic	  evidence	  implicating	  the	  
autophagy	  pathway	  in	  ALS,	  suggests	  that	  autophagy	  could	  still	  be	  playing	  an	  important	  role	  
in	  the	  biology	  of	  motor	  neuron	  disease.	  Nonetheless,	  the	  nature	  of	  this	  role	  remains	  
opaque.	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On	  one	  hand,	  autophagy	  may	  be	  playing	  a	  protective	  role.	  As	  I	  showed	  in	  Chapter	  2,	  
the	  autophagosomes	  that	  form	  in	  SOD1G93A	  motor	  neurons	  contain	  ubiquitin,	  suggesting	  
they	  might	  be	  involved	  in	  degrading	  potentially	  toxic	  ubiquitinated	  proteins.	  On	  the	  other	  
hand,	  autophagy	  could	  be	  playing	  a	  detrimental	  role.	  This	  is	  supported	  by	  data	  from	  mice	  
expressing	  mutant	  SOD1,	  in	  which	  autophagy	  activation	  by	  rapamycin	  worsens	  the	  disease	  
phenotype	  and	  hamploinsufficiency	  of	  beclin-­‐1	  improves	  it	  (Zhang,	  Li	  et	  al.	  2011,	  Nassif,	  
Valenzuela	  et	  al.	  2014).	  Lastly,	  we	  must	  also	  consider	  the	  possibility	  that	  both	  hypotheses	  
are	  true:	  autophagy	  may	  play	  both	  beneficial	  and	  detrimental	  roles	  in	  ALS	  disease	  
progression.	  
Our	  finding	  that	  autophagy	  inhibition	  is	  compatible	  with	  motor	  neuron	  survival	  
makes	  it	  possible	  to	  test	  these	  hypotheses.	  By	  breeding	  Atg7	  cKO	  mice	  to	  the	  SOD1G93A	  
disease	  model,	  we	  can	  address	  the	  role	  of	  autophagy	  with	  unprecedented	  specificity.	  
Through	  phenotypic	  analysis	  of	  these	  mice,	  I	  will	  show	  that	  autophagy	  plays	  a	  protective	  
role	  early	  in	  disease	  progression	  by	  helping	  to	  maintain	  neuromuscular	  integrity,	  but	  




Autophagy	  inhibition	  in	  motor	  neurons	  accelerates	  disease	  onset	  but	  extends	  survival	  in	  
SOD1G93A	  mice	  
To	  investigate	  the	  involvement	  of	  motor	  neuron	  autophagy	  in	  ALS	  disease	  
pathogenesis,	  we	  bred	  Atg7	  cKO	  mice	  to	  SOD1G93A	  mice	  to	  generate	  Atg7	  cKO;	  SOD1G93A	  
double	  mutant	  mice.	  We	  hypothesized	  that	  structural	  and	  functional	  defects	  at	  motor	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neuron	  presynaptic	  terminals	  might	  exacerbate	  neuromuscular	  denervation	  in	  SOD1G93A	  
mice.	  However,	  temporal	  changes	  in	  p62	  aggregation	  and	  engulfment	  by	  GABARAPL1-­‐
positive	  autophagosomes	  suggested	  that	  the	  role	  of	  autophagy,	  and	  therefore	  the	  effects	  of	  
autophagy	  inhibition,	  could	  vary	  during	  the	  course	  of	  disease	  progression.	  	  
	   To	  measure	  disease	  onset	  in	  Atg7	  cKO;	  SOD1G93A	  mice,	  we	  monitored	  mice	  for	  the	  
onset	  of	  hindlimb	  tremor	  and	  the	  onset	  of	  disease-­‐associated	  weight	  loss.	  We	  found	  that	  
Atg7	  cKO;	  SOD1G93A	  mice	  exhibited	  accelerated	  onset	  of	  hindlimb	  tremor	  compared	  to	  Atg7	  
cWT;	  SOD1G93A	  controls	  (Figure	  4.1A,	  median	  age	  of	  onset:	  78	  days	  versus	  100	  days,	  Log-­‐
rank	  test	  =	  21.49;	  p	  <	  0.001).	  Though	  this	  metric	  of	  disease	  onset	  was	  robustly	  accelerated,	  
we	  did	  not	  find	  any	  difference	  in	  the	  onset	  of	  disease-­‐associated	  weight	  loss	  between	  Atg7	  
cKO;	  SOD1G93A	  mice	  and	  Atg7	  cWT;	  SOD1G93A	  controls	  (Figure	  4.1B,	  median	  age	  of	  onset:	  
105	  days	  versus	  98	  days,	  Log-­‐rank	  test	  =	  0.1039;	  p	  =	  0.7472).	  This	  data	  indicates	  that	  these	  
two	  metrics	  of	  disease	  onset	  can	  be	  dissociated,	  and	  that	  autophagy	  inhibition	  specifically	  
accelerates	  early	  neurological	  symptoms	  of	  disease.	  
	   We	  measured	  the	  lifespan	  of	  Atg7	  cKO;	  SOD1G93A	  	  mice	  as	  described	  in	  Chapter	  1.	  
Surprisingly,	  we	  found	  a	  dramatic	  21.7%	  extension	  of	  lifespan	  compared	  to	  Atg7	  cWT;	  
SOD1G93A	  controls	  (Figure	  4.1C,	  median	  age	  of	  disease	  endstage:	  185	  days	  versus	  152	  days,	  
Log-­‐rank	  test	  =	  38.03;	  p	  <	  0.0001).	  This	  data	  indicates	  that	  loss	  of	  autophagy	  in	  motor	  
neurons	  delays	  the	  later	  stages	  of	  disease	  progression.	  Taken	  together	  with	  the	  early	  onset	  
of	  neurological	  dysfunction	  in	  these	  mice,	  our	  data	  suggest	  that	  motor	  neuron	  autophagy	  
can	  have	  counteracting	  effects	  on	  the	  SOD1G93A	  disease	  phenotype.	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Autophagy	  inhibition	  does	  not	  prevent	  motor	  neuron	  cell	  death	  but	  alters	  the	  course	  of	  
neuromuscular	  denervation	  
	   We	  asked	  whether	  changes	  in	  symptom	  onset	  and	  survival	  could	  be	  explained	  by	  
changes	  in	  motor	  neuron	  survival.	  We	  quantified	  the	  number	  of	  ChAT-­‐positive	  motor	  
neurons	  in	  the	  L4-­‐L5	  lumbar	  segments	  across	  the	  course	  of	  disease	  progression	  in	  Atg7	  
cWT	  and	  Atg7	  cKO	  mice	  with	  and	  without	  the	  SOD1G93A	  transgene.	  This	  analysis	  revealed	  
significant	  effects	  of	  age	  and	  genotype	  on	  motor	  neuron	  survival	  (Figure	  4.2,	  two-­‐way	  
ANOVA,	  effect	  of	  age:	  F	  (2,	  40)	  =	  21.35,	  p	  <	  0.0001;	  effect	  of	  genotype:	  F	  (3,	  40)	  =	  20.42,	  p	  <	  
0.0001;	  age	  ×	  genotype	  interaction:	  F	  (6,	  40)	  =	  5.812,	  p	  =	  0.0002).	  Disease-­‐associated	  
motor	  neuron	  loss	  was	  significant	  at	  P150,	  but	  there	  was	  no	  difference	  in	  motor	  neuron	  
number	  between	  Atg7	  cKO;	  SOD1G93A	  mice	  and	  Atg7	  cWT;	  SOD1G93A	  controls	  at	  this	  
timepoint	  (mean	  ±	  SEM:	  16.12	  ±	  0.79	  motor	  neurons/70	  µm	  section	  versus	  18.23	  ±	  1.13	  
motor	  neurons/70	  µm	  section).	  	  This	  data	  indicates	  that	  the	  effect	  of	  motor	  neuron	  
autophagy	  inhibition	  on	  lifespan	  is	  not	  due	  to	  enhanced	  motor	  neuron	  survival.	  	  
	   Next	  we	  asked	  whether	  phenotypic	  differences	  could	  be	  explained	  by	  changes	  in	  
neuromuscular	  innervation.	  We	  began	  by	  assessing	  the	  tibialis	  anterior	  muscle.	  We	  
quantified	  the	  percent	  of	  α-­‐bungarotoxin-­‐labeled	  endplates	  that	  were	  at	  least	  partially	  
occupied	  by	  synaptophysin-­‐immunoreactive	  presynaptic	  terminals.	  This	  analysis	  revealed	  
significant	  effects	  of	  age	  and	  genotype	  on	  neuromuscular	  innervation	  (Figure	  4.3A	  and	  
4.3B,	  two-­‐way	  ANOVA,	  effect	  of	  age:	  F	  (2,	  33)	  =	  15.40,	  p	  <	  0.0001;	  effect	  of	  genotype:	  F	  (3,	  
33)	  =	  30.70,	  p	  <	  0.0001;	  age	  ×	  genotype	  interaction:	  F	  (6,	  33)	  =	  7.190,	  p	  <	  0.0001).	  As	  
expected,	  Atg7	  cWT;	  SOD1G93A	  mice	  showed	  progressive	  denervation	  in	  this	  muscle	  over	  
the	  course	  of	  disease	  progression.	  However,	  autophagy	  inhibition	  in	  motor	  neurons	  altered	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the	  course	  of	  denervation.	  Initial	  denervation	  was	  markedly	  accelerated	  in	  Atg7	  cKO;	  
SOD1G93A	  mice	  compared	  Atg7	  cWT;	  SOD1G93A	  controls.	  Nonetheless,	  subsequent	  
denervation	  proceeded	  more	  slowly	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  and	  by	  P150	  they	  retained	  
a	  higher	  percentage	  of	  innervated	  NMJs	  than	  their	  Atg7	  cWT;	  SOD1G93A	  counterparts.	  Thus,	  
loss	  of	  autophagy	  in	  motor	  neurons	  accelerated	  early	  deneveration	  of	  the	  tibialis	  anterior	  
but	  eventually	  led	  to	  synaptic	  protection	  late	  in	  disease.	  
	   Then	  we	  extended	  our	  analysis	  of	  neuromuscular	  innervation	  to	  the	  soleus	  muscle.	  
This	  analysis	  also	  revealed	  significant	  effects	  of	  age	  and	  genotype	  on	  neuromuscular	  
innervation	  (Figure	  4.3A	  and	  4.3B,	  two-­‐way	  ANOVA,	  effect	  of	  age:	  F	  (2,	  31)	  =	  18.54,	  p	  <	  
0.0001;	  effect	  of	  genotype:	  F	  (3,	  31)	  =	  14.41,	  p	  <	  0.0001;	  age	  ×	  genotype	  interaction	  F	  (6,	  
31)	  =	  11.56,	  p	  <	  0.0001).	  Consistent	  with	  the	  relative	  resistance	  of	  the	  soleus	  in	  motor	  
neuron	  disease,	  we	  did	  not	  detect	  denervation	  in	  any	  genotype	  until	  P150.	  At	  this	  
timepoint,	  Atg7	  cWT;	  SOD1G93A	  mice	  showed	  significant	  denervation	  that	  was	  attenuated	  in	  
Atg7	  cKO;	  SOD1G93A	  mice.	  Thus,	  autophagy	  inhibition	  had	  no	  effect	  on	  neuromuscular	  
innervation	  of	  the	  soleus	  early	  in	  disease	  but	  exerted	  a	  protective	  effect	  late	  in	  disease.	  	  
	  
Decreased	  SOD1	  aggregation	  in	  Atg7	  cKO	  mice	  
	   Mutant	  SOD1	  forms	  detergent	  insoluble	  aggregates	  in	  ALS	  mouse	  models,	  and	  it	  is	  
thought	  that	  these	  aggregates	  may	  contribute	  to	  disease	  progression.	  Though	  initial	  studies	  
reported	  that	  SOD1	  aggregation	  occurs	  early	  in	  disease,	  more	  rigorous	  analysis	  has	  shown	  
it	  to	  be	  a	  late	  event	  in	  disease	  progression	  that	  immediately	  precedes	  hindlimb	  paralysis	  
(Karch,	  Prudencio	  et	  al.	  2009).	  Because	  autophagy	  inhibition	  specifically	  ameliorated	  late	  
features	  of	  SOD1G93A	  disease	  pathology,	  we	  asked	  whether	  SOD1	  aggregation	  was	  reduced	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in	  Atg7	  cKO;	  SOD1G93A	  mice.	  	  We	  prepared	  detergent-­‐soluble	  and	  detergent-­‐insoluble	  
fractions	  from	  the	  lumbar	  spinal	  cords	  of	  Atg7	  cKO;	  SOD1G93A	  mice	  Atg7	  cWT;	  SOD1G93A	  
controls.	  Strikingly,	  we	  found	  that	  autophagy	  inhibition	  in	  motor	  neurons	  reduced	  the	  level	  
of	  insoluble	  SOD1	  by	  more	  than	  two-­‐fold	  (Figure	  4.4A	  and	  4.4B).	  In	  contrast,	  there	  was	  no	  
difference	  in	  the	  level	  of	  soluble	  SOD1	  between	  Atg7	  cKO;	  SOD1G93A	  mice	  Atg7	  cWT;	  
SOD1G93A	  controls	  (Figure	  4.4A	  and	  4.4B).	  
	   In	  Chapter	  1,	  we	  demonstrated	  that	  SOD1	  co-­‐immunoprecipitated	  with	  p62	  in	  spinal	  
cord	  lysates	  from	  SOD1G93A	  mice.	  We	  hypothesized	  that	  that	  the	  biochemical	  interaction	  
between	  these	  proteins	  in	  the	  soluble	  fraction	  might	  serve	  as	  a	  precursor	  to	  the	  outright	  
accumulation	  of	  SOD1	  in	  the	  insoluble	  fraction.	  Therefore,	  we	  immunoprecipitated	  p62	  
from	  the	  soluble	  lumbar	  spinal	  cord	  lysates	  of	  Atg7	  cKO;	  SOD1G93A	  and	  Atg7	  cWT;	  SOD1G93A	  
mice.	  We	  found	  a	  dramatic	  reduction	  in	  the	  amount	  of	  co-­‐immunoprecipitating	  SOD1,	  
indicating	  that	  autophagy	  inhibition	  in	  motor	  neurons	  attenuated	  the	  interaction	  between	  
p62	  and	  SOD1	  (Figure	  4.4C	  and	  4.4D).	  
	   In	  Chapter	  1,	  we	  also	  demonstrated	  that	  SOD1	  colocalizes	  with	  p62	  in	  SLIs.	  Based	  on	  
the	  reduced	  biochemical	  interaction	  between	  p62	  and	  SOD1	  in	  Atg7	  cKO;	  SOD1G93A	  spinal	  
cords,	  we	  asked	  whether	  autophagy	  inhibition	  prevented	  the	  formation	  of	  SLIs	  in	  
autophagy-­‐deficient	  motor	  neurons.	  However,	  close	  examination	  of	  p62-­‐labeled	  motor	  
neurons	  revealed	  that	  these	  aggregates	  still	  formed	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  (Figure	  
4.4E).	  To	  determine	  whether	  there	  was	  a	  quantitative	  difference	  in	  SLI	  formation,	  we	  
compared	  the	  percent	  of	  motor	  neurons	  exhibiting	  this	  pathology	  across	  disease	  
progression	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  and	  Atg7	  cWT;	  SOD1G93A	  controls.	  This	  analysis	  
revealed	  a	  trend	  toward	  decreased	  SLI	  formation	  upon	  autophagy	  inhibition	  that	  was	  most	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pronounced	  at	  P100	  (Figure	  4.4F,	  two-­‐way	  ANOVA,	  effect	  of	  genotype:	  F	  (1,	  24)	  =	  4.236,	  p	  =	  
0.0506;	  effect	  of	  age:	  F	  (2,	  24)	  =	  42.62,	  p	  <	  0.0001;	  genotype	  ×	  age	  interaction:	  F	  (2,	  24)	  =	  
1.368,	  p	  =	  0.2738).	  But	  at	  P150,	  the	  percent	  of	  motor	  neurons	  with	  SLIs	  was	  equivalent	  
(mean	  ±	  SEM:	  7.62	  ±	  1.07%	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  versus	  8.77	  ±	  1.80%	  in	  Atg7	  cWT;	  
SOD1G93A	  controls).	  Thus,	  while	  there	  might	  be	  a	  delay	  in	  the	  induction	  of	  this	  pathology,	  
this	  is	  unlikely	  to	  explain	  the	  dramatic	  change	  in	  biochemical	  measures	  of	  protein	  
aggregation	  at	  the	  P150	  timepoint.	  	  
	   	  
Non-­‐cell-­‐autonomous	  effects	  of	  motor	  neuron	  autophagy	  inhibition	  
	  	   The	  discrepancy	  between	  unchanged	  motor	  neuron	  SLI	  pathology	  and	  dramatically	  
decreased	  SOD1	  aggregation	  in	  spinal	  cord	  lysates	  led	  us	  to	  ask	  whether	  autophagy	  
inhibition	  in	  motor	  neurons	  might	  lead	  to	  non-­‐cell	  autonomous	  effects	  in	  the	  spinal	  cord.	  
We	  began	  by	  examining	  spinal	  interneurons,	  which	  develop	  SLI	  pathology	  late	  in	  SOD1G93A	  
disease	  progression.	  Strikingly,	  SLIs	  were	  virtually	  absent	  from	  spinal	  interneurons	  in	  Atg7	  
cKO;	  SOD1G93A	  mice	  at	  P150	  (Figure	  4.5A).	  We	  quantified	  the	  percent	  of	  Nissl-­‐positive,	  
ChAT-­‐negative	  interneurons	  with	  SLI	  pathology	  and	  found	  a	  significant	  reduction	  
throughout	  the	  dorsal-­‐ventral	  axis	  of	  the	  spinal	  cord	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  relative	  to	  
Atg7	  cWT;	  SOD1G93A	  controls	  (Figure	  4.5B,	  two-­‐way	  ANOVA,	  effect	  of	  genotype:	  F	  (1,	  12)	  =	  
14.64,	  p	  =	  0.0024;	  effect	  of	  zone:	  F	  (2,	  12)	  =	  0.5975,	  p	  =	  0.5658;	  genotype	  ×	  zone	  
interaction:	  F	  (2,	  12)	  =	  0.6716,	  p	  =	  0.5291).	  The	  reduction	  in	  SLI	  pathology	  was	  also	  
associated	  with	  dramatically	  reduced	  p-­‐c-­‐Jun	  immunoreactivity	  in	  the	  nuclei	  of	  spinal	  
interneurons	  (Figure	  4.5A,	  inset),	  which	  was	  also	  evident	  from	  Western	  blotting	  of	  spinal	  
cord	  lysates	  (Figure	  4.5C).	  Quantification	  confirmed	  increased	  p-­‐c-­‐Jun	  in	  lysates	  from	  Atg7	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cWT;	  SOD1G93A	  mice	  but	  not	  Atg7	  cKO;	  SOD1G93A	  mice	  (Figure	  4.5D).	  	  Thus,	  autophagy	  
inhibition	  in	  motor	  neurons	  led	  to	  a	  non-­‐cell	  autonomous	  reduction	  in	  p62	  aggregation	  and	  
p-­‐c-­‐Jun	  upregulation	  within	  spinal	  interneurons.	  
There	  have	  been	  reports	  of	  interneuron	  cell	  death	  in	  human	  ALS	  patients	  and	  
SOD1G93A	  mice	  (Stephens,	  Guiloff	  et	  al.	  2006,	  Vinsant,	  Mansfield	  et	  al.	  2013,	  Wootz,	  
Fitzsimons-­‐Kantamneni	  et	  al.	  2013).	  Therefore	  we	  asked	  whether	  the	  differential	  induction	  
of	  SLI	  pathology	  was	  associated	  with	  changes	  in	  interneuron	  survival.	  However,	  we	  were	  
not	  able	  to	  detect	  any	  changes	  in	  interneuron	  number	  when	  we	  counted	  all	  Nissl-­‐positive	  
interneurons	  (one-­‐way	  ANOVA,	  F	  =	  1.168,	  p	  =	  0.3803).	  Given	  the	  differential	  vulnerability	  
of	  motor	  neurons	  of	  different	  sizes,	  we	  hypothesized	  that	  larger	  interneurons	  might	  be	  
particularly	  vulnerable	  in	  the	  SOD1G93A	  mice.	  When	  we	  restricted	  our	  analysis	  to	  
interneurons	  with	  nuclei	  larger	  than	  60	  µm2,	  we	  were	  able	  to	  detect	  a	  significant	  effect	  of	  
genotype	  on	  interneuron	  survival	  (Figure	  4.5E,	  one-­‐way	  ANOVA,	  F	  =	  6.810,	  p	  =	  0.0136).	  
Importantly,	  disease-­‐associated	  interneuron	  cell	  death	  was	  attenuated	  in	  Atg7	  cKO;	  
SOD1G93A	  mice.	  Thus,	  SLI	  pathology	  in	  large	  interneurons	  was	  associated	  with	  their	  
degeneration,	  and	  both	  of	  these	  phenomena	  were	  attenuated	  upon	  autophagy	  inhibition	  in	  
motor	  neurons.	  	  
	   Next	  we	  asked	  whether	  glial	  cells	  were	  also	  affected	  by	  autophagy	  inhibition	  in	  
motor	  neurons.	  First	  we	  focused	  on	  astrocytes,	  which	  are	  known	  to	  undergo	  activation	  in	  
SOD1G93A	  mice	  and	  play	  a	  can	  be	  labeled	  with	  antibodies	  against	  GFAP.	  We	  quantified	  GFAP	  
immunoreactivity	  in	  the	  ventral	  horn,	  intermediate	  zone	  and	  dorsal	  horn.	  This	  analysis	  
revealed	  significant	  effects	  of	  genotype	  and	  spinal	  cord	  zone	  on	  GFAP	  immunoreactivity	  
(Figure	  4.6A	  and	  4.6B,	  two-­‐way	  ANOVA,	  effect	  of	  genotype:	  F	  (3,	  24)	  =	  137.8,	  p	  <	  0.0001;	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effect	  of	  zone:	  F	  (2,	  24)	  =	  17.33,	  p	  <	  0.001;	  genotype	  ×	  zone	  interaction:	  F	  (6,	  24)	  =	  4.862,	  p	  
=	  0.0022).	  We	  observed	  dramatic	  upregulation	  of	  GFAP	  along	  the	  entire	  dorsal-­‐ventral	  axis	  
of	  the	  spinal	  cord	  in	  Atg7	  cWT;	  SOD1G93A	  mice	  compared	  to	  Atg7	  cWT	  controls.	  In	  contrast,	  
we	  found	  a	  global	  reduction	  in	  these	  markers	  in	  spinal	  cord	  sections	  from	  Atg7	  cKO;	  
SOD1G93A	  mice.	  This	  reduction	  was	  especially	  pronounced	  in	  the	  intermediate	  zone	  and	  
dorsal	  horn,	  where	  there	  was	  no	  significant	  upregulation	  of	  GFAP	  immunoreactivity	  
relative	  to	  Atg7	  cKO	  controls.	  Thus,	  motor	  neuron	  degeneration	  in	  Atg7	  cKO;	  SOD1G93A	  
mice	  still	  elicits	  a	  local	  astroglial	  reaction,	  but	  this	  reaction	  is	  confined	  to	  the	  ventral	  horn.	  
	  Immunostaining	  microglia	  with	  an	  antibody	  against	  Iba1	  revealed	  a	  similar	  effect	  of	  
motor	  neuron	  autophagy	  inhibition	  (Figure	  4.6C	  and	  4.6D,	  two-­‐way	  ANOVA,	  effect	  of	  
genotype:	  F	  (3,	  24)	  =	  32.52,	  p	  <	  0.0001;	  effect	  of	  zone:	  F	  (2,	  24)	  =	  5.146,	  p	  =	  0.0138;	  
genotype	  ×	  zone	  interaction:	  F	  (6,	  24)	  =	  1.074,	  p	  =	  0.4052).	  	  However,	  in	  contrast	  to	  
astrocytes,	  microglial	  activation	  was	  barely	  detectable	  even	  in	  the	  ventral	  horn.	  Thus,	  
activation	  of	  microglia	  was	  even	  more	  subdued	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  than	  activation	  
of	  astrocytes.	  	  This	  may	  indicate	  that	  they	  are	  more	  directly	  affected	  by	  loss	  of	  autophagy	  in	  
motor	  neurons,	  whereas	  the	  effect	  of	  autophagy	  inhibition	  on	  astrogliosis	  could	  be	  
secondary	  to	  changes	  in	  microglial	  activation.	  
	  
Motor	  neuron	  autophagy	  inhibition	  modulates	  gene	  expression	  in	  SOD1G93A	  mice	  
	   As	  described	  above,	  our	  analysis	  of	  Atg7	  cKO;	  SOD1G93A	  mice	  revealed	  that	  
autophagy	  inhibition	  in	  motor	  neurons	  led	  to	  non-­‐cell	  autonomous	  effects	  on	  interneurons	  
and	  glial	  cells	  late	  in	  disease	  progression.	  We	  hypothesized	  that	  these	  changes	  might	  be	  
associated	  with	  altered	  gene	  expression	  in	  the	  spinal	  cord.	  We	  were	  especially	  interested	  in	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the	  transcriptional	  effects	  of	  p-­‐c-­‐Jun	  upregulation	  in	  spinal	  interneurons.	  We	  predicted	  that	  
attenuated	  activation	  of	  this	  transcription	  factor	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  would	  lead	  to	  
reduced	  expression	  of	  established	  c-­‐Jun	  target	  genes.	  Lastly,	  we	  hypothesized	  that	  
unbiased	  analysis	  of	  expression	  data	  could	  reveal	  genes	  and	  pathways	  involved	  in	  the	  non-­‐
cell	  autonomous	  effects	  of	  autophagy	  inhibition.	  
	   To	  determine	  changes	  in	  gene	  expression,	  we	  sequenced	  RNA	  from	  lumbar	  spinal	  
cords	  of	  P150	  Atg7	  cWT,	  Atg7	  cWT;	  SOD1G93A,	  	  Atg7	  cKO	  and	  Atg7	  cKO;	  SOD1G93A	  mice.	  First	  
we	  asked	  which	  genes	  were	  differentially	  expressed	  upon	  autophagy	  inhibition	  in	  motor	  
neurons.	  In	  the	  absence	  of	  disease,	  very	  few	  genes	  were	  differentially	  expressed	  in	  the	  Atg7	  
cKO	  spinal	  cord	  (Figure	  4.7A,	  3	  up	  and	  7	  down,	  FDR	  <	  0.01).	  Strikingly,	  the	  two	  most	  
downregulated	  genes	  were	  Mmp-­‐9	  and	  Chodl,	  which	  were	  each	  downregulated	  
approximately	  40%.	  These	  are	  both	  considered	  specific	  markers	  for	  fast	  motor	  neurons	  
(Enjin,	  Rabe	  et	  al.	  2010,	  Kaplan,	  Spiller	  et	  al.	  2014).	  If	  autophagy	  inhibition	  is	  detrimental	  to	  
fast	  motor	  neurons,	  it	  is	  possible	  that	  downregulation	  of	  these	  genes	  could	  allow	  them	  to	  
adapt	  by	  adopting	  characteristics	  of	  slow	  motor	  neurons.	  The	  most	  upregulated	  gene	  in	  the	  
Atg7	  cKO	  spinal	  cord	  was	  Fgf-­‐21,	  which	  encodes	  a	  protein	  with	  neuroprotective	  and	  pro-­‐
metabolic	  functions	  (Kim,	  Jeong	  et	  al.	  2013,	  Leng,	  Wang	  et	  al.	  2015).	  Interestingly,	  both	  
MMP-­‐9	  and	  FGF-­‐21	  are	  secreted	  proteins,	  which	  may	  help	  explain	  how	  autophagy	  
inhibition	  in	  motor	  neurons	  could	  lead	  to	  non-­‐cell	  autonomous	  effects.	  	  
	  Next	  we	  asked	  how	  motor	  neuron	  autophagy	  inhibition	  altered	  gene	  expression	  in	  
the	  SOD1G93A	  context.	  We	  found	  many	  differentially	  expressed	  genes	  (3673	  up	  and	  3412	  
down,	  FDR	  <	  0.01).	  In	  order	  to	  analyze	  such	  widespread	  changes	  in	  gene	  expression,	  we	  
turned	  to	  gene	  set	  enrichment	  analysis	  (GSEA).	  This	  approach	  can	  help	  determine	  whether	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a	  priori	  defined	  gene	  sets	  are	  differentially	  regulated	  between	  experimental	  groups.	  
Pathways	  involved	  in	  innate	  immunity	  and	  cytokine	  signaling	  were	  the	  most	  differentially	  
enriched	  in	  Atg7	  cWT;	  SOD1G93A	  mice	  relative	  to	  Atg7	  cKO;	  SOD1G93A	  mice	  (Figure	  4.7B).	  
This	  is	  consistent	  with	  our	  histological	  findings	  suggesting	  differences	  in	  
neuroinflammation	  upon	  motor	  neuron	  autophagy	  inhibition.	  Pathways	  involved	  in	  
neuronal	  function	  and	  synaptic	  transmission	  were	  the	  most	  differentially	  enriched	  in	  Atg7	  
cKO;	  SOD1G93A	  mice	  relative	  to	  Atg7	  cWT;	  SOD1G93A	  mice	  (Figure	  4.7B).	  This	  is	  consistent	  
with	  reduced	  interneuron	  pathology	  upon	  autophagy	  inhibition	  in	  motor	  neurons.	  	  	  	  
To	  specifically	  address	  the	  transcriptional	  activity	  of	  c-­‐Jun	  in	  interneurons,	  we	  
analyzed	  the	  expression	  of	  a	  group	  of	  eight	  experimentally	  validated	  neuronal	  c-­‐Jun	  target	  
genes.	  This	  set	  included	  genes	  involved	  in	  apoptosis	  (Bim,	  Hrk,	  Mkp1,	  Puma),	  ER	  stress	  	  
(CHOP,	  Trib3,	  Txnip,)	  and	  Jun	  itself,	  which	  autoregulates	  its	  own	  transcription	  (Coffey	  
2014).	  	  We	  observed	  specific	  upregulation	  of	  these	  genes	  in	  Atg7	  cWT;	  SOD1G93A	  spinal	  
cords	  that	  was	  suppressed	  in	  Atg7	  cKO;	  SOD1G93A	  spinal	  cords	  (Figure	  4.7C).	  Thus,	  the	  
reduction	  in	  SLI	  pathology	  and	  p-­‐c-­‐Jun	  upregulation	  in	  spinal	  interneurons	  leads	  to	  a	  
corresponding	  decrease	  in	  the	  transcription	  of	  c-­‐Jun	  target	  genes	  involved	  apoptosis	  and	  
ER	  stress.	  
	   Finally,	  we	  harnessed	  our	  RNA-­‐seq	  data	  to	  address	  changes	  in	  the	  cellularity	  of	  the	  
spinal	  cord	  in	  different	  genotypes.	  To	  do	  this	  we	  used	  cell-­‐type	  specific	  transcriptional	  
signatures	  identified	  by	  previous	  studies	  (Cahoy,	  Emery	  et	  al.	  2008,	  Bandyopadhyay,	  
Cotney	  et	  al.	  2013,	  Phatnani,	  Guarnieri	  et	  al.	  2013,	  Zhang,	  Chen	  et	  al.	  2014).	  Then	  we	  used	  
single	  sample	  GSEA	  to	  derive	  cell	  type	  specific	  enrichment	  scores	  (Yoshihara,	  
Shahmoradgoli	  et	  al.	  2013).	  We	  found	  selective	  enrichment	  of	  astrocyte	  and	  microglial	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markers	  in	  Atg7	  cWT;	  SOD1G93A	  mice	  that	  was	  absent	  in	  Atg7	  cKO;	  SOD1G93A	  mice.	  We	  also	  
found	  that	  motor	  neuron	  markers	  were	  depleted	  in	  SOD1G93A	  mice	  regardless	  of	  autophagy	  
inhibition.	  This	  is	  in	  contrast	  to	  general	  neuronal	  markers,	  which	  were	  specifically	  depleted	  
in	  Atg7	  cWT;	  SOD1G93A	  mice	  but	  were	  relatively	  preserved	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  
(Figure	  4.7D).	  Thus,	  the	  transcriptional	  data	  was	  entirely	  consistent	  with	  our	  histological	  
findings:	  autophagy	  inhibition	  had	  little	  effect	  on	  motor	  neuron	  abundance	  but	  led	  to	  non-­‐
cell	  autonomous	  effects	  on	  neuroinflammatory	  cells	  and	  other	  neuronal	  subtypes.	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Figure 4.1 Autophagy inhibition in motor neurons alters the SOD1G93A disease 
phenotype. 
 
A-C. Kaplan-Meier plots showing time to (A) onset of tremor, (B) body mass decrease 
and (C) disease endstage. n = 23 animals per genotype. 
 
A. Onset of tremor is accelerated by 22.0% in Atg7 cKO; SOD1G93A mice relative to 
Atg7 cWT; SOD1G93A controls. Log-rank test = 21.49; p < 0.0001. 
 
B. Genotype had no effect on the onset of weight loss. Log-rank test = 0.1039; p = 
0.7472. 
 
C. Lifespan is extended by 21.7% in Atg7 cKO; SOD1G93A mice relative to Atg7 cWT; 
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Figure 4.2 
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Figure 4.2 Autophagy inhibition does not prevent motor neuron death in SOD1G93A mice.  
 
A. Quantification of motor neuron survival showed no differences between Atg7 cKO; 
SOD1G93A mice relative to Atg7 cWT; SOD1G93A controls. In both genotypes motor 
neuron loss became statistically significant at P150. n = 3-5 animals per genotype per 
timepoint. ****p < 0.0001 (two-way ANOVA, Tukey post hoc test). 
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Figure 4.3 Altered course of neuromuscular denervation in the absence of motor neuron 
autophagy. 
 
A. Tibialis anterior NMJs revealed by presynaptic synaptophysin (green) and 
postsynaptic α-bungarotoxin (red) labeling. Scale bar, 50 µm. 
 
B. Autophagy inhibition potentiates denervation of the tibialis anterior at P50 but leads 
to synaptic protection at P150. n = 3-5 animals per genotype per timepoint. *p < 0.05, 
**p < 0.01, ****p < 0.0001 (two-way ANOVA, Tukey post hoc test). 
 
C. Soleus NMJs revealed by presynaptic synaptophysin (green) and postsynaptic α-
bungarotoxin (red) labeling. Scale bar, 50 µm. 
 
D. Autophagy inhibition reduces denervation of the soleus at P150. n = 3-5 animals per 
genotype per timepoint. **p < 0.01, ****p < 0.0001 (two-way ANOVA, Tukey post hoc 
test).
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Figure 4.4 Effect of motor neuron autophagy inhibition on measures of protein 
aggregation. 
 
A. Western blot analysis of soluble and insoluble hSOD1 levels in lumbar spinal cord 
homogenates from P150 Atg7 cKO; SOD1G93A mice and Atg7 cWT; SOD1G93A controls. 
 
B. Quantification of soluble and insoluble hSOD1 levels, normalized to actin. n = 3 
animals per genotype. **p < 0.01 (two-tailed t-test). 
 
C. Western blot analysis of p62 immunoprecipitates from P150 Atg7 cKO; SOD1G93A 
mice and Atg7 cWT; SOD1G93A controls. 
 
D. Quantification hSOD1 co-immunoprecipitating with p62 reveals decreased interaction 
upon autophagy inhibition. n = 4 animals per genotype. *p < 0.05 (two-tailed t-test). 
 
E. Immunofluorescent labeling of p62 aggregates in motor neurons from Atg7 cKO; 
SOD1G93A mice and Atg7 cWT; SOD1G93A controls (ChAT labeling not shown). Arrows 
indicate motor neurons with skein-like inclusions (SLIs). Arrowheads indicate 
autophagy-deficient motor neurons lacking SLIs. Scale bar, 40 µm. 
 
F. Quantification of motor neurons with SLI pathology. There was a trend toward fewer 
SLI-positive motor neurons in Atg7 cKO; SOD1G93A mice. n = 5 animals per genotype. p 
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Figure 4.5 
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Figure 4.5 Non-cell autonomous effect of motor neuron autophagy inhibition on 
interneuron SLI pathology. 
 
A. Immunofluorescence labeling of ChAT (blue), p62 (red), and p-c-Jun (green). Inset, 
high magnification of boxed region of interest shows immunofluorescence labeling of 
Nissl-positive interneurons (blue), p62 (red), and p-c-Jun (green). Scale bar, 20 µm. 
 
B. Quantification of Nissl-positive, ChAT-negative interneurons reveals a lower 
frequency of SLI pathology in Atg7 cKO; SOD1G93A mice compared to Atg7 cWT; 
SOD1G93A controls. n = 3 animals per genotype. VH, dorsal horn, IZ, intermediate zone, 
DH, dorsal horn. **p < 0.01 (two-way ANOVA). 
 
C. Western blot analysis reveals elevated levels of p-c-Jun and c-Jun only in lumbar 
spinal cord lysates from Atg7 cWT; SOD1G93A mice.  
 
D. Quantification of p-c-Jun levels normalized to actin. n = 3 animals per genotype. *p < 
0.05 (two-way ANOVA, Tukey post hoc test 
 
E. Quantification of large interneurons in a 3×106 µm3 region of interest spanning the 
dorsal-ventral axis of the spinal cord. n = 3 animals per genotype. *p < 0.05 (two-way 
ANOVA, Tukey post hoc test). 
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Figure 4.6 
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Figure 4.6 Non-cell autonomous effect of motor neuron autophagy inhibition on glial 
reactivity. 
 
A. Immunofluorescent labeling of GFAP in lumbar spinal sections from Atg7 cWT, Atg7 
cWT; SOD1G93A, Atg7 cKO and Atg7 cKO; SOD1G93A mice at P150. Scale bar, 200 µm. 
 
B. Quantification of GFAP intensity in the ventral horn (VH) intermediate zone (IZ) and 
dorsal horn (DH), normalized to Atg7 cWT. n = 3 animals per genotype. ***p < 0.001, 
****p < 0.0001 (two-way ANOVA, Tukey post hoc test). 
 
C. Immunofluorescent labeling of Iba1 in lumbar spinal sections from Atg7 cWT, Atg7 
cWT; SOD1G93A, Atg7 cKO and Atg7 cKO; SOD1G93A mice at P150. Scale bar, 200 µm. 
 
D. Quantification of Iba1 intensity in the ventral horn (VH) intermediate zone (IZ) and 
dorsal horn (DH), normalized to Atg7 cWT. n = 3 animals per genotype. *p < 0.05, **p < 
0.01, ***p < 0.001, ****p < 0.0001 (two-way ANOVA, Tukey post hoc test). 
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Figure 4.7 Autophagy inhibition in motor neurons alters gene expression. 
 
A. Differentially expressed genes in Atg7 cKO mice relative to Atg7 cWT controls. 
Green and red denote up and down-regulated genes, respectively. 
 
B. Differentially enriched pathways in Atg7 cKO; SOD1G93A mice relative to Atg7 cWT; 
SOD1G93A mice. Green and red denote up and down-regulated pathways, respectively. 
 
C. Heatmap showing relative expression level of neuronal c-Jun target genes in the 
indicated genotypes. Subcolumns represent biological replicates.  
 
D. Heatmap of normalized enrichment scores for cell-type specific transcriptional 
signatures as determined by GSEA. Subcolumns represent biological replicates. 
 
Collaboration with Paolo Guarnieri  
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4.3	  Discussion:	  
In	  Chapter	  1,	  I	  characterized	  autophagy	  dysregulation	  in	  SOD1G93A	  motor	  neurons	  
and	  demonstrated	  that	  autophagy	  is	  differentially	  regulated	  in	  motor	  neuron	  subtypes.	  In	  
Chapter	  2,	  I	  demonstrated	  that	  loss	  of	  autophagy	  is	  compatible	  with	  motor	  neuron	  survival	  
but	  leads	  to	  deleterious	  effects	  at	  a	  subset	  of	  NMJs	  innervating	  the	  vulnerable	  tibialis	  
anterior	  muscle.	  In	  this	  chapter,	  I	  show	  that	  autophagy	  inhibition	  has	  counteracting	  effects	  
early	  and	  late	  in	  SOD1G93A	  disease	  progression.	  Early	  in	  disease,	  autophagy	  inhibition	  
accelerates	  denervation	  of	  the	  tibialis	  anterior	  and	  hastens	  the	  onset	  of	  neurological	  
dysfunction.	  Despite	  these	  early	  deficits,	  autophagy	  inhibition	  eventually	  leads	  to	  an	  
extension	  of	  lifespan	  in	  SOD1G93A	  mice.	  This	  protection	  is	  associated	  with	  the	  preservation	  
of	  neuromuscular	  innervation	  and	  non-­‐cell	  autonomous	  reductions	  in	  interneuron	  and	  glial	  
pathology	  late	  in	  disease	  progression.	  
	  
Loss	  of	  autophagy	  hastens	  disease	  onset	  but	  extends	  lifespan	  in	  SOD1G93A	  mice	  
Here	  we	  generated	  SOD1G93A	  mice	  with	  autophagy	  deficiency	  in	  motor	  neurons	  and	  
monitored	  several	  phenotypic	  measures	  of	  disease	  severity.	  We	  found	  a	  striking	  
acceleration	  of	  hindlimb	  tremor	  in	  Atg7	  cKO;	  SOD1G93A	  mice.	  Tremor	  is	  considered	  to	  be	  
one	  of	  the	  earliest	  neurological	  symptoms	  in	  this	  mouse	  model,	  so	  our	  result	  suggests	  that	  
autophagy	  inhibition	  leads	  to	  early	  motor	  neuron	  dysfunction.	  Though	  the	  exact	  
physiological	  basis	  of	  tremor	  in	  ALS	  remains	  unclear,	  recurrent	  inhibition	  mediated	  by	  
Renshaw	  cells	  is	  thought	  to	  suppress	  physiological	  tremor	  (Williams	  and	  Baker	  2009).	  As	  
we	  demonstrated,	  autophagy	  inhibition	  caused	  abnormalities	  in	  the	  motor-­‐neuron	  
Renshaw	  circuit,	  and	  these	  may	  contribute	  to	  accelerated	  onset	  of	  tremor.	  Moreover,	  the	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contributions	  of	  fast	  motor	  neurons	  to	  Renshaw	  cell	  activation	  dwarf	  those	  of	  slow	  motor	  
neurons	  (Hultborn,	  Katz	  et	  al.	  1988),	  suggesting	  that	  acceleration	  of	  tremor	  reflects	  specific	  
dysfunction	  in	  fast	  motor	  units	  in	  Atg7	  cKO;	  SOD1G93A	  mice.	  
The	  accelerated	  onset	  of	  tremor	  in	  Atg7	  cKO;	  SOD1G93A	  mice	  was	  accompanied	  by	  
accelerated	  denervation	  of	  the	  tibialis	  anterior.	  Because	  this	  muscle	  is	  preferentially	  
innervated	  by	  fast	  motor	  neurons,	  this	  provides	  further	  evidence	  that	  autophagy	  inhibition	  
is	  specifically	  detrimental	  to	  these	  cells.	  In	  contrast,	  innervation	  of	  the	  soleus	  was	  not	  
impaired	  by	  autophagy	  inhibition	  at	  any	  stage	  of	  disease	  progression.	  These	  results	  are	  
consistent	  with	  the	  specific	  accumulation	  of	  GABARAPL1-­‐positive	  autophagosomes	  in	  fast	  
motor	  neurons	  described	  in	  Chapter	  2.	  Taken	  together,	  our	  data	  indicate	  that	  fast	  motor	  
neurons	  utilize	  autophagy	  to	  maintain	  neuromuscular	  innervation	  early	  in	  SOD1G93A	  
disease	  progression,	  but	  that	  slow	  motor	  neurons	  are	  less	  dependent	  on	  autophagy	  for	  
maintaining	  neuromuscular	  innervation.	  	  
Despite	  the	  early	  onset	  of	  tremor	  and	  denervation	  in	  Atg7	  cKO;	  SOD1G93A	  mice,	  they	  
showed	  a	  dramatic	  extension	  of	  lifespan	  compared	  to	  Atg7	  cWT;	  SOD1G93A	  controls.	  This	  
phenotype	  was	  associated	  with	  preserved	  innervation	  of	  both	  the	  tibialis	  anterior	  and	  the	  
soleus	  late	  in	  disease.	  Because	  this	  was	  not	  accompanied	  any	  change	  in	  motor	  neuron	  
survival,	  maintenance	  of	  neuromuscular	  innervation	  likely	  reflects	  improved	  health	  of	  the	  
remaining	  motor	  units.	  	  
	  
Loss	  of	  autophagy	  in	  motor	  neurons	  reduces	  interneuron	  and	  glial	  pathology	  
As	  described	  in	  Chapter	  1,	  there	  is	  extensive	  crosstalk	  between	  motor	  neurons	  and	  
other	  cell	  types	  in	  ALS.	  Here	  we	  show	  that	  loss	  of	  autophagy	  in	  motor	  neurons	  leads	  to	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several	  non-­‐cell	  autonomous	  changes.	  First,	  we	  show	  that	  interneuron	  SLIs	  were	  markedly	  
reduced	  in	  Atg7	  cKO;	  SOD1G93A	  mice.	  This	  was	  associated	  with	  a	  dramatic	  reduction	  in	  
insoluble	  SOD1	  relative	  to	  Atg7	  cKO;	  SOD1G93A	  controls.	  This	  result	  is	  notable	  because	  it	  
suggests	  that	  the	  formation	  of	  protein	  aggregates	  in	  interneurons	  is	  a	  significant	  
contributor	  to	  the	  total	  levels	  of	  insoluble	  SOD1	  in	  this	  mouse	  model.	  This	  is	  consistent	  
with	  the	  observation	  that	  insoluble	  SOD1	  does	  not	  accumulate	  to	  high	  levels	  until	  disease	  
endstage,	  when	  the	  protein	  aggregation	  in	  interneurons	  becomes	  prominent	  (Karch,	  
Prudencio	  et	  al.	  2009,	  Hossaini,	  Cardona	  Cano	  et	  al.	  2011).	  
Reduced	  SLI	  formation	  in	  interneurons	  from	  Atg7	  cKO;	  SOD1G93A	  mice	  was	  
associated	  with	  decreased	  p-­‐c-­‐Jun	  levels	  relative	  to	  Atg7	  cWT;	  SOD1G93A	  controls.	  
Attenuated	  activation	  of	  this	  transcription	  factor	  had	  functional	  consequences	  on	  gene	  
expression.	  RNA-­‐sequencing	  revealed	  that	  loss	  of	  autophagy	  in	  motor	  neurons	  blocked	  
SOD1G93A-­‐induced	  transcription	  of	  neuronal	  c-­‐Jun	  target	  genes.	  The	  JNK	  pathway	  and	  
downstream	  activation	  of	  c-­‐Jun	  target	  genes	  are	  involved	  in	  neuronal	  apoptosis	  (Ma,	  Ying	  
et	  al.	  2007).	  Moreover,	  this	  neuronal	  stress	  pathway	  is	  aberrantly	  activated	  in	  
neurodegenerative	  diseases	  including	  ALS	  and	  Alzheimer’s	  disease	  (Virgo	  and	  de	  
Belleroche	  1995,	  Mairet-­‐Coello	  and	  Polleux	  2014).	  Consistent	  with	  this	  role,	  we	  found	  that	  
upregulation	  of	  c-­‐Jun	  and	  its	  transcriptional	  targets	  was	  associated	  with	  the	  death	  of	  large	  
interneurons	  in	  Atg7	  cWT;	  SOD1G93A	  mice	  but	  that	  this	  was	  blocked	  in	  Atg7	  cKO;	  SOD1G93A	  
mice.	  Reduced	  interneuron	  pathology	  may	  be	  beneficial	  by	  preserving	  synaptic	  inputs	  onto	  
motor	  neurons	  that	  are	  reportedly	  abnormal	  in	  SOD1G93A	  mice	  (Schutz	  2005,	  Chang	  and	  
Martin	  2009).	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Reduced	  interneuron	  pathology	  was	  also	  associated	  with	  decreased	  
neuroinflammation	  throughout	  the	  spinal	  cord	  in	  Atg7	  cKO;	  SOD1G93A	  mice.	  Both	  astrocytes	  
and	  microglia	  showed	  low-­‐level	  activation	  in	  the	  ventral	  horn,	  but	  this	  did	  not	  spread	  to	  the	  
rest	  of	  the	  spinal	  cord.	  This	  reduced	  neuroinflammatory	  response	  was	  also	  reflected	  in	  
RNA-­‐sequencing	  data,	  which	  showed	  dramatic	  downregulation	  of	  glial	  cell	  type	  markers	  in	  
Atg7	  cKO;	  SOD1G93A	  mice	  relative	  to	  Atg7	  cWT;	  SOD1G93A	  controls.	  While	  SLI	  pathology	  in	  
interneurons,	  astrogliosis	  and	  microgliosis	  were	  all	  downregulated	  by	  autophagy	  inhibition	  
in	  motor	  neurons,	  we	  cannot	  definitively	  determine	  the	  causal	  relationships	  between	  these	  
seemingly	  correlated	  phenomena.	  	  
Another	  key	  question	  is	  the	  mechanism	  through	  which	  autophagy	  inhibition	  in	  
motor	  neurons	  leads	  to	  these	  non-­‐cell	  autonomous	  protective	  effects.	  It	  seems	  likely	  
secreted	  factors	  might	  be	  involved.	  On	  one	  hand,	  it	  is	  possible	  that	  autophagy	  inhibition	  
might	  prevent	  the	  secretion	  of	  toxic	  factors	  that	  contribute	  to	  interneuron	  pathology	  and	  
glial	  activation.	  One	  intriguing	  candidate	  is	  mutant	  SOD1	  itself,	  which	  has	  been	  proposed	  to	  
undergo	  extracellular	  secretion	  (Urushitani,	  Sik	  et	  al.	  2006,	  Basso,	  Pozzi	  et	  al.	  2013).	  As	  
described	  in	  Chapter	  1,	  autophagy	  machinery	  can	  be	  used	  for	  the	  secretion	  of	  toxic	  proteins	  
associated	  with	  neurodegenerative	  disease	  (Ejlerskov,	  Rasmussen	  et	  al.	  2013,	  Nilsson,	  
Loganathan	  et	  al.	  2013).	  Further	  work	  is	  needed	  to	  determine	  whether	  autophagy	  is	  
involved	  in	  the	  secretion	  of	  SOD1	  as	  well.	  On	  the	  other	  hand,	  it	  is	  possible	  that	  autophagy	  
inhibition	  promotes	  the	  secretion	  of	  protective	  factors.	  One	  intriguing	  candidate	  is	  FGF-­‐21,	  
which	  is	  transcriptionally	  upregulated	  in	  Atg7	  cKO	  mice.	  FGF-­‐21	  has	  been	  shown	  to	  reduce	  
neuronal	  cell	  death	  due	  to	  excitotoxicity,	  an	  established	  disease	  mechanism	  in	  ALS	  (Leng,	  
Wang	  et	  al.	  2015).	  Interestingly,	  expression	  of	  FGF-­‐21	  can	  be	  induced	  in	  vitro	  by	  co-­‐
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administration	  of	  lithium	  and	  vaproic	  acid,	  and	  treatment	  of	  SOD1G93A	  mice	  with	  these	  
drugs	  in	  combination	  yields	  a	  greater	  protective	  effect	  on	  the	  disease	  phenotype	  than	  
either	  in	  isolation	  (Feng,	  Leng	  et	  al.	  2008).	  It	  is	  possible	  that	  some	  of	  this	  benefit	  might	  be	  
mediated	  by	  upregulation	  of	  FGF-­‐21.	  While	  the	  hypotheses	  outlined	  above	  remain	  highly	  
speculative,	  they	  offer	  exciting	  avenues	  for	  further	  research.	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Chapter	  5:	  General	  Discussion	  
	  
ALS	  pathogenesis	  is	  mediated	  by	  a	  multitude	  of	  cell	  types	  that	  differentially	  
contribute	  to	  early	  and	  late	  phases	  of	  the	  disease.	  Studies	  in	  the	  SOD1G93A	  mouse	  model	  
have	  revealed	  that	  motor	  neurons	  dictate	  symptom	  onset,	  but	  further	  progression	  is	  
mediated	  largely	  by	  other	  cell	  types	  including	  astrocytes	  and	  microglia	  (Boillee,	  Yamanaka	  
et	  al.	  2006,	  Yamanaka,	  Chun	  et	  al.	  2008).	  Here,	  we	  show	  that	  loss	  of	  autophagy	  in	  motor	  
neurons	  differentially	  impacts	  these	  two	  phases	  of	  disease.	  Early	  in	  disease,	  fast	  motor	  
neurons	  utilize	  autophagy	  to	  maintain	  neuromuscular	  innervation.	  Blocking	  this	  protective	  
mechanism	  accelerates	  early	  denervation	  and	  neurological	  dysfunction.	  However,	  we	  also	  
show	  that	  motor	  neuron	  autophagy	  promotes	  non-­‐cell	  autonomous	  pathology	  in	  
interneurons	  and	  glial	  cells.	  Autophagy	  inhibition	  reduces	  the	  spread	  of	  protein	  
aggregation	  to	  interneurons,	  attenuates	  neuroinflammation	  and	  preserves	  neuromuscular	  
innervation	  late	  in	  disease.	  	  
Most	  ALS-­‐causing	  mutations	  are	  found	  in	  genes	  that	  are	  ubiquitously	  expressed	  
throughout	  the	  body,	  yet	  for	  reasons	  that	  are	  poorly	  understood,	  motor	  neurons	  are	  
exquisitely	  vulnerable	  to	  these	  genetic	  insults.	  Our	  results	  build	  on	  previous	  studies	  using	  
mutant	  SOD1	  mice	  in	  which	  autophagy	  was	  manipulated	  in	  all	  tissues	  of	  the	  body.	  
Rapamycin	  administration	  activated	  autophagy	  and	  exacerbated	  disease,	  whereas	  
haploinsufficiency	  for	  Beclin-­‐1	  inhibited	  autophagy	  and	  extended	  survival	  (Zhang,	  Li	  et	  al.	  
2011,	  Nassif,	  Valenzuela	  et	  al.	  2014).	  Despite	  demonstrating	  a	  detrimental	  role	  for	  
autophagy,	  these	  phenotypes	  likely	  reflect	  the	  composite	  effects	  of	  manipulating	  autophagy	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in	  many	  different	  cell	  types.	  We	  extend	  these	  findings	  by	  showing	  that	  inhibition	  of	  
autophagy	  specifically	  in	  motor	  neurons	  is	  sufficient	  to	  prolong	  lifespan.	  
Even	  amongst	  motor	  neurons,	  some	  subtypes	  are	  more	  susceptible	  to	  degeneration	  
than	  others.	  Fast	  motor	  neurons	  are	  affected	  very	  early,	  while	  slow	  motor	  neurons	  do	  not	  
degenerate	  until	  late	  in	  disease	  (Kanning,	  Kaplan	  et	  al.	  2010).	  Understanding	  the	  
mechanisms	  that	  confer	  vulnerability	  to	  some	  motor	  neurons	  and	  resiliency	  to	  others	  could	  
have	  tremendous	  therapeutic	  value.	  Our	  results	  suggest	  that	  motor	  neurons	  differ	  in	  their	  
dependence	  on	  autophagy	  for	  maintaining	  neuromuscular	  innervation.	  This	  differential	  
dependence	  was	  apparent	  upon	  autophagy	  inhibition	  alone,	  but	  became	  accentuated	  in	  the	  
context	  of	  the	  SOD1G93A	  disease	  model.	  An	  exciting	  future	  direction	  will	  be	  to	  understand	  
why	  autophagy	  is	  regulated	  differently	  in	  different	  motor	  neuron	  subtypes.	  Molecular	  
markers	  such	  as	  MMP-­‐9	  mediate	  selective	  degeneration	  of	  fast	  motor	  neurons	  (Kaplan,	  
Spiller	  et	  al.	  2014),	  and	  it	  will	  be	  important	  to	  determine	  whether	  they	  also	  interact	  with	  
the	  autophagy	  pathway.	  	  
Despite	  the	  unique	  vulnerability	  of	  motor	  neurons	  in	  ALS,	  eventually	  many	  cell	  
types	  are	  affected.	  These	  include	  interneurons,	  which	  degenerate	  late	  in	  disease	  
progression,	  as	  well	  as	  non-­‐neuronal	  cells	  such	  as	  astrocytes	  and	  microglia.	  We	  find	  that	  
autophagy	  inhibition	  in	  motor	  neurons	  attenuates	  all	  of	  these	  pathological	  features.	  In	  
contrast,	  there	  was	  no	  effect	  on	  motor	  neuron	  survival.	  These	  results	  suggest	  that	  
autophagy	  is	  involved	  in	  intercellular	  propagation	  of	  ALS-­‐associated	  pathology.	  This	  is	  
consistent	  with	  accumulating	  evidence	  suggesting	  a	  role	  for	  autophagy	  in	  the	  spread	  of	  
neurodegeneration.	  In	  a	  mouse	  model	  of	  Alzheimer’s	  disease,	  loss	  of	  Atg7	  dramatically	  
reduced	  the	  amount	  of	  extracellular	  Aβ	  (Nilsson,	  Loganathan	  et	  al.	  2013).	  In	  Parkinson’s	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disease,	  autophagy	  has	  been	  implicated	  in	  the	  unconventional	  secretion	  of	  α-­‐synuclein	  
(Ejlerskov,	  Rasmussen	  et	  al.	  2013).	  Thus,	  future	  wok	  must	  examine	  whether	  similar	  
mechanisms	  are	  involved	  in	  ALS.	  	  If	  autophagy-­‐dependent	  secretory	  pathways	  are	  involved	  
in	  ALS	  pathogenesis,	  then	  it	  will	  be	  critical	  to	  determine	  the	  identity	  of	  these	  putative	  toxic	  
factors.	  
Our	  study	  examined	  the	  role	  of	  autophagy	  in	  the	  SOD1G93A	  mouse	  model	  of	  ALS,	  
which	  made	  it	  possible	  to	  investigate	  both	  early	  and	  late	  disease	  mechanisms	  in	  a	  
physiological	  context	  with	  the	  help	  of	  targeted	  genetic	  manipulations.	  It	  is	  likely	  that	  many	  
of	  our	  findings	  can	  be	  extrapolated	  to	  human	  ALS.	  The	  existence	  of	  p62-­‐positive,	  LC3-­‐
positive	  round	  bodies	  and	  p62-­‐positive,	  LC3-­‐negative	  skein-­‐like	  inclusions	  in	  ALS	  patients	  
suggests	  that	  the	  SOD1G93A	  mouse	  model	  accurately	  recapitulates	  the	  autophagy	  
abnormalities	  that	  are	  found	  in	  the	  human	  disease	  (Sasaki	  2011).	  Moreover,	  the	  selective	  
vulnerability	  of	  motor	  neuron	  subtypes	  is	  a	  core	  feature	  of	  human	  ALS	  rather	  than	  a	  
specific	  feature	  of	  the	  SOD1G93A	  mouse	  (Kanning,	  Kaplan	  et	  al.	  2010).	  The	  degeneration	  of	  
interneurons,	  activation	  of	  the	  c-­‐Jun	  pathway,	  and	  reactive	  gliosis	  are	  also	  seen	  in	  ALS	  
patients	  (Virgo	  and	  de	  Belleroche	  1995,	  Stephens,	  Guiloff	  et	  al.	  2006,	  Philips	  and	  
Robberecht	  2011).	  Nonetheless,	  future	  work	  should	  specifically	  investigate	  whether	  
autophagy	  plays	  similar	  role	  in	  ALS	  caused	  by	  other	  pathogenic	  mutations.	  This	  work	  will	  
require	  the	  use	  of	  newly	  developed	  mouse	  models	  as	  well	  as	  motor	  neurons	  differentiated	  
from	  patient-­‐derived	  induced	  pluripotent	  stem	  cells.	  It	  will	  also	  be	  critical	  to	  determine	  the	  
role	  of	  autophagy	  in	  other	  cell	  types	  besides	  motor	  neurons.	  
Our	  findings	  have	  important	  therapeutic	  implications.	  It	  has	  been	  suggested	  that	  
activation	  of	  the	  autophagy	  pathway	  might	  clear	  protein	  aggregates	  and	  improve	  the	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prognosis	  of	  ALS	  patients.	  However,	  most	  ALS	  patients	  present	  to	  the	  clinic	  after	  symptom	  
onset.	  Our	  findings	  suggest	  counteracting	  roles	  for	  motor	  neuron	  autophagy	  early	  and	  late	  
in	  disease	  progression,	  and	  imply	  that	  activation	  of	  autophagy	  could	  be	  detrimental	  late	  in	  
disease.	  In	  contrast,	  activation	  of	  motor	  neuron	  autophagy	  early	  in	  disease	  might	  help	  
protect	  vulnerable	  motor	  neurons.	  If	  there	  were	  a	  way	  to	  detect	  ALS	  at	  presymptomatic	  
stages,	  then	  promoting	  autophagy	  could	  be	  a	  more	  viable	  therapeutic	  strategy.	  Taken	  
together,	  our	  results	  show	  that	  autophagy	  is	  a	  critical	  player	  in	  motor	  neuron	  disease	  but	  
that	  its	  role	  is	  highly	  context-­‐dependent.	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Chapter	  6:	  Methods
Transgenic	  mice	  
SOD1G93A,	  ChAT-­‐Cre	  and	  Thy1-­‐YFP-­‐16	  mice	  were	  obtained	  from	  Jackson	  Laboratory	  
(Bar	  Harbor,	  ME).	  p62-­‐/-­‐	  mice	  were	  a	  gift	  of	  Jaekyoon	  Shin	  (Sungkyunkwan	  University	  
School	  of	  Medicine	  and	  Samsung	  Biomedical	  Research	  Institute).	  GFP-­‐LC3	  and	  Atg7flox/flox	  
mice	  were	  a	  gift	  of	  Masaaki	  Komatsu	  (Tokyo	  Metropolitan	  Institute	  of	  Medical	  Sciences).	  All	  
of	  these	  mice	  were	  obtained	  on	  a	  C57/Bl6	  background	  except	  for	  ChAT-­‐Cre	  mice,	  which	  
were	  backcrossed	  four	  generations	  prior	  to	  generating	  mice	  for	  analysis.	  SOD1G93A	  mice	  
were	  bred	  to	  p62-­‐/-­‐	  mice	  to	  generate	  SOD1G93A	  mice	  deficient	  for	  p62.	  SOD1G93A	  mice	  were	  
bred	  to	  GFP-­‐LC3	  mice	  for	  analysis	  of	  autophagy	  dysregulation.	  Atg7flox/flox	  mice	  were	  bred	  
to	  ChAT-­‐Cre	  mice	  to	  generate	  Atg7	  cKO	  mice	  with	  autophagy	  deficiency	  in	  motor	  neurons	  
(Atg7flox/flox;	  ChAT-­‐Cre).	  They	  were	  compared	  to	  Atg7	  cWT	  littermates	  with	  intact	  Atg7	  
expression	  (Atg7flox/flox	  or	  Atg7	  flox/+;	  ChAT-­‐Cre).	  Atg7	  cWT	  and	  Atg7	  cKO	  mice	  were	  bred	  to	  
Thy1-­‐YFP-­‐16	  mice	  for	  analysis	  of	  synaptic	  morphology.	  All	  mouse	  experimental	  procedures	  




	   Mice	  were	  monitored	  on	  a	  weekly	  basis	  throughout	  disease	  progression.	  Weight	  
was	  recorded	  on	  a	  weekly	  basis,	  and	  the	  age	  of	  peak	  weight	  was	  used	  as	  one	  measure	  of	  
disease	  onset.	  For	  neurological	  testing,	  mice	  were	  allowed	  to	  rest	  their	  forelimbs	  on	  the	  
cagetop	  and	  observed	  for	  evidence	  of	  hindlimb	  tremor.	  The	  age	  at	  which	  tremor	  became	  
apparent	  served	  as	  an	  additional	  marker	  for	  disease	  onset.	  When	  either	  of	  these	  became	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apparent,	  diet	  was	  supplemented	  with	  gel-­‐based	  food.	  Disease	  endstage	  was	  defined	  as	  the	  
age	  at	  which	  SOD1G93A	  mice	  could	  no	  longer	  right	  themselves	  within	  15	  seconds	  of	  being	  
put	  on	  their	  side.	  	  
	  
Immunohistochemistry	  
Animals	  were	  deeply	  anesthetized	  with	  tribromoethanol	  (300	  mg/kg)	  and	  
transcardially	  perfused	  with	  phosphate-­‐buffered	  saline	  (PBS)	  followed	  by	  4%	  
paraformaldehyde	  (PFA)	  in	  PBS.	  Tibialis	  anterior	  and	  soleus	  muscles	  were	  washed	  in	  PBS	  
overnight	  and	  cryopreserved	  by	  successive	  incubations	  in	  10%,	  20%	  and	  30%	  sucrose	  in	  
PBS	  prior	  to	  embedding	  in	  O.C.T.	  compound	  (Sakura,	  Torrance,	  CA)	  and	  freezing	  at	  −80°C.	  	  
Consecutive	  sections	  30	  μm	  sections	  were	  collected	  onto	  Superfrost	  Plus	  Micro	  Slides	  
(VWR,	  Radnor,	  PA)	  using	  a	  freezing	  microtome	  (Leica	  CM	  1950)	  and	  stored	  at	  −80°C.	  Spinal	  
cords	  were	  post-­‐fixed	  in	  4%	  PFA	  overnight	  and	  washed	  in	  PBS.	  The	  L4-­‐L5	  lumbar	  region	  
was	  isolated	  based	  on	  ventral	  root	  anatomy	  and	  embedded	  in	  4%	  agarose	  (WorldWide	  
Medical	  Products,	  Bristol,	  PA)	  prior	  to	  collecting	  free-­‐floating,	  transverse	  70	  μm	  sections	  
using	  a	  vibratome	  (Leica	  VT	  1200	  S).	  	  
Tissue	  samples	  were	  incubated	  in	  blocking	  solution	  (100	  mM	  Tris-­‐HCl	  pH	  7.5,	  150	  
mM	  NaCl,	  0.5%	  Triton	  X-­‐100,	  5%	  Donkey	  serum)	  and	  incubated	  with	  primary	  antibodies	  
(Table)	  diluted	  in	  blocking	  solution.	  	  After	  washing,	  tissue	  sections	  were	  washed	  and	  
incubated	  with	  secondary	  antibodies	  raised	  in	  donkey	  and	  conjugated	  to	  Alexa	  Fluor	  405,	  
488,	  568,	  633	  or	  647	  (Thermo	  Fisher)	  or	  Cy3	  (Jackson	  Immunoresearch).	  For	  muscle	  
sections,	  primary	  antibody	  incubations	  were	  performed	  overnight	  at	  4°C	  and	  secondary	  
antibody	  incubations	  were	  performed	  for	  2	  hours	  at	  room	  temperature.	  During	  secondary	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antibody	  incubation,	  α-­‐bungarotoxin	  conjugated	  to	  Alexa	  fluor	  488	  or	  647	  (Thermo	  Fisher)	  
was	  included	  for	  visualization	  of	  motor	  endplates	  .	  For	  spinal	  cord	  sections,	  primary	  and	  
secondary	  antibody	  incubations	  were	  performed	  overnight	  at	  room	  temperature.	  For	  some	  
experiments,	  Neurotrace	  435/455	  blue	  fluorescent	  Nissl	  stain	  (Thermo	  Fisher)	  was	  
included	  with	  secondary	  antibodies	  for	  pan-­‐neuronal	  staining.	  Sections	  were	  washed	  and	  
mounted	  on	  slides	  with	  Flouromount-­‐G	  (Southern	  Biotech,	  Birmingham,	  Alabama).	  
	  
Analysis	  of	  muscle	  innervation	  
Muscle	  sections	  stained	  with	  synaptophysin	  and	  α-­‐bungarotoxin	  were	  imaged	  with	  
an	  Olympus	  FV1000	  confocal	  microscope	  using	  a	  10X	  objective	  and	  individual	  images	  were	  
stitched	  together	  to	  reconstruct	  the	  entire	  muscle	  using	  Fluoview	  software.	  The	  resulting	  
images	  were	  processed	  using	  CANJI,	  a	  custom	  image	  analysis	  suite	  developed	  in	  
collaboration	  with	  Paolo	  Guarnieri	  using	  RStudio	  and	  ImageJ.	  Source	  code	  is	  available	  upon	  
request.	  Neuromuscular	  junctions	  were	  considered	  to	  be	  innervated	  if	  at	  least	  10%	  of	  the	  
α-­‐bungarotoxin-­‐labeled	  motor	  endplate	  was	  overlapped	  by	  synaptophysin-­‐labeled	  
presynaptic	  terminal.	  	  
	  
Motor	  neuron	  analyses	  
Spinal	  cord	  sections	  were	  imaged	  by	  confocal	  microscopy	  using	  a	  20X	  objective	  and	  
the	  resulting	  images	  were	  manually	  analyzed	  in	  ImageJ.	  ChAT-­‐positive	  neurons	  in	  the	  
lateral	  motor	  column	  were	  individually	  traced	  in	  the	  plane	  at	  which	  the	  nucleolus	  was	  
visible	  and	  cell	  size	  was	  determined	  using	  ImageJ.	  For	  analysis	  of	  intracellular	  aggregates,	  
circular	  p62	  structures	  greater	  than	  3	  μm	  in	  diameter	  were	  considered	  to	  be	  round	  bodies.	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Linear	  p62	  structures	  present	  in	  proximal	  dendrites	  were	  considered	  to	  be	  skein-­‐like	  
inclusions.	  Analysis	  of	  p62	  aggregates	  was	  subsequently	  verified	  by	  manual	  inspection	  of	  
each	  neuron	  at	  60X	  magnification.	  	  
	  
Quantification	  of	  Astroglisosis	  and	  Microgliosis	  
Spinal	  cord	  sections	  stained	  with	  antibodies	  against	  GFAP	  and	  Iba1	  were	  imaged	  by	  
confocal	  microscopy	  using	  a	  20X	  objective	  and	  pixel	  intensities	  were	  maintained	  within	  a	  
linear	  range	  to	  ensure	  accurate	  quantification.	  Individual	  images	  were	  stitched	  together	  to	  
reconstruct	  the	  entire	  section	  and	  regions	  of	  interest	  corresponding	  to	  the	  ventral	  horn,	  
intermediate	  zone	  and	  dorsal	  horn	  were	  superimposed	  onto	  maximum	  intensity	  
projections.	  Subsequently,	  mean	  fluorescence	  intensity	  for	  each	  region	  was	  determined	  
using	  ImageJ.	  	  
	  
Analysis	  of	  Motor	  Neuron-­‐Renshaw	  Cell	  Synapses	  
Spinal	  cord	  sections	  stained	  with	  antibodies	  against	  calbindin	  and	  VAChT	  were	  
imaged	  by	  confocal	  microscopy	  using	  a	  60X	  objective	  and	  1.5X	  digital	  zoom.	  Individual	  
images	  were	  stitched	  together	  to	  reconstruct	  the	  Renshaw	  cell	  area	  and	  individual	  
calbindin-­‐positive	  cells	  and	  VAChT-­‐positive	  presynaptic	  terminals	  were	  reconstructed	  and	  
analyzed	  using	  Neurolucida	  software	  (MBF	  Bioscience,	  Williston,	  VT).	  	  
	  
Electron	  Microscopy	  
Animals	  were	  deeply	  anesthetized	  with	  tribromoethanol	  (300	  mg/kg)	  and	  
transcardially	  perfused	  with	  100	  mM	  phosphate	  buffer	  (PB)	  followed	  by	  4%	  PFA	  and	  2.5%	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Gluteraldehyde	  in	  PB.	  Tibialis	  anterior	  was	  dissected	  and	  post-­‐fixed	  in	  the	  same	  fixative	  
prior	  to	  collecting	  300	  µm	  vibratome	  sections.	  Samples	  were	  processed	  using	  the	  
sequential	  osmium	  tetroxide-­‐thiocarbohydrazide-­‐osmium	  (OTO)	  method	  as	  described	  
previously	  (Tapia,	  Kasthuri	  et	  al.	  2012).	  Samples	  were	  imaged	  with	  a	  SIGMA	  field	  emission	  
scanning	  electron	  microscope	  (Zeiss)	  in	  collaboration	  with	  Juan	  Carlos	  Tapia.	  
	  
Analysis	  of	  protein	  levels	  
To	  analyze	  total	  levels	  of	  specific	  proteins,	  lumbar	  spinal	  cord	  (L4-­‐L5	  region)	  was	  
homogenized	  in	  RIPA	  buffer	  [50	  mM	  Tris-­‐HCl	  pH	  7.5,	  150	  mM	  NaCl,	  0.1%	  SDS,	  0.5%	  Na	  
Deoxycholate,	  1%	  Triton	  X-­‐100	  and	  1	  mM	  EDTA	  supplemented	  with	  Complete	  Protease	  
Inhibitor	  Cocktail	  and	  PhosphoSTOP	  (Roche)]	  and	  centrifuged	  at	  15,000g	  for	  10	  min	  at	  4°C.	  
The	  supernatant	  was	  collected,	  quantified	  using	  the	  micro-­‐BCA	  assay	  (Pierce)	  and	  
denatured	  in	  LDS	  sample	  buffer	  (Thermo	  Fisher).	  Proteins	  were	  resolved	  by	  SDS-­‐PAGE	  
using	  4-­‐12%	  Bis-­‐Tris	  gels	  and	  transferred	  to	  PVDF	  membrane	  (Bio-Rad) using an X-cell II 
Blot module transfer unit (Thermo Fisher). Membranes were incubated with the primary 
antibodies indicated in Table 6.2 and bands were visualized using HRP-conjugated secondary 
antibodies (GE Healthcare Life Sciences).  	  
	  
Fractionation	  and	  Immunoprecipitation	  	  
Lumbar	  spinal	  cord	  (L4-­‐L5	  region)	  was	  homogenized	  in	  Triton	  buffer	  [50	  mM	  Tris-­‐
HCl	  pH	  7.5,	  150	  mM	  NaCl,	  1%	  Triton	  X-­‐100	  and	  1	  mM	  EDTA	  supplemented	  with	  Complete	  
Protease	  Inhibitor	  Cocktail	  and	  PhosphoSTOP	  (Roche)]	  and	  centrifuged	  at	  15,000g	  for	  10	  
min	  at	  4°C.	  The	  supernatant	  was	  collected	  as	  the	  Triton	  soluble	  fraction.	  The	  pellet	  was	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washed	  3	  times	  in	  Triton	  buffer,	  resuspended	  in	  SDS	  buffer	  [Triton	  buffer	  plus	  5%	  SDS]	  
and	  heated	  to	  95°C	  for	  10	  min.	  After	  centrifugation	  at	  15,000g	  for	  10	  min	  at	  room	  
temperature,	  the	  supernatant	  was	  collected	  as	  the	  Triton	  insoluble	  fraction.	  Protein	  
concentration	  was	  quantified	  using	  the	  micro-­‐BCA	  assay	  (Pierce)	  and	  aliquots	  of	  each	  
fraction	  were	  denatured	  in	  LDS	  sample	  buffer.	  The	  remainder	  of	  the	  soluble	  fraction	  was	  
used	  for	  p62	  immunoprecipitation. 
Antibody	  against	  p62	  or	  normal	  IgG	  was	  bound	  to	  a	  mixture	  of	  Protein	  A/G	  
dynabeads	  and	  incubated	  with	  soluble	  protein	  extract	  for	  12	  hours	  at	  4°C.	  Beads	  were	  
washed	  4	  times	  in	  Triton	  buffer	  and	  immunoprecipitated	  protein	  was	  eluted	  in	  LDS	  sample	  
buffer.	  The	  levels	  of	  proteins	  in	  the	  soluble,	  insoluble	  and	  immmunoprecipitated	  fractions	  
were	  analyzed	  by	  Western	  blot	  as	  described	  above.	  
	  
Electrophysiology	  
The experiment procedures employed to measured QC in the mouse tibialis anterior have 
been extensively described in previous publications (Wang, Engisch et al. 2004, Wang, Li et al. 
2005, Wang, Wang et al. 2010).  Briefly, 100-day-old mice were sacrificed using CO2 inhalation 
and the tibialis anterior was removed and pinned in a sylgard plated dish. After staining with 10 
µM 4-(4-diethylaminostyryl)-N-methylpyridinium iodide (4-Di-2ASP; Thermo Fisher), NMJs 
were visualized using an epifluorescence microscope, and perfused at a speed of 3-6 mL per 
minute with a external solution containing 118 mM NaCl, 0.7 mM Mg2SO4, 2 mM CaCl2, 3.5 
mM KCl, 26.2 mM NaHCO3, 1.7 mM NaH2PO4 and 5.5 mM glucose (pH 7.3-7.4, 20-22°C), 
equilibrated with 95% O2 and 5% CO2.  When concentrations of CaCl2 and/or Mg2SO4 were 
changed, equivalent amounts of NaCl were added/reduced to keep osmolarity unchanged. 
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Endplate currents were recorded using two electrodes voltage clamp. The nerve to the TA 
muscle was stimulated via an extracellular Tungsten electrode (FHC Inc. USA). 
When	  external	  Ca2+	  was	  normal,	  muscle	  fibers	  were	  crushed	  on	  both	  ends	  of	  TA	  
away	  from	  the	  endplate	  band	  to	  eliminate	  contractions	  upon	  nerve	  stimulation	  and	  the	  
holding	  potential	  was	  set	  at	  -­‐45	  mV.	  	  When	  external	  Ca2+	  was	  low	  or	  there	  was	  high	  
external	  Mg2+,	  muscle	  fibers	  were	  not	  crushed	  and	  the	  holding	  potential	  was	  set	  at	  -­‐70	  mV.	  
Nested	  analysis	  of	  variance	  (SYSTAT)	  was	  used	  for	  comparing	  the	  effect	  of	  drugs	  and	  other	  
experimental	  manipulations.	  Plots	  and	  curve	  fittings	  were	  made	  using	  Sigmaplot	  software.	  	  
	  
Retrograde	  Labeling	  
P45	  SOD1G93A	  mice	  were	  deeply	  anesthetized	  with	  isofluorane.	  CTB	  conjugated	  to	  
Alexa	  fluor	  488	  was	  injected	  was	  injected	  into	  the	  tibialis	  anterior	  of	  one	  hindlimb,	  and	  CTB	  
conjugated	  to	  Alexa	  fluor	  594	  was	  injected	  into	  the	  soleus	  of	  the	  opposite	  hindlimb	  in	  
collaboration	  with	  Juan	  Carlos	  Tapia.	  Animals	  were	  perfused	  and	  spinal	  cords	  were	  
collected	  5	  days	  later.	  
	  
Gene	  expression	  analysis	  
	   Lumbar	  spinal	  cords	  were	  dissected	  from	  each	  mouse	  genotype	  in	  quadruplicate.	  
RNA	  was	  isolated	  using	  Trizol	  (Thermo	  Fisher)	  and	  the	  RNeasy	  mini	  kit	  (Qiagen).	  RNA	  
concentration	  and	  integrity	  were	  assessed	  on	  assessed	  on	  RNA	  6000	  Chips	  using	  an	  Agilent	  
2100	  Bioanalyzer	  (Agilent	  Technologies,	  Santa	  Clara,	  CA).	  Poly-­‐A	  pull-­‐down	  was	  used	  to	  
enrich	  mRNAs	  (200ng-­‐1ug	  per	  sample,	  sample	  RIN	  was	  above	  8.0)	  and	  then	  libraries	  were	  
prepared	  using	  single-­‐end	  100bp	  reads	  for	  each	  sample	  with	  Illumina	  TruSeq®	  RNA	  prep	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kits	  (Illumina,	  San	  Diego,	  CA).	  Libraries	  were	  sequenced	  using	  Illumina	  HiSeq2000	  at	  the	  
Columbia	  Genome	  Center.	  Illumina	  RTA	  was	  used	  to	  perform	  base	  calling	  and	  CASAVA	  
(version	  1.8.2)	  was	  used	  for	  converting	  base	  call	  files	  (.BCL)	  to	  FASTQ	  format	  and	  also	  to	  
perform	  sequence	  adaptor	  trimming.	  Reads	  were	  then	  mapped	  to	  the	  mouse	  reference	  
genome	  (mm9)	  using	  Tophat	  (version	  2.0.4),	  allowing	  4	  mismatches	  (-­‐-­‐read-­‐mismatches	  =	  
4)	  and	  a	  maximum	  of	  10	  multiple	  hits	  (-­‐-­‐max-­‐multihits	  =	  10).	  The	  relative	  expression	  was	  
calculated	  using	  Cufflinks	  (version	  2.0.2)	  with	  default	  settings.	  Gene	  expression	  levels	  were	  
normalized	  by	  library	  size	  and	  gene	  length	  into	  FPKMs	  and	  log2	  transformed.	  Counts	  tables	  
were	  generated	  with	  HTSeq	  (http://www-­‐huber.embl.de/users/anders/HTSeq)	  version	  
0.6.1.	  Transcripts	  with	  0	  counts	  across	  all	  samples	  were	  removed	  and	  mathematical	  
artifacts	  (e.g.	  negative	  infinites)	  were	  replaced	  with	  “NA”.	  Statistical	  analysis	  was	  
performed	  in	  R	  version	  3.2.1	  and	  additional	  Bioconductor	  packages	  were	  part	  of	  release	  
3.1.	  Differentially	  expressed	  genes	  were	  identified	  using	  edgeR	  package	  version	  3.10.2.	  We	  
used	  Benjamini	  &	  Hochberg	  procedure	  for	  controlling	  false	  discovery	  rate	  (FDR)	  of	  the	  
multiple	  tests	  and	  accepted	  as	  significant	  a	  q-­‐value	  <	  0.01.	  Enrichment	  analysis	  was	  
performed	  using	  GSEA	  against	  MSigDB	  Reactome	  from	  the	  curated	  gene	  sets	  v4.0.	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Target Source Catalog-Number Species Dilution
Calbindin Swant CB38 Rabbit 1:500
Calretinin Swant CG1 Goat 1:1000
ChAT Millipore AB144P Goat 1:250
Ubiquitin EnzoDLifeDSciences BMLIPW8810 Mouse 1:500
GABARAPL1 ProteinTech 11010I1IAP Rabbit 1:1000
GFAP Abcam ab4674 Chicken 1:500
GFP Aves GFPI1020 Chicken 1:1000
Iba1 Abcam ab5076 Goat 1:500
LC3B CellDSignalingDTechnologies 2775 Rabbit 1:500
MMPI9 SigmaDAldrich M9570D Goat 1:1000
NBR1 Abnova H00004077IMOI Mouse 1:100
p62 Abcam ab91526 Rabbit 1:500
p62 Abcam ab56416 Mouse 1:500
Parvalbumin JessellDLab N/A Chicken 1:1000
pIcIJunD(Ser63) CellDSignalingDTechnologies 9261 Rabbit 1:100
hSOD1 Abcam 79390 Rabbit 1:2000
SynaptophysinD1 SynapticDSystems 101004 GuineaDPig 1:500
VAChT ColumbiaDMotorDNeuonDCenter N/A GuineaDPig 1:500
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Table 6.1: Antibodies used for immunofluorescence experiments
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Target Source Catalog-Number Species Dilution
Actin Millipore MAB1501 Mouse 1:4000
Atg5 Cell6Signaling6Technologies 12994 Rabbit 1:1000
hSOD1 Abcam 79390 Rabbit 1:10000
LC3B Novus 100G2220 Rabbit 1:2000
p62 Abcam ab56416 Mouse 1:1000
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Table 6.2: Antibodies used for Western blotting experiments.
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